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There is a growing body of evidence supporting the association between cannabis use and 
the development of mental health disorders, but few studies have addressed this 
association following the recent increase in marijuana legalization laws. Therefore, using 
the social ecological model and the self-medication theory of addiction as theoretical 
frameworks, the purpose of this retrospective database study was to assess the 
relationship between marijuana use and major depression and suicidal ideation in both 
adults and adolescents in 2008 and 2017. Data from the National Survey on Drug Use 
and Health were analyzed using logistic regression at the p < .05 threshold for statistical 
significance. Results demonstrated positive, statistically significant relationships between 
marijuana use and both major depression and suicidal ideation for both adults and 
adolescents in both 2008 and 2017. Further, the strengths of these relationships generally 
increased between 2008 and 2017, coincident with the increase in marijuana legalization 
laws. These findings provide empirical support to the association between cannabis use 
and the development of mental health disorders, and that the strength of these 
associations is increasing following the increase in marijuana legalization laws. This 
study has important implication for positive social change by identifying significant 
relationships between cannabis use and the development of mental health disorders and 
revealing that these relationships are strengthening over time, coincident with the 
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Chapter 1: Introduction to the Study 
 Substance use, abuse, and misuse is an important public health problem in the 
United States. According to the National Institute on Drug Abuse (NIDA) over $700 
billion dollars is spent annually on the following substance use related issues: the 
associated health care cost (such as cancer, heart disease, and mental illness); loss 
productivity and wages; and crime associated with driving while impaired; accidents; 
violence; and child abuse (NIDA-The Science of Drug Abuse, 2016; NIDA-Magnitude, 
2017). In addition to the aforementioned health care complications, substance abuse is 
also associated with other cost due illness, injuries, and death as “approximately 40 
million debilitating illnesses or injuries occur” each year as a result of substance use, 
misuse, or abuse (NIDA-Magnitude, 2017, para.4). Among the substances of abuse, 
marijuana is the most widely used substance in the United States. In 2018, approximately 
43 million Americans reportedly used marijuana in the past year (Statista, 2019). Among 
these were approximately 11.8 million young adults that reported using marijuana in 
2018 (NIH-NIDA, 2019). The World Health Organization (WHO; 2018) further 
emphasized the widespread use of marijuana in a report indicating that approximately 
147 million people or 2.5% of the world population use marijuana in some form each 
year. This is compared to 0.4% combined total of the world’s population that consume 
cocaine and opiates annually (World Health Organization [WHO], 2018). Thus, 
marijuana is by far the most widely used substance in the world. 
 More importantly, in the United States differential marijuana legalization policies 
have introduced considerable controversy regarding the public health impact of these 
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policy changes. While increased use has led to therapeutic effects against certain medical 
conditions, other researchers argue that there is an increase in deleterious consequences. 
Therefore, understanding the nature of the relationship between marijuana, psychosis, 
and mental health conditions is important to developing evidence-based health policies as 
this information can serve to inform policy makers, practitioners, and public health 
professionals. This is especially important given the changing attitude and increasing 
legalization of marijuana which has led to the production of marijuana strains with higher 
levels of THC (Briggs, 2015; Cabrera, 2016). 
Currently, 33 states and the District of Columbia plus Guam and Puerto Rico have 
passed laws legalizing medical marijuana with 11 of these states and the District of 
Columbia also implementing recreational marijuana laws (Governing Data, 2019; Hartig 
& Geiger, 2018). However, these laws vary by state. For instance, in addition to 
legalization of medical marijuana, California’s Prop 64 measure permits adults that 21 
and older to possess up to one ounce of marijuana and grow six plants (Governing Data, 
2018). In contrast, states like Georgia have legalized the use of marijuana for medical 
purposes only (Governing Data, 2018). The Georgia law which passed on April 16, 2015 
allows for the use of cannabidiol (CBD) to treat various medical conditions (Governing 
Data, 2018). Some these of these uses include: seizure disorders; sickle cell anemia; 
cancer; Crohn's disease; ALS (Lou Gehrig's disease); multiple sclerosis; mitochondrial 
disease; and Parkinson's disease (ProCon, 2016). CBD is a compound found in marijuana 
that is being used for medical benefits (citation). CBD does not produce the psychoactive 
effects caused by tetrahydrocannabinol (THC) also found in marijuana (citation). In fact, 
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CBD can serve to counteract the psychoactive effects of THC and is used in treat 
marijuana induced psychosis (Niesink & van Laar, 2013). 
Prior to legalization, THC levels ranged from a low of 4% to a high of 13% 
(Ramaekers et al., 2006). However, since legalization these ranges have increased 
dramatically. For instance, growers in Colorado have produce strains that range from a 
low of 6% THC to a high of 28% THC in the Williams’ Screaming Gorilla strain 
(Cabrera, 2016). While numerous studies have been conducted assessing the lower levels 
of THC, fewer studies have been conducted to assess higher levels. In this study, I sought 
to address this gap in the research by assessing the effects of rising THC levels in 
legalized marijuana on mental health. This study may contribute to positive social change 
by informing future generations of the risk associated with highly potent marijuana and 
the implications of marijuana legalization on the prevalence of mental illnesses like 
depression. 
Background 
Lab tests reveal that the potency of marijuana in Colorado since legalization is 
more than twice as potent as illegal marijuana of the past 10 years and some strains of 
legal marijuana is three times as potent (Briggs, 2015). Prior to legalization the levels of 
THC were typically below 10%. However, research now indicates that the post 
legalization levels of Colorado’s marijuana averages around 18.7 % with some marijuana 
strains containing THC levels of 30 % or more (Briggs. 2015). These findings 
demonstrate that legalization and relaxation of marijuana policies have created an 
environment that has led to increased availability of highly potent marijuana. This fact 
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justifies the need to address this gap in the research as most previous studies have been 
conducted on lower THC levels prior to legalization.  
In 2016, Colorado state legislators made efforts to limit THC levels to 16% by 
proposing an amendment (Cabrera, 2016). However, these efforts failed as the 
amendment did not get enough support. Among the health and safety concerns addressed, 
the effects of THC on adolescent brains was one of the primary concerns of the 
proponents of this amendment (Cabrera, 2016). Thus, adolescents are included in the 
target population of this study which intends to contribute to positive social change by 
making information available to inform and understand the effects on future generations 
as a return on investment going forward.  
The higher levels of THC have had a serious health toll on inexperienced users. 
For instance, according to the Colorado Department of Public Health and Environment, 
emergency room visits for marijuana associated conditions, such as psychosis has 
increased 29% for all Colorado residents since legalization (Cabrera, 2016). However, 
when inexperienced users take in too much of the highly potent marijuana, they are more 
likely to experience extreme anxiousness and report feelings of “impending doom” when 
compared to the regular heavy marijuana users that have built up a tolerance (Cabrera, 
2016). This is evidenced by out of state users that are inexperienced when it comes to the 
high levels of THC elicited by Colorado’s legal marijuana (Manella, 2016). Wherein 
hospitalizations for out of state visitors has risen dramatically from “78 per 10,000 visits, 
to 112 per 10,000 in 2013, to 163 per 10,000 in 2014” reflecting an increase of 109% 
between the years of 2012 and 2014 (Manella, 2016, para. 4). Thus, marijuana 
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legalization has led to a dramatic increase in hospitalizations especially among the 
inexperienced user. 
Nevertheless, possible marijuana related hospitalizations for Colorado residents in 
2000 prior to medical marijuana legalization (MML) was 575 per 100,000 (Colorado 
Department of Public Safety [CDPS], 2016). Between the years of 2001 to 2009 post 
MML (but prior to commercialization) the rates of hospitalizations rose to 803 per 
100,000 (CDPS, 2016). However, between the years of 2010 to 2013 which reflects post 
commercialization of medical marijuana the rates of hospitalization rose dramatically to 
1,440 per 100,000 (CDPS, 2016). With the most dramatic increase demonstrated after 
retail commercialization between the years of 2014 to June 2015 which demonstrated 
“2,413 hospitalizations per 100,000 visits” (CDPS, 2016, p.7). The THC in marijuana 
elicit its effects by over activating specific regions of the brain that has highest number of 
cells with receptors specific for THC (National Institute of Health [NIH] – Marijuana, 
2016). Therefore, marijuana with higher levels of THC would be expected to have a more 
profound effect. 
The notion that marijuana use is associated with the development of psychosis 
and mental health disorders is well founded as previous research has demonstrated that in 
addition to psychosis, anxiety and depression are also associated with regular marijuana 
use (Moore et al., 2007; Volkow, Ruben, Baler, Compton, & Weiss, 2014). Nevertheless, 
relatively few studies have addressed this association since the rise in THC demonstrated 
after legalization. The mental health effects are reportedly associated with long-term 
marijuana use in susceptible users (Cabrera, 2016). The mental effects may include 
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temporary symptoms of hallucinations and paranoia, which are exacerbated in 
schizophrenia patients. Another mental health issue associated with marijuana is suicidal 
thoughts in teens (Cabrera, 2016). This should be a serious public health concern 
especially when considering the rising THC levels which may serve to compound this 
problem. 
 As previously indicated, marijuana laws vary by state. Therefore, the availability 
of highly potent marijuana also varies by state as research has demonstrated a spillover 
effect of highly potent medical marijuana into the recreational using population 
(Salomonsen-Saulel, et al., 2012; Wen, Hockenberry, & Cummings, 2015). This trend 
has also been demonstrated in states adjacent to states with medical and recreational 
marijuana laws as highly potent marijuana is more readily available in states adjacent to 
states with relaxed marijuana laws (Hao & Cowan, 201; Ingold, 2014 7). For instance, 
representatives of states like Oklahoma and Nebraska have attempted to sue Colorado 
citing that legalized marijuana is spilling over state lines and is more readily available in 
these states because of legalization in Colorado (Hao & Cowan, 2017; Ingold, 2014). 
This understanding is evidenced in a study by Hao and Cowan (2017) wo posited that 
counties bordering states with recreational marijuana legalization (RML) demonstrated a 
significant increase in arrests for marijuana possession when compared to counties that 
did not border states with RML. Thus, legalization and the relaxation of marijuana 
policies have increased distribution of highly potent marijuana. However, Hao and 
Cowan (2017) did not find evidence indicating that arrest for the selling and growing 
marijuana, DUI arrest, and/or arrest for possession of opium/cocaine are affected by 
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RML in border states. Nevertheless, the aim of this current study was intended to assess 
the effect of marijuana policy on mental health. 
Problem Statement 
The level of THC in marijuana has been increasing potency since legalization 
began in 2012 (Cabrera, 2016). This is a growing concern since THC elicits the desired 
psychological effects most marijuana users seek (Bradford, 2015). Addressing this 
concern now is particularly important because at present 33 states and the District of 
Columbia have passed laws legalizing the use of marijuana for medicinal purposes 
(Governing Data, 2019; NCSL, 2018). With 11 of these states and the District of 
Columbia also legalizing recreational marijuana use (Governing Data, 2019; National 
Conference of State Legislatures [NCSL], 2019). Due to this widespread legalization, 
commercial growers of marijuana have been able to significantly improve the potency 
(THC content) of their marijuana containing products (Cabrera, 2016). Thus, states like 
Colorado now has one of the highest marijuana potency levels in the United States 
(Cabrera, 2016). As commercial growers can now produce marijuana strains with 
potency levels that can average between 6% to 28% in THC (Cabrera, 2016).  
These higher levels of THC are of concern for researchers and public health 
officials as adolescents and young adults may be more affected psychologically 
(American Psychological Association [APA], 2015; Meier, 2012). Although numerous 
studies have been conducted to assess the effects of low THC levels (4% to 13%), few 
studies have been conducted to assess the effects of these higher THC levels (6% to 28%) 
(Cabrera, 2016; Ramaekers et al., 2006). Since lower levels of THC have been 
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demonstrated to have an impact on health then one would expect higher doses to have a 
more profound effect. Nevertheless, since legalization only began recently then time has 
not permitted adequate study of the effects associated with high potency marijuana. This 
lack of research demonstrates a gap in the knowledge that needs further study. An 
indication of this gap is further justified in an article presented by the American 
Psychological Association, wherein the author posited that "what's clearly lacking and 
sorely needed are studies that look at the effect of increased potency, and different modes 
and methods of use, on brain-related measures” (Weir, 2015, p.48). Therefore, further 
justify the purpose of the study which is intended to address the effects of marijuana on 
mental health conditions since potency has increased. 
Addressing the modes and methods of use is another area of concern that may 
well provide support for this gap in the research. For instance, one method of use results 
in the production of highly concentrated resins (Weir, 2015). These resins contain even 
higher concentrations of THC than the high potency marijuana strains that are currently 
being produced (Weir, 2015). Thus, resins produced from high potency marijuana would 
be expected to have an even higher concentration of THC. Production of these 
concentrated resins could further compound the issues surrounding the future of 
marijuana use and the potential repercussions on health. The aim of this study is to 
provide a broader understanding associated with continued marijuana legalization and 
rising THC levels. The results of these efforts may also serve to inform the effects 




NIDA (2016) reported that many marijuana users experience feelings associated 
with relaxation and euphoria while other users may experience anxiety, fear, distrust, or 
panic. Additionally, higher doses of marijuana have been associated with symptoms of 
acute psychosis (NIDA, 2016). These symptoms are more profound and include 
hallucinations, delusions, and a loss personal identity (NIDA, 2016). NIDA further 
posited that “these effects are more common when too much is taken, the marijuana has 
an unexpectedly high potency, or a user is inexperienced” (para. 3). These concerns 
provide support and justification for this study which is intended to explore the 
relationship between marijuana legalization and the higher levels of THC in marijuana 
products and the effects on mental health. The primary gap in the knowledge that this 
study intends to address is the effect of marijuana legalization and the relationship 
between rising THC levels (intensity of marijuana affects) and any association with 
mental illness which has not been studied in a nationally representative sample.  
In this study, I assessed the association between the continued widespread 
legalization of marijuana on mental health. More specifically, I compared an early period 
in marijuana legalization when only a few states had implemented MML to a later period 
in marijuana legalization, when several states have MMLs with many also implementing 
RML. At this point, it is important to emphasize that MML refers to a comprehensive 
medical marijuana program that allows the use of both CBD products and smokable THC 
products (National Conference of State Legislatures [NCSL], 2018). However, some 
states only have limited CBD laws and these states are not included among states with 
comprehensive Medical Marijuana Laws (NCSL, 2018).  
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Marijuana has become increasingly more available to the general public as 
legalization spreads across the country. Since the implementation of MML, a sort of 
quasi-legalization has occurred making highly potent marijuana more available to those 
who otherwise might not have access (Salomonsen-Saulel, et al., 2012). Quasi-
legalization refers to the diversion of MML. More specifically, Salmonsen-Saulel et al. 
(2012) describes this diversion of MML as “the process in which a supply of marijuana 
recommended for one person is given, traded, or sold to someone else who is not a 
registered medical marijuana user” (para. 5). This is process is examined in a study by 
Salomonsen-Saulel, et al., (2012), in which the researchers used several tools to measure 
and analyze adolescent use of medical marijuana among patients treated at two substance 
abuse facilities in Denver, Colorado. The results of this study demonstrated that many 
adolescents, approximately 74% of the 164 adolescents in treatment, had used medical 
marijuana obtained from registered medical marijuana patients (Salomonsen-Saulel, et 
al., 2012). Thus, demonstrating a high rate and widespread pattern of medical marijuana 
use by the non-patient recreational using population (Salomonsen-Saulel, et al., 2012). 
In 2019, 33 states and the District of Columbia plus Guam and Puerto Rico have 
passed laws legalizing medical marijuana, with 11 of these states and the District of 
Columbia also implementing recreational marijuana laws (Governing Data, 2019; Hartig 
& Geiger, 2018; NCSL, 2019). Table 1 provides a timeline for the legalization of both 
medical and recreational marijuana by state. I began with 2008 since I analyzed the years 
2008 and 2017 to assess the effects of legalization on mental health. In 2008, only 13 
states and the District of Columbia had implemented laws legalizing marijuana use for 
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medical purposes only (Governing Data, 2018; NCSL, 2019;). Whereas, in 2019, 33 
states and the District of Columbia had medical marijuana laws with 11 of these states 
and the District of Columbia also implementing recreational marijuana laws (Governing 
Data, 2019; Hartig & Geiger, 2018; NCSL, 2019).   
Table 1 
Medical & Recreational Marijuana Legalization Timeline by State 
Year Medical Marijuana Laws Recreational Marijuana Laws 
2008 California (1996, 2003);  
Alaska, Oregon & Washington (1998);  
Maine (1999);  
Colorado, Hawaii & Nevada (2000);  
Montana & Vermont (2004);  
New Mexico & Rhode Island (2007); 
Michigan (2008); 
 
2009 New Jersey & Washington D.C.  
2010 Arizona  
2011 Delaware  
2012 Connecticut & Massachusetts Colorado & Washington 
2013 Illinois & New Hampshire  
2014 Maryland, Minnesota, & New York Alaska, Oregon, & Washington D.C. 
2016 Arkansas, Florida, North Dakota, 
Pennsylvania, & Ohio 
California, Nevada, & 
Massachusetts 
2017 West Virginia  
2018 Oklahoma, Missouri, & Utah Vermont, Michigan 
2019 Louisiana  Maine 
Note. From “State Medical Marijuana Laws,” by National Conference of State 





Some states with no marijuana laws approved do allow access for special 
situations. For instance, Alabama and Mississippi permit access for severe epileptic 
conditions (Governing Data, 2018). Another special situation is Virginia, which enacted 
laws years before most states that allow individual possession of marijuana if prescribed 
by a physician (Governing Data, 2018). However, federal law does not allow physicians 
to prescribe marijuana but, doctors can write a recommendation for medical marijuana 
(Governing Data, 2018). In addition, several states have CBD only laws that allow the 
use of products that are high in CBDs but low in THC (Governing Data, 2018). At 
present, only Idaho, South Dakota, Kansas, and Nebraska do not have access to a public 
marijuana program of any type (medical or recreational) (NCSL, 2019). Table 2 provides 
a breakdown of states which allow limited medical marijuana products for specific 
conditions.  
Table 2 
Limited Medical Marijuana Products [Low THC/High CBD-cannabidiol] 
State Year Specific Conditions 
Florida 2014 Cancer, and medical conditions or seizure disorders treatable 
with low THC products 
Kentucky 2014 Intractable Seizure Disorders 
Mississippi 2014 Debilitating Epileptic condition or related illness 
Missouri 2014 Nonresponsive Intractable Epilepsy 
North Carolina 2014 Intractable Epilepsy 
South Carolina 2014 Lennox-Gastaut Syndrome; Dravet Syndrome (Severe 
Myoclonic Epilepsy of Infancy); or any other form of 
Refractory Epilepsy;  
13 
 
State Year Specific Conditions 
Tennessee 2014 Intractable Seizure conditions 
Utah 2014 Nonresponsive Intractable Epilepsy 
Wisconsin 2014 Seizure Disorders 
Georgia 2015 Cancer (end stage); Amyotrophic Lateral Sclerosis; Multiple 
Sclerosis; Seizure Disorders; Crohn's; Mitochondrial Disease; 
Parkinson's; Sickle Cell disease 
Idaho 2015 Cancer; Amyotrophic Lateral Sclerosis; Seizure 
Disorders; Multiple Sclerosis; Crohn's Disease; Mitochondrial 
Disease; Fibromyalgia; Parkinson's Disease or Sickle Cell 
Disease 
Oklahoma 2015 Minors with Lennox-Gastaut Syndrome, Dravet Syndrome, or 
other severe Epilepsy 
Wyoming 2015 Intractable Epilepsy or Seizure disorders 
Texas 2015  Intractable Epilepsy 
Alabama 2016 Debilitating Epileptic conditions; life-threatening Seizures; 
Wasting Syndrome; Chronic Pain; Nausea; Muscle Spasms; 
any other sever condition resistant to conventional medicine 
Pennsylvania 2016 Amyotrophic lateral sclerosis; Anxiety disorders; Autism; 
Cancer, including remission therapy; Crohn’s disease; 
Damage to the nervous tissue of the central nervous system 
(brain-spinal cord) with objective neurological indication of 
intractable spasticity, and other associated neuropathies; 
Dyskinetic and spastic movement disorders; Epilepsy; 
Glaucoma; HIV / AIDS; Huntington’s disease; Inflammatory 
bowel disease; Intractable seizures; Multiple sclerosis; 
Neurodegenerative diseases; Neuropathies; Opioid use 
disorder for which conventional therapeutic interventions are 
contraindicated or ineffective, or for which adjunctive therapy 
is indicated in combination with primary therapeutic 
interventions; Parkinson’s disease; Post-traumatic stress 
disorder; Severe chronic or intractable pain of neuropathic 
origin or severe chronic or intractable pain; Sickle cell 
anemia; Terminal illness; Tourette syndrome. 
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State Year Specific Conditions 
Indiana 2017 Resistant Epilepsy 
Virginia 2017 Intractable Epilepsy 
Note. From “State Medical Marijuana Laws,” by National Conference of State 
Legislatures, 2019, Retrieved from http://www.ncsl.org/research/health/state-medical-
marijuana-laws.aspx; “Wisconsin Medical Marijuana Laws and Regulations,” Americans 
For Safe Access, 2019, Retrieved from 
https://www.safeaccessnow.org/wisconsin_medical_marijuana_laws_and_regulations;  
Marijuana Policy Project (MPP) (2019). “Virginia’s Limited CBD and THC-A Oil Law,” 
Marijuana Policy Project, 2019, Retrieved from 
https://www.mpp.org/states/virginia/virginias-limited-cbd-and-thc-a-oil-law/; Wenner, D. 
(2019). “These 23 conditions can qualify you to get medical marijuana in Pa,” by 
Wenner, 2019, Penn Live-Patriot News. September 3, 2019 
  
Purpose 
The purpose of this study was to provide a greater understanding of the 
relationship between marijuana use, legalization and the availability of highly potent 
marijuana and the effects on mental health. As previously indicated, since legalization the 
THC level of marijuana can now range from 6% to 28 % as oppose to pre-legalization 
lower potency levels that typically ranged between 4% to 13 % (Cabrera, 2016; 
Ramaekers, et al., 2006). To my knowledge, there have been relatively few studies 
conducted post legalization to investigate the potential effects of higher THC levels. 
Thus, the originality of this study or gap in the research associated with this study is 
based on the premise that most previous studies were conducted based on pre-legalization 
low THC levels. However, these studies may prove to be obsolete to informing the public 
and health care professionals in the future especially when considering the rising THC 
levels, current trend in attitude and continued legalization of high potency marijuana. I 
used quantitative secondary data and logistic regression analysis to assess the association 
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between marijuana legalization, highly potent marijuana use and mental health conditions 
like depression and suicide ideation (see Center for Disease Control [CDC], 2015). 
The results of this study are intended to provide relevant information for future 
use to advise and/or inform health care professionals and public health personnel who 
deal with the health and medical needs of the THC using population. They are also 
intended to inform policy makers in states that have legalized marijuana and those 
considering marijuana legalization. The general population may also gain knowledge of 
the risk associated with high potency legalized marijuana use from this study. 
Theoretical Frameworks  
There are several theoretical models developed for understanding drug use, abuse, 
prevention, and cessation. For instance, there is a growing body of evidence supporting 
the association between self-medicating with marijuana and depression (see Shonesy et 
al., 2014). In addition, research supports the use of the social ecological model to 
understand substance use and abuse from a multifaceted perspective (American College 
Health Association [ACHA], 2018). Therefore, for the purpose of this study, the self-
medication theory of addiction and social ecological model served as the conceptual 
framework.  
The self-medication theory of addiction developed by Khantzian (1977, 1974), is 
a theory with over 30 years of use in research (Hall & Queener, 2007). This hypothesis 
suggests that individuals who are afflicted with substance abuse may also have a 
predisposition for psychological conditions or psychosis (Burnett & Reiman, 2014). An 
example appropriate to the aim of this study is described by Hallowell a physician 
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experience with attention deficit hyperactivity disorder (ADHD); (Khantzian, 2003). Per 
Hallowell, marijuana has been described as having both stimulating and sedating 
properties that appeal to individuals with ADHD (Khantzian, 2003). Thus, individuals 
with this condition presumably use marijuana for these properties to counter the 
restlessness and emotional instability associated with ADHD (Khantzian, 2003).  
In a related study, Shonesy (2014) explored the relationship between mental 
health conditions like depression and anxiety, and receptors that respond to THC in the 
central nervous system. This system is known as the endocannabinoid system and is 
medicated by two cannabinoid receptors, CB1 & CB2 (Shonesy et al., 2014). These 
receptors respond to both endogenous and exogenous stimulation (Shonesy et al., 2014). 
Natural endogenous stimulation of CB1 receptors occurs through one of two THC-like, 
anandamide (AEA) and 2-arachidonoylglycerol (2-AG) (Shonesy et al., 2014). According 
to Shonesy et al., this system “is heavily implicated in the modulation of anxiety and 
depression” (p. #). For instance, the THC in marijuana is capable of binding CB1 
receptors of the system and affecting mood (Shonesy et al., 2014). Such that reduced 
stimulation of these receptors results in mood destabilization and increased feelings of 
anxiety and depression (Shonesy et al., 2014). Thus, marijuana users who suffer from 
these conditions may not be able to synthesize enough of THC-like molecules 
(particularly 2-AG) so they use marijuana to compensate (Shonesy et al., 2014). Research 
suggests that individuals may actually self-medicate without knowing it to compensate 
for their inherent low levels of THC-like molecules (Curry, 2014; Shonesy et al., 2014). 
These concepts are revisited in Chapter 2. 
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In contrast, the social ecological model (SEM) is a theory-based multifaceted 
approach to understanding the dynamics associated individual and population level 
determinants of health (American College Health Association [ACHA], 2018). The SEM 
theorists recognize that health is determined by influences from multiple societal and 
environmental factors that affect the individual (ACHA, 2018). According to SEM, the 
dynamic interrelationships between five levels or factors of health determinants are 
significant and essential to the health behaviors of the individual (ACHA, 2018). These 
five levels include (a) individual, (b) interpersonal, (c) organizational/institutional, (d) 
community, and (e) policy (CDC-SEM, 2018). The first level is concerned with 
sociodemographic (i.e., age, gender, religion, etc.) and intrapersonal factors or 
characteristics such as knowledge, beliefs, attitudes, and behaviors of the individual that 
affect health decisions and outcomes (ACHA, 2018; CDC-SEM, 2018). The second or 
interpersonal level is concerned with close personal relationships or associates that 
influence the behavior and contributes to the life experience of the individual (ACHA, 
2018; CDC-SEM, 2018). This can include family members, friends, coworkers, health 
care providers, and community health workers (ACHA, 2018; CDC-Socioecological 
Model [SEM], 2018). The third level is concerned with local organizations and 
institutions that affect individual and population health by influencing organizational 
systems and policies (ACHA, 2018; CDC-SEM, 2018). This includes health care 
systems, state and local health departments, professional organizations, and healthcare 
plans (ACHA, 2018; CDC-SEM, 2018). The fourth level explores community and social 
relationships that influence individual health determinants. This can include 
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employers/worksites; businesses such as bars and restaurants; community-based 
organizations; the media; and community; state; and regional organizations (ACHA, 
2018; CDC-SEM, 2018). The final or fifth level is associated with interpreting and 
implementing local, state, national, and federal laws and policies (ACHA, 2018; CDC-
SEM, 2018). This level is of particular interest to this study especially given the current 
trend in marijuana policies that favor relaxed laws and increased community acceptance 
of legalization for recreational and medicinal purposes. Therefore, this model can be used 
to inform states’ local marijuana policies and may serve to inform the implementation of 
federal laws and regulations as well.  
Research Questions 
RQ1: Is marijuana use associated with depression and suicidal ideation in adults 
in 2008 and 2017, either in isolation using raw (unadjusted) values or using values 
adjusted for age, sex, annual family income, and education? 
RQ2: Is marijuana use associated with depression and suicidal ideation in 
adolescents in 2008 and 2017, either in isolation using raw (unadjusted) values or using 
values adjusted for age, sex, annual family income, and education? 
RQ3: Are the associations between marijuana use and depression and between 
marijuana use and suicide ideation higher in 2017 than in 2008 for both adults and 
adolescents, either in isolation using raw (unadjusted) values or using values adjusted for 




 In accordance with the study research questions, the hypotheses for this study, 
each stated in null form, were as follows. 
For the 2008 data: 
H01: There will be no statistically significant relationship between marijuana use 
and depression (major depressive episode in the last year) in the adult 2008 
cohort, either in isolation using raw (unadjusted) values or using values adjusted 
for age, sex, annual family income, and education. 
H02: There will be no statistically significant relationship between marijuana use 
and suicidal ideation in the adult 2008 cohort, either in isolation using raw 
(unadjusted) values or using values adjusted for age, sex, annual family income, 
and education. 
H03: There will be no statistically significant relationship between marijuana use 
and depression (major depressive episode in the last year) in the adolescent 2008 
cohort, either in isolation using raw (unadjusted) values or using values adjusted 
for age, sex, annual family income, and education. 
H04: There will be no statistically significant relationship between marijuana use 
and suicidal ideation in the adolescent 2008 cohort, either in isolation using raw 
(unadjusted) values or using values adjusted for age, sex, annual family income, 
and education. 
For the 2017 data: 
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H05: There will be no statistically significant relationship between marijuana use 
and depression (major depressive episode in the last year) in the adult 2017 
cohort, either in isolation using raw (unadjusted) values or using values adjusted 
for age, sex, annual family income, and education. 
H06: There will be no statistically significant relationship between marijuana use 
and suicidal ideation in the adult 2017 cohort, either in isolation using raw 
(unadjusted) values or using values adjusted for age, sex, annual family income, 
and education. 
H07: There will be no statistically significant relationship between marijuana use 
and depression (major depressive episode in the last year) in the adolescent 2017 
cohort, either in isolation using raw (unadjusted) values or using values adjusted 
for age, sex, annual family income, and education. 
H08: There will be no statistically significant relationship between marijuana use 
and suicidal ideation in the adolescent 2017 cohort, either in isolation using raw 
(unadjusted) values or using values adjusted for age, sex, annual family income, 
and education. 
For comparing 2008 and 2017 data: 
H09: There will be no statistically significant increase in the strength of the 
relationships between marijuana use and depression (Major Depressive Episode in 
the last year) in the adult 2017 cohort compared to the adult 2008 cohort. 
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H010: There will be no statistically significant increase in the strength of the 
relationships between marijuana use and suicidal ideation in the adult 2017 cohort 
compared to the adult 2008 cohort. 
H011: There will be no statistically significant increase in the strength of the 
relationships between marijuana use and depression (Major Depressive Episode in 
the last year) in the adolescent 2017 cohort compared to the adolescent 2008 
cohort. 
H012: There will be no statistically significant increase in the strength of the 
relationships between marijuana use and suicidal ideation in the adolescent 2017 
cohort compared to the adolescent 2008 cohort. 
Nature of the Study  
For this study, I used a quantitative secondary data analysis using archived data. 
Logistic regression was used to assess the association between the predictor variable, 
marijuana and the response or outcome variable, mental health (see CDC, 2015). The 
analysis also used multiple logistic regression to analyze any associations between “no 
marijuana use” and “marijuana use” on mental health conditions like depression and 
suicide ideation based on national marijuana legality status. The study considered 
increasing marijuana potency that has risen drastically since legalization as a potential 
reason for increased mental health conditions from marijuana use (see CDC, 2015). The 
study data for 2008 and 2017 were collected by the National Survey on Drug Use and 
Health (NSDUH) datasets, which consisted of responses from 67,928 and 68,032 
participants respectively, in the target population sample sizes (National Survey on Drug 
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Use and Health [NSDUH]-codebook, 2008; NSDUH-codebook, 2017). These were 
noninstitutionalized civilians 12 years and older living in the United States at the time of 
the survey (NSDUH-codebook, 2008; NSDUH-codebook, 2017).  
Operational Definitions 
 Throughout this dissertation, terminology specific to this topic may not be 
familiar to the reader. Therefore, the following terms have been defined for clarification: 
2-arachidonoylglycerol (2-AG): A natural ligand, 2-arachidonoylglycerol 
specifically activates CB1 receptors of the endocannabinoid system (Shonesy et al., 
2014) Low levels of this ligand are associated with increase anxiety and depression as 
demonstrated in animal and human studies (Shonesy et al., 2014).   
Anandamide (AEA): Anandamide is a THC-like ligand found naturally 
(endogenous) in the human body interacts with cannabinoid receptors of the 
endocannabinoid system (Shonesy et al., 2014).  
Cannabidiol (CBD): Cannabidiol is a cannabinoid found in cannabis (marijuana) 
and is preferred for its medicinal value and is used to treat various conditions(Atakan, 
2012). CBD also interacts with the endocannabinoid system of the body (Atakan, 2012). 
However, CBD does not bind CB1 receptors and therefore does not have psychoactive 
properties. CBD is used to reverse effects of marijuana-induced psychosis (Atakan, 
2012).   
Cannabis: Cannabis refers to a subspecies of plant, Cannabis Indica and 




Δ9-tetrahydrocannabinol (THC): one of many cannabinoids found in cannabis 
(marijuana) and is primarily responsible for the psychoactive effects that recreational 
users seek (Atakan, 2012). Binds to CB1 receptors in the brain and central nervous 
system acting as a partial agonist to elicit its effects (Atakan, 2012). 
Dabbing: Dabbing is a slang term used to describe a method of using marijuana 
concentrates (i.e. wax) that involves conduction as the form of heating (Krauss et al., 
2015). In this process the user heats the dab (marijuana or BHO concentrate) to a high 
temperature using a torch on a conduction surface or “hot plate” which is typically a nail; 
the user then inhales the vapor produced (Krauss, et al., 2015). 
Depression: Depression is operationally defined as a state of an individual “who 
reported that during the past 12 months they had a period of depression lasting 2 weeks or 
longer, while also having some of the other symptoms mentioned, were classified as 
having past year depression” (NSDUH-codebook, 2015, p. 848).   
Endocannabinoid system:  Endocannabinoid system “refers to endocannabinoids 
and the proteins that regulate their production and degradation, as well as to the receptors 
through which they signal” (Silvestri & Di Marzo, 2013, para. 2). 
Endogenous: Endogenous refers to the bodies naturally occurring ligands, 
molecules, and substances (Onaivi, Sugiura, & Di Marzo, 2005; Shonesy et al., 2014). 
Such as the naturally occurring cannabinoids that interact with the endocannabinoid 
system (Onaivi, Sugiura, & Di Marzo, 2005; Shonesy et al., 2014).  
Exogenous: Exogenous refers to ligands, and other molecules and substances that 
are produced outside the body but are capable of interacting within the body (Onaivi, 
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Sugiura, & Di Marzo, 2005; Shonesy et al., 2014). Such as the THC in marijuana that 
interacts with receptors of the endocannabinoid system (Onaivi, Sugiura, & Di Marzo, 
2005; Shonesy et al., 2014;).  
Marijuana (aka cannabis): Marijuana “refers to the dried leaves and flowers from 
the cannabis plant which contain the mind-altering chemical delta-9-
tetrahydrocannabinol (Δ9-THC) and other related compounds” (Addiction Policy Forum, 
2019, para. 1). 
Marijuana use: For the purpose of this study, marijuana use refers to frequency of 
use and states legality status (only medical marijuana legal; both recreational and medical 
marijuana legal; no legal marijuana status), as detailed in Chapter 3. 
Rhabdomyolysis: Rhabdomyolysis is muscle injury/damage leading to breakdown 
and release of these contents which can in turn serious health complications such as renal 
failure (WebMD, 2019). 
Schedule I Narcotic: A Schedule I Narcotic is a substance or chemical that does 
not have a currently accepted medical use and has a high potential for abuse (Drug 
Enforcement Agency, 2018). Examples of these drugs/narcotics include: marijuana, 
heroin, lysergic acid diethylamide (LSD), ecstasy (3,4-
methylenedioxymethamphetamine), methaqualone, and peyote (DEA, 2018). 
Vaping: Vaping is a slang term used to describe a method of using marijuana, 
marijuana products such as butane hash oil (BHO), CBD oils, synthetic marijuana and 
nicotine use in e-cigarettes (Budney, Sargent & Lee, 2015; Yang et al., 2018). During the 
vaping process, the substance to be used (liquid, oil, or plant material) is vaporized using 
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convection heat which releases the aerosolized active ingredients of the desired substance 
(i.e. THC) in the form of a water vapor mixture that is inhaled by the user (Budney, 
Sargent & Lee, 2015; Lepkoff, 2018; Yang et al., 2018).  
Assumptions 
There are several assumptions associated with this study that must be considered 
when reviewing the results. The first two assumptions are concerned with the sampling 
method as this study used secondary data. Therefore, one assumption is that the NSDUH 
survey provides an adequate national sample that is representative of the U.S. population. 
Second, since the NSDUH survey uses self-reporting then recall bias and honesty in 
survey responses are a serious concern. I therefore assumed that research participants 
answered questions truthfully and to the best of their ability, as recall bias and dishonest 
answers can limit the reliability and of study results (see Davis et al., 2013). Another 
assumption is concerned with the legal status of states under consideration and their 
geographical location to other states with differing laws. This is an important concern, as 
states with relaxed marijuana laws and policies that border states without marijuana laws 
may significantly affect the data obtained in the states without marijuana laws. I assumed 
that bordering states had no effect and the marijuana laws in the state of interest is the 
primary source of influence on the data obtained in the NSDUH survey.  
Scope and Delimitations 
The scope of this study was concerned with the association between legalization 
and the relaxation of marijuana policies that have made high potency marijuana more 
readily available. This study was intended to assess the effect of marijuana policy on 
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mental health. The study was limited to respondents of the 2008 and 2017 NSDUH, 
which included 67,928 and 68,032 respondents respectively, in the target population 
sample sizes (NSDUH-codebook, 2008; NSDUH-CODEBOOK, 2017). These were 
noninstitutionalized civilians 12 years and older living in the United States at the time of 
the survey (NSDUH-codebook, 20008; NSDUH-CODEBOOK, 2017).  
Limitations 
There are a several limitations associated with this study. First, since this study 
used secondary data, one possible limitation is residual confounding which can occur 
when variables that are critical to the current study have been omitted from the data set 
being used (see LaMorte & Sullivan, 2016). For instance, variables deleted to protect the 
confidentiality of the respondents. Therefore, data such as race, names of respondents, 
and zip codes that are important to the intended study may have been deleted. Residual 
confounding can also occur when data collected on variables of interest is not precise 
enough for the current study, or when no attempt is made to adjust for confounding 
factors as would be the case when critical variables are not included in the dataset 
(LaMorte & Sullivan, 2016). Another limitation is associated with the NSDUH survey 
which uses self-reporting to gather data on the participants. This is a concern because the 
reliability of self-reporting on sensitive issues like substance use and mental health issues 
is questionable as respondents may not be truthful due to the potential stigma associated 
with substance use (Davis et al., 2013). In addition, self-reporting may also be subject to 
recall bias and memory bias that would further limit the reliability of study results. 
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(Hasan, 2005). And finally, the cross-sectional nature of this study may limit inferences 
on causality as observations are made at one point in time (Davis et al. (2013).  
Additionally, there is another potentially limiting factor associated with the 
NSDUH. The survey does not differentiate between the marijuana patient and nonpatient 
populations participating in the study (Wen, Hockenberry, & Cummings, 2015). Thus, 
the spillover effect may not solely reflect an increased marijuana use among registered 
marijuana patients as the non-patient or recreational using population may potentially 
contribute to a greater percentage of the individuals participating in the study (Wen et al., 
2015). This limitation is evidenced in a study by Wen et al. (2015) which indicates that, 
among the states studied with MMLs, medical marijuana patients comprised only 0.8% of 
the total population.  
Significance of the Study 
There is a growing body of evidence supporting the association between cannabis 
use and the development of psychosis and mental health disorders (Moore et al., 2007). 
However, few studies have addressed this association since the rise in THC demonstrated 
post legalization. From a public health stance, addressing this concern is essential as 
individual with marijuana use disorder are likely to continue use despite findings of 
clinically significant conditions such as mental health disorders (NIDA, 2016). For many 
years, substance abuse and substance dependence were considered two separate 
categories. However, in 2013 the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5) was updated such that abuse, and dependence are classified under the category 
of substance use disorder (NIDA, 2016). In this case marijuana or cannabis use disorder. 
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Note, throughout this paper the terms marijuana and cannabis are used interchangeable 
and considered to have the same meaning. This will become evident as some scholarly 
sources used in the literature and other areas of this study use cannabis whereas other 
sources use marijuana.  
 Volkow et al., (2014) posited that previous research has demonstrated that 
anxiety, depression, and psychosis are associated with regular marijuana use. However, 
causality is not well founded as addressing this association is hindered by confounders 
that also contribute to the development of these conditions (Volkow et al., 2014). For 
instance, individuals with a family history of schizophrenia and psychosis have a greater 
risk of developing these conditions (Volkow et al., 2014). In addition, heavy use of 
marijuana, highly potent marijuana, and using marijuana at an early age also exacerbate 
the occurrence of mental health conditions like psychosis (Volkow et al., 2014). These 
findings provide additional support for the current study which intends to explorer the 
effects of marijuana legalization on rising THC levels (increased drug potency) and 
mental health conditions, such as depression and suicide ideation psychosis and mental 
illness.  
Furthermore, several studies have demonstrated that heavy marijuana use has the 
potential to cause psychosis or exacerbate a pre-existing psychotic illness (Bushak, 2013; 
Sevigny, Pacula, & Healon, 2014). Bushak (2013) listed the following symptoms of 
marijuana induced psychosis: hallucinations, paranoia, confusion, and anxiety. One 
would expect marijuana with higher THC levels to have a more profound effect. This 
assumption was demonstrated in a study which found that in areas where marijuana was 
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legalized there was a statistical correlation between increased THC levels and hospital 
admissions for marijuana induced psychosis (Bushak, 2013). This conjectured 
relationship between marijuana use and psychiatric illness is an established area of 
interest. Previous epidemiological studies have demonstrated that there is an increased 
risk of developing psychiatric disorders such as schizophrenia, associated with increased 
frequency of marijuana use (see Kahn & Akella, 2009). Studies have also demonstrated 
that marijuana is the most commonly abused substance among individuals diagnosed 
with bipolar disorder (Kahn & Akella, 2009). In addition, Kahn and Akella (2009) 
indicated that short-term, intense use of marijuana can produce exacerbations of 
psychotic symptoms in those with preexisting conditions. In a related study, researchers 
surveyed marijuana users to assess the association between marijuana and the occurrence 
of psychotic like symptoms (Kahn & Akella, 2009). The results of this study revealed 
that psychosis-like symptoms were demonstrated in 15% of survey respondents (Kahn & 
Akella, 2009). The most common symptoms reported included hearing voices and 
unwarranted feelings of persecution (Kahn & Akella, 2009). Additional related symptoms 
of acute marijuana intoxication include depersonalization, fear of dying, irrational panic, 
and paranoid ideas (Kahn & Akella, 2009). Thus, knowing how marijuana effects 
psychosis is also important to informing the community as well as health care and public 
health professionals.  
As indicated, previous studies have demonstrated that brief episodes of psychosis 
can lead to more serious psychotic disorders, such as schizophrenia, which causes the 
most severe health loss of all human disorders affecting how these individuals think, feel, 
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and behave, and many of these patients seem to lose touch with reality (NIH, 2016). This 
disorder not only impacts the health of the individual but also impacts the community and 
effects public health (NIH, 2016), (Schoeler, Petros, & Forti, 2016). Thus, knowing how 
marijuana effects mental health is particularly important to the formulation of evidence-
based health policies concerned with marijuana use (Schoeler et al., 2016). This is 
especially important considering changing public attitudes and continued legalization of 
marijuana (Schoeler et al., 2016). In addition, psychotic disorders such as schizophrenia 
are associated with a significant financial burden and are also associated with a high rate 
of comorbid abuse of marijuana (Schoeler et al., 2016). Therefore, knowing how 
marijuana effects mental conditions is important to inform policy makers and 
practitioners to reduce the burden of these conditions and the impact on the health of 
individual users, as well as public health, and the community at large (Schoeler et al., 
2016). Furthermore, understanding the potential effects of increasing THC levels is 
essential as most studies addressing these concerns were conducted based on pre-
legalization lower THC levels.  
As previously stated, this research project addressed a gap in the literature by 
providing a better understanding of the relationship between marijuana legalization, 
highly potent marijuana, and the indicated variables associated with mental conditions 
like depression and suicide ideation. The results of this study can support professional 
practice by expanding the body of knowledge available to health care and public health 
professionals, thereby informing the practical applications addressing this concern. In 
addition, as indicated practical applications of the research may be demonstrated in the 
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form of policy making and the development of informational campaigns. These efforts 
may also serve in the development of training programs for personnel involved with 
informing the public about the responsible use of marijuana.  
Finally, it is also important to understand that the effects of marijuana have a 
more profound neurological effect in those who started persistent use at an early age 
versus those who started smoking in adulthood (APA, 2015). Studies have also 
demonstrated that approximately 9% of adults who use marijuana become addicted 
versus 17% for those who began smoking as teenagers (Weir, 2015). Thus, marijuana 
producers have added incentive to market their product to younger users. (Weir, 2015). 
Therefore, I focused on younger generations for this study with the premise of effecting 
positive social change as a return on investment in future generations. In addition, this 
study is intended to contribute to positive social change by providing information 
relevant to informing the development of policy on states marijuana legality status and 
the development of evidence-based health policies as well as training programs for 
personnel involved with informing the public about the responsible use of marijuana. 
Summary and Transition 
 Marijuana use is associated with both mental health issues and psychosis or 
psychotic events (Moore et al. 2007). Nationwide marijuana laws vary by state as 33 
states and the District of Columbia plus Guam and Puerto Rico have passed laws 
legalizing medical marijuana with 11 of these states and the District of Columbia also 
implementing recreational marijuana laws (Governing Data, 2019; Hartig & Geiger, 
2018). Wherein, widespread marijuana legalization and the relaxation of marijuana 
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policies has made high potency marijuana more readily available (Sevigny et al., 2014). 
This study is intended to assess the effect of marijuana policy on mental health conditions 
like depression and suicide ideation. Chapter 2 will provide a more detailed synthesis of 
available literature related to the epidemiology of marijuana use and the effects on mental 
health and psychosis. In Chapter 2, the following topics are discussed: history of 
marijuana, marijuana in the United States, health effects of marijuana use, marijuana 
legalization and potency, marijuana and mental health disorders, marijuana and 
psychosis, therapeutic effects of marijuana on mental health, the endocannabinoid 
system, and lessons learned from states with legalized marijuana.  
Chapter provides an in-depth description of the research design and statistical 
analysis of the NSDUH data set. In addition, Chapter 4 presents an analysis of the data 
explored. And finally, Chapter 5 presents the final summary of these findings, provide a 




Chapter 2: Literature Review 
Introduction 
In the United States, substance abuse and addiction cost the American taxpayer 
over $700 billion dollars a year (NIDA, 2016). This spending is related to the increased 
cost of health care, loss of productivity and earnings in the workplace, and crime 
associated with theft, drugged driving, accidents, violence, and child abuse (NIDA, 2016; 
NIDA-Magnitude, 2017). The consequences of substance abuse are evidenced by 
approximately 90,000 Americans that die every year as a result of illicit and prescription 
drug and alcohol use (NIDA, 2016). Thus, substance abuse is an important public health 
concern that has a prodigious impact on our society.  
Among the substances of abuse, marijuana is by far the most commonly used as n 
2018, approximately 43 million Americans reportedly used marijuana in the past year 
(Statista, 2019). Among these were approximately 11.8 million young adults that reported 
using marijuana in the past year in 2018(NIH-NIDA, 2019). Additionally, marijuana is 
second only to alcohol for the highest rates of dependence and abuse, and in 2013 
statistics indicated that with exception to marijuana and methamphetamine, the rate of 
use for all other drugs had stabilized or declined (NIDA-Nationwide Trends, 2015). This 
includes prescription drugs (i.e. pain relievers, tranquilizers, stimulants, and sedatives); 
hallucinogens (i.e. ecstasy and LSD); and cocaine (NIDA-Nationwide Trends, 2015). 
And as indicated, methamphetamine use increased between 2010 to 2013 (NIDA-
Nationwide Trends, 2015). 
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In 2016, the NIDA reported the following rates of marijuana use among high 
school students: “5.4 percent among 8th graders, 9.8 percent among 10th graders, and 
14.3 percent among 12th graders” (NIDA-Monitoring the Future Survey, 2016, p. or 
para. #). In contrast, the overall trend for “past-year prevalence of marijuana use was 
4.1% (SE, 0.15) in 2001-2002 and 9.5% (SE, 0.27) in 2012-2013, a significant increase 
(P < .05)” (Hasin et al., 2015, p. #). An interesting finding that may prove relevant to this 
current study is that the highest rates of marijuana use was observed in states where 
marijuana has been legalized for medicinal purposes (NIDA-Monitoring the Future 
Survey, 2016). 
This quantitative study focused on the use of high potency marijuana and the 
association with mental health disorders as it pertains to state marijuana legality status 
after controlling for age, sex, and socioeconomic status. Since the legalization of 
marijuana, the level of THC has been rising in medical and recreational marijuana 
(Cabrera, 2016). Thus, the purpose of this study is to provide a better understanding of 
the relationship between highly potent marijuana use and the indicated variables—
depression and suicide ideation. The level of THC in marijuana has been increasing in 
potency since legalization began in 2012 (Cabrera, 2016). Since THC elicits the desired 
psychological effects most marijuana users seek, addressing this concern now is 
particularly important. Additionally, as of 2019, 33 states and the District of Columbia 
plus Guam and Puerto Rico have passed laws legalizing medical marijuana with 11 of 
these states and the District of Columbia also implementing recreational marijuana laws 
(Governing Data, 2019; Hartig & Geiger, 2018).  
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Literature Review Strategy 
Part of my strategy for this literature review included using the following search 
terms and/or phrases: marijuana; THC levels; mental health disorders; psychosis; 
substance use, abuse and misuse; marijuana and THC levels; THC levels and 
legalization; marijuana and mental health disorders; history of marijuana; health effects 
of marijuana; marijuana and psychosis; adolescents, young adults and marijuana; at risk 
behavior; personality traits; quasi-legalization; de facto legalization of marijuana; 
marijuana distribution and trafficking; methods of marijuana use; vaping; dabbing; and 
consumption of marijuana/cannabis-infused edibles. The search was limited to articles or 
text written in English from the following search engines or sources: Google and Google 
Scholar, Walden University library, ProQuest, SAGE Premier, Academic Premier 
database, MEDLINE, CINHAL Plus, and Science Direct Database. 
This literature review also includes a history of marijuana in the United States, 
which will cover drug scheduling or classification, consumption, and medicinal use. In 
addition, the literature review was organized to discuss the following topics: physical, 
psychological and pharmacological effects of marijuana; an understanding of mental 
health and psychosis; rising THC levels and improved growing techniques since 
legalization; increasing/Rising emergency room and hospitalizations post legalization and 
association with rising THC levels (pre- vs. post legalization comparisons); marijuana 
and employment in zero tolerance environments (post legalization); marijuana and public 
health; substance use versus abuse; trends in marijuana consumption; at risk groups (high 
usage groups & age ranges); implications of marijuana legalization; previous studies on 
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association between marijuana, mental health disorders and psychosis; and marijuana 
distribution and preference. 
History of Marijuana 
Understanding the history of marijuana is an important aspect of this study. Thus, 
human consumption and utilization of marijuana (cannabis) began around 10,000 BC 
during the Neolithic period or the “dawn of agriculture” (Lee, 2012, p. 3). These early 
people realized the versatility of this resource and cultivated marijuana making use of the 
entire plant for various purposes. For instance, Lee (2012) posited that the plant’s stem 
and stalk are rich in fiber and were utilized to make cords/rope and clothing; the seeds in 
addition to providing a source for continued cultivation were also eaten as this portion of 
the plant provided a source of protein and essential fatty acids; finally, the roots, leaves, 
and flowers were utilized for both medicinal and ritualistic purposes. While the plant is 
native to central Asia, knowledge of its multiple uses as a tough fiber and therapeutic 
agent gradually spread around the world. Thus, use of this plant or herb spread from its 
early origins in the Kush region of the Himalayan foothills across Eurasia into northern 
Europe and beyond (Lee, 2012). Documentation of marijuana for medicinal purposes 
occurred in 2008, when a gravesite in northwest China was discovered containing well 
preserved marijuana flower tops. These flower tops contained THC, the psychoactive and 
pharmacological agent of marijuana (Lee, 2012). The researchers concluded that this was 
a demonstration that the plant was being cultivated for its psychoactive properties nearly 
27 centuries ago (Lee, 2012). This determination is supported by Chinese history dating 
back to 2700 BC during the reign of Emperor Shen Nung, commonly called the father of 
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traditional Chinese medicine (Lee, 2012). During this period, marijuana was introduced 
as a drinking tea that was utilized for a host of ailments (Lee, 2012). According to Lee 
(2012), a few of these uses included “female weakness; gout; rheumatism; malaria; 
constipation; beri-beri, and absent-mindedness” (Lee, 2012, p.5). Thus, marijuana has a 
long-standing history with many uses among several cultures throughout the world.  
Marijuana in the United States 
In the United States, marijuana has experienced a controversial and highly 
debated path. For many years during the 1800s and early 1900s, marijuana had multiple 
medicinal uses in Western world medicine (Thomas, 2010). During this time, over 100 
articles were published in American and European medical journals enthusiastically 
praising the herb’s (marijuana) medicinal purposes (Thomas, 2010). In fact, in the United 
States marijuana was specifically recommended for several medical conditions and was 
prescribed on a regular basis until the late 1930s when the Marijuana Tax Act of 1937 
was enacted (Thomas, 2010). This action resulted in a tax on marijuana for both medical 
purposes ($1 per ounce) and recreational or other purposes ($100 per ounce) Thomas, 
2010). This tax act was viewed as deception by artful subterfuge in the form of a health 
care policy that required the completion of arduous and burdensome amounts of 
paperwork required to prescribe marijuana (Thomas, 2010). The process became so 
troublesome that physicians eventually stopped prescribing marijuana not long after the 
enactment of the Tax Act of 1937 (Thomas, 2010).  
Then in 1970, during the Nixon administration, the Controlled Substance Act 
(CSA) was signed into law (Thomas, 2010). This action placed regulated substances into 
38 
 
one of five categories or schedules based on the substances medicinal value, potential for 
abuse, and psychological and physical effects (Thomas, 2010). Marijuana was initially 
placed in the Schedule I category, which is the highest category and the only one that 
prohibits all use of the substance whether medicinal or recreational. Other drugs placed in 
a schedule I category include: “heroin; ecstasy; Lysergic acid diethylamide (LSD); (γ-
Hydroxybutyric acid) GHB; and peyote” (Thomas, 2010, para. 8). In contrast, the 
following substances were placed in a less restrictive Schedule II category, that allows 
medicinal use by prescription: “cocaine; codeine; OxyContin; and methamphetamine” 
(Thomas, 2010, para. 8). However, marijuana’s categorization as a Schedule I narcotic 
was intended to be temporary pending additional reconsideration based on an upcoming 
report from the National Commission on Marijuana and Drug Abuse (Thomas, 2010). 
This study group was comprised of members appointed and commissioned by President, 
Nixon. The group was in favor of decriminalizing marijuana for personal possession and 
private use as well non-profit private distribution of the substance in small amounts 
(Thomas, 2010). However, President Nixon was adamantly opposed to this decision. 
Ultimately the president’s opinion prevailed and to this day marijuana remains a 
Schedule I narcotic. Being classified as a Schedule I Narcotic means that the substance is 
not recognized as having any medical use in the United States (U.S. Department of 
Justice, 2017). It also means that the substance has a high abuse potential and cannot be 
used safely even under medical supervision (U.S. Department of Justice, 2017). Schedule 
I narcotics are considered the most dangerous and as a substance scheduling numeral 
increases, the less dangerous they are considered (U.S. Department of Justice, 2017). For 
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instance, substances classified as Schedule II Narcotics are considered less dangerous 
than those classified as a Schedule I Narcotic with drugs classified as Schedule V 
Narcotics being the least dangerous.  
Health Effects of Marijuana Use 
A current trend in attitude favoring marijuana use for medical and recreational 
purposes is growing. This is evidenced by reports indicating a decline in individuals who 
consider the occasional use (1-2 times per week) of marijuana as a perceived risk 
(Schuermeyer et al., 2014). For instance, in Colorado the percent of a those who believe 
marijuana use is a perceived risk declined from 45% to 31% between groups studied from 
2007 to 2008 and those studied from 2010 to 2011, respectively (Schuermeyer et al, 
2014). This trend was consistent for all age groups studied during these time frames. 
While medical marijuana was approved in Colorado in November 2000, it was not until 
2012 that residents of Colorado voted for Amendment 64 legalizing marijuana for 
recreational use as 55% of voters approved (Monte, Zane & Kennon, 2015).    
In light of this current trend in marijuana liberalization, it is important for policy 
makers, public health, and health care personnel to emphasize or reiterate the potential 
adverse effects of the substance. This is especially important given the rising THC levels 
seen in recreational marijuana and products produced from marijuana. It is also 
reasonable to assume that as legalization gains greater acceptance the use of marijuana 
will also increase and therefore so will the occurrence of adverse effects.  
The adverse effects of marijuana include a host of considerations. For instance, 
despite the notion that marijuana is not addictive, evidence to the contrary is widely 
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available and risk of dependence is based on several factors (Volkow, Baler, Compton, 
Weiss, 2014). This understanding is based on the dependence criteria outlined in the 
Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). The DSM-IV 
dependence criteria indicate that approximately nine percent or 1 out of 11 individuals 
who experiment with marijuana will become addicted (Volkow et al., 2014). In contrast, 
for those who begin using marijuana in adolescents, approximately 16% or one out of six 
will become addicted and the same is true for approximately 25 to 50% of those who 
smoke marijuana daily (Volkow et al., 2014). Thus, among other factors the risk of 
dependence is based on age of initial use and regularity of use. However, these criteria 
were presumably set prior to or does not take into consideration the rising THC content 
of marijuana. Hence, demonstrating support for this current study which intends to 
address this gap in the literature (rising THC levels). This presumption is further 
supported by NIDA which posited that  
Researchers do not yet know the full extent of the consequences when the body 
and brain (especially the developing brain) are exposed to high concentrations of 
THC or whether the recent increases in emergency department visits by people 
testing positive for marijuana are related to rising potency. (NIDA – Marijuana, 
2017, p. 16) 
 Addiction to marijuana is associated with the body’s endocannabinoid system of 
neurotransmitters within the brain. This system is concentration dependent such that large 
amounts of marijuana can result in reduced sensitivity of this system which causes an 
increased dependence on marijuana. (NIDA-Marijuana, 2017).  
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When someone smokes or ingest marijuana, there are effects on both cognitive 
and motor functions. These effects can range from impairments associated with memory 
and perception of time to impairments in coordination (Volkow et al., 2014). Regular use 
can have long term consequences that affect education and professional accomplishments 
as well as affect one’s social interaction (Volkow et al., 2014). These effects can be 
hazardous to the public as marijuana intoxication can affect one’s ability to drive and 
therefore operate machinery. This is evidenced by driving simulation studies which 
demonstrate a dose dependent relationship between blood THC concentration and an 
increased risk of getting involved in an accident while driving (Volkow et al., 2014). The 
statistical analysis presented in Volkow et al. (2014) indicated that  
Persons testing positive for THC (typical minimum level of detection, 1 ng per 
milliliter), and particularly those with higher blood levels, were 3 to 7 times as 
likely to be responsible for a motor-vehicle accident as persons who had not used 
drugs or alcohol before driving. (para. 12).  
Add summary and synthesis to fully integrate the quote into the paragraph and create a 
solid conclusion.  
Consequently, marijuana has promising clinical applications for treatment of 
various conditions. According to Volkow et al. (2014) the following conditions are 
receptive to treatment with marijuana or other form of cannabinoid: “Glaucoma, Nausea, 
AIDS – associated anorexia and wasting syndrome, Chronic pain, Inflammation, and 
Multiple sclerosis” (Volkow et al., 2014, para. 1-7). These are only a few of the 
medicinal uses of marijuana as the substance has shown to be beneficial for many more.  
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Marijuana Legalization and Potency 
Lab test reveal that the potency of marijuana in Colorado since legalization is 
more than twice as potent as illegal marijuana of the past ten years and some strains of 
legal marijuana is three times as potent (Briggs, 2015). Prior to legalization the levels of 
THC were typically below ten percent. However, research now indicates that the post 
legalization levels of Colorado’s marijuana averages around 18.7 % with some marijuana 
strains containing THC levels of 30% or more (Briggs. 2015). These results were 
provided by Charas Scientific, a Denver based lab licensed and hired by the state to test 
and measure the THC levels of marketable marijuana (Briggs, 2015).  
 Samples were also tested for the amount of cannabidiol (CBD), which is the 
component in marijuana with medicinal value. These samples averaged around 0.1 
percent CBD and many families have relocated to Colorado to obtain a strain of 
marijuana referred to as ‘Charlotte’s Web’, which reportedly can control seizures due to 
its CBD concentration (Briggs. 2015). Thus, while CBD has the potential to control 
depression, anxiety, and pain; a product with little CBD that has high THC levels could 
potentially exacerbate these conditions and may even increase seizures (Briggs, 2015).  
 In a related study, Sevigny, Pacula & Heaton (2014) addressed the potency of 
medical marijuana that has reportedly increased since legalization. This increase in 
potency is presumably due to less restrained regulations that created an environment of 
improved cultivation and production techniques (Sevigny, Pacula & Heaton, 2014). The 
researchers identify two marijuana markets, medical and recreational, indicating that 
these markets are interrelated such that cross over in technological advances for 
43 
 
production and cultivation occurs (Sevigny, Pacula & Heaton, 2014). The authors further 
posited that surplus medical marijuana is being diverted to the recreational market 
(Sevigny, Pacula & Heaton, 2014). In fact, this reported diversion of marijuana has been 
documented by the Denver area drug trafficking program. This agency implicates 
marijuana dispensaries, registered marijuana receiving patients and licensed caregivers as 
potential sources of medical marijuana diverted to the recreational market (Sevigny, 
Pacula & Heaton, 2014). In a related study Salomonsen-Sautel, et al. (2012) presented 
evidence that adolescents in two Denver substance abuse treatment programs used 
medical marijuana obtained from registered medical marijuana patients. Thus, the effects 
of producing high-potency medical marijuana potentially impacts the quality and 
availability of these highly potent marijuana strains to the recreational using market. 
  To address the effects of medical marijuana on potency, Sevigny, Pacula & 
Heaton, (2014) utilized data obtained from approximately 39,000 marijuana samples 
seized from all 50 states and the District of Columbia. The data was retrieved from the 
Mississippi’s Potency Monitoring Program (PMP) which measured and reported the THC 
content for all samples observed. The results of this study initially demonstrated a 
significant increase in marijuana THC content in jurisdictions that legalized marijuana for 
medical purposes (Sevigny, Pacula & Heaton, 2014). The study also completed four other 
models which gradually increased in sophistication with each model by the addition of 
control and other potentially competing variables (Sevigny, Pacula & Heaton, 2014). This 
sequential increase in model complexity or competitiveness resulted in a decrease in the 
effects on marijuana potency (Sevigny, Pacula & Heaton, 2014). For instance, while the 
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addition of observable control variables, such as states decriminalization status of 
marijuana, and state law enforcement policies, resulted in a slight reduction in model two. 
The relationship was still positive and statistically significant, approximately 1.5 
percentage points higher THC content. As oppose to the remaining three models which 
demonstrated results that were not statistically significant, approximately 0.5 percentage 
points higher THC content.     
This study is important to this study because it provides information relevant to 
the premise that marijuana acceptance, use, potency, and adverse effects have been on the 
rise. This is evident as the article presented by Sevigny, Pacula & Heaton (2014) 
referenced several studies that support the association between the rising THC levels in 
marijuana and a host of negative mental health consequences, such as psychosis and 
anxiety. 
In another study, Salomonsen-Saulel, et al. (2012) addressed the extent of medical 
marijuana use by the non-registered (non-patient) marijuana using population. This was 
achieved by assessing adolescents in substance abuse treatment programs to determine 
the extent of medical marijuana use among this group (Salomonsen-Saulel, et al. (2012). 
This sort of de facto legalization is believed to occur because of loopholes in the 
regulations that allows surplus medical marijuana to find its way into the hands of the 
non-patient recreational marijuana using population (Anderson & Rees, 2014). For 
instance, in Colorado medical marijuana caregivers can have up to two ounces of 
marijuana on-hand for distribution and three mature growing plants for each patient the 
caregiver supplies (Wirfs-Brock, Seaton, & Sutherland, 2010). The mature plants can 
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produce more than one pound of marijuana per plant and since there are roughly 100,000 
registered marijuana users in Colorado, that transpires into approximately 300,000 plants 
or 300,00 pounds (150 tons) of potential surplus marijuana. (Wirfs-Brock, Seaton, & 
Sutherland, 2010). In fact, the Colorado Department of Public Health and Environment 
estimates a 20 to 64-ton surplus and that’s if the plants only produce three to eight ounces 
per plant as oppose to the 16 ounces per pound max yield per plant (Wirfs-Brock, Seaton, 
& Sutherland, 2010). Most of which is surplus based on current Colorado regulations and 
therefore subject to diversion to the non-patient recreational using population. 
The study by Salomonsen-Saulel, et al. (2012) is based on the premise that 
legalizing marijuana for medical use promotes the perception that marijuana is safe for 
recreational use (Salomonsen-Saulel, et al., 2012). Thus, increasing acceptance and 
encouraging recreational use as the risk or the perception of harmful health consequences 
decreases (Salomonsen-Saulel, et al., 2012). This premise is in converse to those who 
would argue that medical marijuana laws have no effect on marijuana use. Nevertheless, 
studies have been conducted that support both positions (Salomonsen-Saulel, et al., 
2012).  
Participants for the study conducted by Salomonsen-Saulel, and colleagues 
consisted of 164 adolescents being treated at two substance abuse facilities in Denver 
Colorado (Salomonsen-Saulel, et al., 2012). Patients were referred to these facilities for 
treatment of ‘conduct and substance use disorder’ by one of the following: “social 
services, the juvenile justice system, primary care physicians, schools as well as self-
admitted participants” (Salomonsen-Saulel, et al., 2012, para. 14). The results of this 
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study demonstrated that, approximately 74% of the 164 adolescents in treatment had used 
medical marijuana obtained from registered medical marijuana patients (Salomonsen-
Saulel, et al., 2012). Thus, demonstrating a high rate and widespread pattern of medical 
marijuana use by the non-patient recreational using population. The results also revealed 
that the likelihood of medical marijuana use increased with decreasing age of onset of 
regular marijuana use (Salomonsen-Saulel, et al., 2012). Such that the younger 
participants began using marijuana the more likely they were to use medical marijuana. 
Additionally, while both the medical marijuana using and non-medical marijuana using 
groups were comprised of individuals with conduct disorder and substance use disorder. 
Salomonsen-Saulel (2012) reports a 16% increase in the likelihood of using medical 
marijuana corresponding to each additional symptom of conduct disorder; such that those 
who used medical marijuana had at least one more symptom of conduct disorder than 
those who did not use medical marijuana. Similar observations were made for 
participants with symptoms of substance abuse or dependence. In this instance, 
Salomonsen-Saulel (2012) reports a 31% increase in the likelihood of using medical 
marijuana corresponding to increasing symptoms of substance abuse or dependence.  
 Wen, Hockenberry, and Cummings (2015) conducted a related study entitled: The 
effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and 
other substances use of marijuana, alcohol, and other substances in ten states with 
medical marijuana laws. This article is relevant to the current study because it presents 
information pertaining to the implementation of medical marijuana laws (MMLs) and the 
availability of high potency marijuana. Wen, Hockenberry, and Cummings (2015) 
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posited that MMLs are intended to provide medicinal use of marijuana to a select group 
of patients. However, the potential for spillover also allows the availability of these 
typically highly potent marijuana strains to the non-patient or recreational using 
population (Wen, Hockenberry, & Cummings, 2015). The process of obtaining legal 
access in states with MMLs, usually involves obtaining a recommendation from a 
qualified physician for a condition considered eligible under state specific MMLs (Wen, 
Hockenberry, & Cummings, 2015). After which the patient can obtain a state issued 
identification card for medical marijuana use. The patient is then allowed to have a 
certain amount of marijuana and may also cultivate marijuana at home. (Wen, 
Hockenberry, & Cummings, 2015). Additionally, the patient can also purchase marijuana 
from nonprofit retail dispensaries, also called compassionate centers in some states 
(Wen, Hockenberry, & Cummings, 2015). This spillover effect which makes these highly 
potent strains available to the non-patient population occurs via one of the following four 
methods: 1) Patients present to physicians requesting medical marijuana for a complaint 
of chronic pain which is difficult to confirm or refute, thus, individuals can deceive 
doctors and obtain prescription MM; 2) Poorly defined eligibility criteria in some states 
fail to adequately distinguish between patient and non-patient populations as some states 
do not use a ‘registry/renewal’ process to re-assess and establish eligibility on a 
continuous basis; 3) As with prescription opioids, medical marijuana makes its way to the 
non-patient population through patients with marijuana prescriptions; and 4) spillover 
occurs because MMLs tend to support or encourage marijuana acceptance which in turn 
results in a reduced risk of association for recreational marijuana use in these states; thus, 
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in areas with MMLs individuals may be more willing to use or experiment with 
marijuana. (Wen, Hockenberry, & Cummings, 2015). Therefore, MMLs can result in a 
sort of de facto legalization through which medical marijuana with a high THC content is 
made available to the non-patient or recreational using population (Anderson & Rees, 
2014).  
 Wen, Hockenberry, and Cummings (2015) pooled cross-sectional data obtained 
between 2004 and 2012 from the National Survey on Drug Use and Health (NSDUH) to 
address the effect of MMLs on the use of marijuana, alcohol, and other hard drugs as well 
as pain medication misuse. This national and state represented survey is conducted 
among those 12 years of age and older and is considered an important source of 
information on substance use behavior within the non-institutionalized portion of this 
population (Wen, Hockenberry, & Cummings, 2015). The study used a self-administered 
audio computer-assisted self-interviewing (ACASI) method for interviewing because this 
approach is private and confidential and tends to promote honesty which is essential as 
substance use behavior is a sensitive subject (Wen, Hockenberry, & Cummings, 2015).  
 This study demonstrated that implementation of MMLs resulted in a parallel 
increase in past-month marijuana use among participants age 21 and older. These 
increases occurred immediately after MMLs were implemented and continued for three 
years after implementation. Conversely, this increase was not observed among 
participants aged 12 to 21. The relative increase was approximately 14% from baseline or 
1.32 percentage points for those age 21 and older (Wen, Hockenberry, & Cummings, 
2015). Bear in mind that the NSDUH data used by this study does not differentiate 
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between medical marijuana and non-medical marijuana populations. Nevertheless, among 
states with available data the registered medical marijuana using population comprised an 
average of 0.8 percent of the state population (Wen, Hockenberry, & Cummings, 2015). 
Thus, the results obtained is not entirely from registered marijuana users and tends to 
support the spillover effect of MMLs on the availability of highly potent marijuana to the 
recreational or self-medicating non-patient using population (Wen, Hockenberry, & 
Cummings, 2015). The results further demonstrate an increase in daily marijuana use 
among those age 21 and older while those aged 12-20 continued to demonstrate no 
increase in frequency of use in the past month (Wen, Hockenberry, & Cummings, 2015). 
However, for adolescents and young adults age 12 to 21 there was a 0.32 increase in 
percentage points for initiation or first-time marijuana use. This translates into a five 
percent increase in the probability of using marijuana for the first time among these 
participants (Wen, Hockenberry, & Cummings, 2015). These results were not consistent 
among those 21 and older as this group did not demonstrate an increase in first-time use 
with the implementation of MMLs (Wen, Hockenberry, & Cummings, 2015). 
 With respect to alcohol use, the results of this study indicated that MML 
implementation did not affect the total number of drinks consumed by those aged 21 and 
older (Wen, Hockenberry, & Cummings, 2015). However, the results further 
demonstrated a positive association between binge drinking and MML implementation 
which was observed as a 10% increase (effect size of 0.16) in the number of binge 
drinking days (Wen, Hockenberry, & Cummings, 2015). This observation was also 
demonstrated in concurrent use of marijuana and binge drinking in the past month for 
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adults aged 21 and older as the simultaneous use of these substances increased by 22 
percent or 1.44 percentage points with the implementation of MMLs (Wen, Hockenberry, 
& Cummings, 2015). In addition, there was an increase of 18% (0.82 percentage points) 
for the probability of using marijuana while drinking among those age 21 and older. 
However, these findings were not observed among the adolescent and young adult 
population age 12 to 20 years as no significant change in alcohol use was observed in this 
group with the implementation of MMLs (Wen, Hockenberry, & Cummings, 2015). 
 In addition, Wen, Hockenberry, & Cummings (2015) report a 10% increase in 
marijuana abuse/dependence among participants age 21 and older. Thus, indicating cause 
for public health concern as MMLs may have the potential to increase risk of progressing 
to marijuana abuse/dependence (Wen, Hockenberry, & Cummings, 2015). However, this 
finding was not consistent in either age group for alcohol abuse/dependence, non-medical 
use of prescription pain meds, and heroin or cocaine use as no increases was observed for 
these variables among adolescents and young adults or the adult population (Wen, 
Hockenberry, & Cummings, 2015). 
Effects of Marijuana Legalization and Lessons Learned from States with Legalized 
Marijuana 
 The long-term effects of marijuana legalization and trends in acceptance have yet 
to be demonstrated. Nevertheless, several studies have been conducted in an attempt to 
assess these effects. One of which conducted by the nonprofit organization known as 
Smart Approaches to Marijuana or SAM was recently released. This study entitled: 
Lessons Learned from Marijuana Legalization in Four U.S. States and D.C. presented 
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some interesting and disturbing findings. The authors of this study posited that “Today’s 
highly potent marijuana represents a growing and significant threat to public health and 
safety, a threat that is amplified by a new marijuana industry intent on profiting from 
heavy use” (Smart Approaches to Marijuana [SAM] 2018, p.3). The authors further 
posited that while the consequences of marijuana legalization will not be realized for 
decades, the results of this study present some disturbing early indicators of the potential 
effects. Thus, marijuana legalization is leading to increased availability of highly potent 
marijuana that public health professionals must address as the long-term effects of highly 
potent marijuana remains to be seen.  
SAM (2018) reports on trends demonstrated in the following five jurisdictions 
since legalization: Colorado; Washington; Oregon; Alaska; and the District of Colombia. 
Among the findings presented by SAM, includes a detailed report on the impact that 
marijuana legalization has had on the youth or adolescent population in these areas. SAM 
(2018) indicated that in the jurisdictions observed adolescents age 12-17 report an 
increase in past-month use of marijuana that continues to rise above the national average. 
In addition, states with marijuana legalization report an increase in marijuana use among 
young adults aged 18 to 25 (SAM, 2018). While Alaska and Oregon also report an 
increase in past-year marijuana use among adolescents (aged 12-17) and Colorado has 
seen a 65% increase in first-time marijuana use among adolescents (SAM, 2018). 
Colorado has also reported an increase in adolescent suicide victims testing positive for 
marijuana and approximately half of adolescents in outpatient treatment report using 
diverted medical marijuana (SAM, 2018).  
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Unfortunately, this is not the end of these disturbing trends as marijuana 
legalization has a multitude of effects on the community and health. For instance, in 
Washington and Oregon law enforcement has documented numerous incidents where 
licensed marijuana retailers were selling marijuana to minors. There has also been a rise 
in arrest for public consumption and distribution as in Washington, D.C. where arrest for 
these offenses nearly tripled. With a disproportionate number of arrests occurring among 
people of color in both D.C. and Colorado (SAM, 2018). In Colorado this racial 
discriminatory trend carries over into school related suspension for marijuana as schools 
with fewer children of color (25% or less) had fewer suspensions (313) when compared 
to schools that had more than 76% children of color which had 658 marijuana related 
suspensions (SAM, 2018). Marijuana legalization is also affecting the use and 
consumption of other drugs as alcohol consumption is not decreasing as some predicted. 
In fact, alcohol consumption is either not affected or increasing as Oregon State 
University reports that underaged (less than 21 years old) binge drinkers are among the 
primary groups of marijuana user’s post-legalization (SAM, 2018). In addition, according 
to the Institute for Behavior and Health, the percentage of marijuana users who are using 
opioids frequently has risen dramatically as peer-reviewed research has also 
demonstrated that the likelihood of opioid use more than doubles for those who began 
using marijuana in early in life (SAM, 2018; Secades-Villa, Garcia-Rodríguez, Jin, Wang 
& Blanco, 2015). SAM (2018) further posited that marijuana legalization in Colorado and 
Washington resulted in the development of a multibillion-dollar addiction-for-profit 
53 
 
industry. With the goal of this industry being to convert adolescents and young adults 
from casual marijuana users into more frequent heavy users (SAM, 2018).  
There is also growing concern to address the adverse health outcomes that can 
result because of increased legalization and acceptance of marijuana as a natural 
substance that is perceived as less harmful and healthier than alcohol and tobacco (SAM, 
2018). This trend continues as the perceived risk of harm associated with marijuana is 
decreasing with increased acceptance and legalization (SAM, 2018). In converse, these 
assumptions and attitudes couldn’t be further from the truth as research has demonstrated 
a direct association between the use of highly potent (higher THC) marijuana and 
increased frequency of marijuana use with the development of mental health conditions 
(SAM, 2018). Which may include conditions like psychosis, depression, anxiety, 
addiction and suicidal tendencies (SAM, 2018). There has also been links made between 
the use of highly potent legalized marijuana with the reshaping of brain matter, lung 
damage and cardiovascular complications like hypertension, heart attack, and stroke 
(SAM 2018). In addition, SAM (2018) also provides information supporting the gateway 
effect whereby marijuana use leads to a risk of progressing from marijuana to the use of 
other illicit. 
  The effects of marijuana policies are impactful and widespread as SAM (2018) 
further posited that in addition to having some of the highest rates of marijuana 
consumption in the country. According to SAM (2018) states with legalized marijuana 
also demonstrate the following trends: higher rates of marijuana-related driving fatalities; 
more marijuana-related emergency room visits, hospitalizations, and accidental 
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exposures; expansion of a lucrative criminal market; increases in marijuana-related 
crimes and juvenile offenses; and increases in workplace problems, including labor 
shortages and accidents as well as disproportionate legal impacts among communities of 
color and low-income populations.  
Regarding marijuana-related driving incidents and fatalities in Colorado between 
2013 and 2015 there was an 88% increase in the number of drivers charged with driving 
while intoxicated with marijuana and fatal car accidents associated with marijuana 
intoxication (SAM, 2018).  In addition, the National Highway Traffic and Safety 
Administration reports a 66% increase in the number of marijuana traffic deaths since 
legalization (SAM, 2018). This trend is common across states with marijuana legalization 
as Washington State reports that traffic deaths related to drugged driving has doubled 
since legalization (SAM, 2018). Driving under the influence of drugs (DUIDs) is on the 
rise across states with marijuana laws (SAM, 2018). For instance, Colorado has seen a 
76% increase in the number of DUIDs where marijuana was involved, and Oregon 
reports that in 2015, 50% of drivers tested positive for THC after being assessed by drug 
recognition experts (SAM, 2018).  
SAM, (2018) also indicated that marijuana-related emergency room visits, 
hospitalizations, and accidental exposures are also on the rise as a result of legalization 
(SAM, 2018). This is evidenced by reports from the poison controls centers in Colorado 
and Washington State that report increases of 210% and 70% respectfully, in the number 
of marijuana related calls received after legalization (SAM, 2018). Colorado also reports 
a 35% increase in the number of individuals seen in hospital emergency rooms (ER) for 
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marijuana-related events. And Central Oregon reports that marijuana-related ER visits 
increased by 200% as in January 2016 there were 434 marijuana-related ER visits, 
whereas prior to legalization ER visits for marijuana averaged around 32 visits per month 
(SAM, 2018).  
In addition, there has also been an increase in problems in the workplace as 
employer’s report problems with labor shortages and on the job accidents (SAM, 2018). 
For example, labor shortages may be associated with the increase in number of 
individuals testing positive for marijuana which is double the national average in both 
Washington and Colorado (2018). Employers are finding it difficult to find employees 
because so many people cannot pass the preemployment drug screen. In one instance, a 
Colorado construction company had to seek employees from out of state because too 
many local construction workers were failing the preemployment drug screening (SAM, 
2018). The drug screening problem has gotten to the point where during the three periods 
from 2013 to 2016 after legalization of recreational marijuana in Colorado and 
Washington, positive oral-fluid screening test for marijuana increased by about 75% and 
urine test for marijuana are now twice that of the national average (SAM, 2018). This is a 
serious concern as on the job accidents and therefore insurance claims are also a growing 
concern among employers and insurance companies in states where marijuana has been 
legalized (SAM, 2018). One study found that among marijuana users, work-related 
injuries and illnesses were 8.9% higher than non-users (SAM, 2018). Thus, companies in 
states with legalized marijuana are at risk of liability claims if marijuana use is tolerated 
or if they choose to eliminate or ignore drug screening (SAM, 2018). 
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SAM (2018) also showed that crime is on the rise in jurisdictions with legalized 
marijuana. In Colorado, since legalization took place, crime has increased at a rate that is 
11 times faster than states without marijuana legalization (SAM, 2018). The Colorado 
Bureau of Investigation (CBI) indicated that property crimes and violent crimes have 
increased by 8.3% and 18.6%, respectively (SAM, 2018). The increase in crime is 
reportedly associated with the distribution of marijuana dispensaries as the National 
Institute of Health demonstrated a correlation between the density of marijuana 
dispensaries and an increase in property crime in regions. Police in Boulder, Colorado 
also report an increase of 54% in citations for public consumption of marijuana post-
legalization (SAM, 2018). This disturbing trend holds true across legalized states as 
Alaska also reports an increase in misdemeanors and vehicle thefts since legalization. 
Prior to legalization, Alaska was ranked nationally as 16th for larceny and motor vehicle 
theft. However, post-legalization statistics has Alaska ranked second and fifth nationally 
for larceny and motor vehicle theft, respectively (SAM, 2018). In contrast, prior to 
legalization Oregon was ranked nationally as 12th for larceny, 13th for motor vehicle theft 
and 17th for property crime However, after legalization statistics has Oregon ranked 7th 
for larceny, 8th for motor vehicle theft and 11th for property crime (SAM, 2018).  
In addition, the Black Market is also thriving and prospering in the wake of 
marijuana legalization as legalization is not only affecting the population within the state 
wherein marijuana is legalized but also effects adjacent states and other states throughout 
the country (SAM, 2018). For instance, SAM (2018) reports that Colorado has seen a 
50% increase in the number of illegal marijuana growers across the rural areas within the 
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state and in 2016 law enforcement officers seized around 7,116 pounds of marijuana and 
made 252 felony arrest. There were also 346 highway trafficking interdictions wherein 
marijuana seized was destined for one of 36 other states in the U.S. (SAM, 2018). Black 
market activity is also affecting the mail system in the United States as there has been an 
844% increase in the number of marijuana seizures since legalization. The situation has 
gotten so extreme that the U.S. Attorney in Oregon stated that “Oregon has a massive 
marijuana overproduction problem” (SAM, 2018, p.22). This comment was made in 
response to seizures in 2017 which amounted to “2,644 pounds of marijuana in outbound 
parcels and over 1.2 million dollars in cash” (SAM, 2018, p.22).  
The claims by SAM (2018) about the effects of marijuana legalization on adjacent 
and other states throughout the nation are supported by other articles and researchers. For 
instance, in an article entitled: The Cross-Border Spillover Effects of Recreational 
Marijuana Legalization by Hao & Cowan (2017) explored this effect on counites in states 
bordering states with Recreation Marijuana Legalization (RML), compared to non-border 
counties in these states. This study focused on Colorado and Washington as these were 
the first two states to pass laws allowing for the use of recreational marijuana (Hao & 
Cowan, 2017). The effects of RML in Colorado was observed in bordering counties of 
the following six states: Wyoming; Utah; New Mexico; Oklahoma; Kansas; and 
Nebraska (Hao & Cowan, 2017). And in Washington, the researchers observed effects of 
RML on bordering counties in Idaho and Oregon (Hao & Cowan, 2017).  
Hao & Cowan (2017) posited that RML may lead to positive fiscal impacts as 
demonstrated in Washington state which collected approximately $186 million in tax 
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revenue generated from the sale of legal recreational marijuana in 2016. RML is also 
expected to generate savings due to reduced cost in law enforcement and the criminal 
justice system which will not be investigating and prosecuting certain crimes related to 
the possession and use of marijuana (Hao & Cowan, 2017). However, RML has the 
potential for negative and detrimental effects on bordering states as marijuana purchased 
and possessed legally in states with RML could increase arrest and convictions for 
marijuana possession and marijuana-related crimes in these neighboring regions (Hao & 
Cowan, 2017). Thus, contributing to an increased burden on law enforcement and the 
criminal justice system. In fact, while the Supreme Court denied the lawsuit. Nebraska 
and Oklahoma, which border Colorado did initiate a lawsuit against Colorado, 
maintaining that legalization of marijuana in Colorado contributed to an increased 
financial burden on law enforcement for marijuana-related crimes and other social cost 
within their state (Hao & Cowan, 2017). This was a sharp increase in arrest for marijuana 
possession as states that shared a physical border saw an increase of 30% for this offense 
(Hao & Cowan, 2017).  
The study by Hao & Cowan (2017), revealed a statistically significant increase in 
arrests for marijuana possession in counties that border regions of Colorado and 
Washington relative to counties that did not border these states. This observation was 
only seen among the adult populations within these regions as RML did appear to impact 
arrests of juveniles for possession of marijuana (Hao & Cowan, 2017). The researchers 
also found that these findings were consistent with previous studies on MMLs 
demonstrating that MMLs do not lead to increased consumption of marijuana by 
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teenagers (Hao & Cowan, 2017). The study further revealed that RML did not have a 
statistically significant effect on arrest for the following: the sale and/or manufacture of 
marijuana; DUIs; or possession of opium/cocaine (Hao & Cowan, 2017). Hao & Cowan 
(2017) recommend that states considering RML, also consider the potential regional and 
national impact as the costs and benefits of these decisions should include the 
consequences of the spillover effect on states without RML. 
 In another study, Cerda, et al., (2012) addressed the association between state-
level medical marijuana legalization and marijuana use, abuse, and dependence. Cerda, et 
al., (2012) acknowledges that individual behaviors are not only influenced by the 
perceived cost and benefits of an individuals’ actions but also by the approval or 
disapproval of society. This study is based on the premise that earlier studies on norms 
that predict marijuana use do not provide information of group-level norms that also 
likely influence individual behavior (Cerda, et al., 2012). These group norms are 
essentially group level acceptance or approval of a particular behavior. Such that 
individuals in regions where marijuana is received with societal or group level approving 
norms have a greater likelihood of using marijuana (Cerda, et al., 2012). The study also 
considers societal norms that may influence behavior independent of individual beliefs as 
well as policies and program interventions aimed at societal norms that have a much 
broader effect than individual interventions (Cerda, et al., 2012). Therefore, with respect 
to marijuana, the implementation of state-level MMLs can be considered an indication of 
group-level approval of marijuana use (Cerda, et a., 2012). Thus, implementation of 
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MMLs can viewed as an indicator of societal-level norms for marijuana acceptance 
because public opinion influences decisions on marijuana policies (Cerda, et al., 2012).  
 Cerda, et al., (2012) addressed the following three research questions: (1) did 
states that legalized medical marijuana by 2004 exhibit higher rates of past-year 
marijuana use and abuse/dependence in 2004-2005 than states that did not legalize it?; (2) 
were individuals living in states that legalized medical marijuana at higher risk for 
marijuana use, abuse and dependence in the past year than individuals who live in states 
that did not legalize medical marijuana?; and (3) among marijuana users, was residence 
in a state that legalized medical marijuana associated with increased risk for meeting 
criteria for marijuana abuse and dependence?  
 The study utilized data for states that had implemented MMLs by 2004. These 
states were coded as exposed and included the following 10 states: Alaska; California; 
Colorado; Hawaii; Maine; Montana; Nevada; Oregon; Vermont; and Washington (Cerda, 
et al., 2012). And the remaining 40 states without MMLs by 2004 were coded 
(designated) as unexposed (Cerda, et al., 2012). Participant data was obtained using 
secondary data from the following two surveys: 1) the National Epidemiologic Survey on 
Alcohol and Related Conditions (NESARC); and 2) National Survey on Drug Use and 
Health (NSDUH) (Cerda, et al., 2012). The NESARC served as the source for primary 
outcome data and is a national survey that used face-to-face surveying techniques to 
gather data on 43,093 participants (Cerda, et al., 2012). The participants were aged 18 
years and older living in the United States in homes or group quarters (Cerda, et al., 
2012). In contrast, the NSDUH served as the secondary data source and is also a national 
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survey that used self-reporting surveying techniques to gather data on approximately 
68,000 respondents (participants) (Cerda, et al., 2012). This study gathers data on U.S. 
residents 12 years and older living in households, non-institutional group quarters and 
civilians living on military bases (Cerda, et al., 2012). Participants were categorized into 
the following three age groups: 1) 12-17 years old; 2) 18-25 years old; and 3) 26 years 
old and older (Cerda, et al., 2012). However, for this study, the researchers used only 
those participants aged 18 years and older, yielding approximately 45,000 respondents 
for this studies sample from the NSDUH (Cerda, et al., 2012). 
 The results of this study for state-level marijuana use, abuse and dependence, 
demonstrated statistically significant differences between states with MMLs versus states 
without MMLs. For instance, based on NESARC data, in states with MMLs the average 
state-level prevalence of past-year marijuana use was higher (7.13%) than in states 
without MMLs (3.57%). In addition, according to NESARC data, the average state-level 
prevalence of marijuana abuse/dependence was also significantly higher in states with 
MMLs (2.61%) than in states without MMLs (1,27%). In contrast, NSDUH data also 
revealed that in states with MMLs the average state-level prevalence of past-year 
marijuana use was significantly higher (12.17%) than in states without MMLs (9.77%) 
(Cerda et al., 2012).  
 In addition, individual level results for odds of past-year marijuana use, abuse and 
dependence also yielded statistically significant results for states with MMLs versus 
states without MMLs (Cerda, et al., 2012). For instance, for individuals living in states 
with MMLs the odds of marijuana use in the past year were 1.92 times higher than 
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individuals living in states without MMLs (Cerda, et al., 2012). In addition, the odds of 
marijuana abuse/dependence were 1.81 times higher for individuals residing in states 
with MMLs versus individuals living in states without MMLs (Cerda, et al., 2012). 
 Cerda et al. (2012) conclude that the results of this study demonstrated that a 
causal relationship exist between MMLs and marijuana use and marijuana 
abuse/dependence. To understand and explain this relationship. Cerda et al. (2012) 
considers the following four mechanisms:  1) state-level community norms more 
supportive of marijuana use may contribute to the legalization of medical marijuana and 
to higher rates of marijuana use; 2) the enactment of medical marijuana laws could lead 
to a change in community attitudes on both medical and non-medical marijuana use, 
including reduced disapproval and perceived riskiness of use, which could subsequently 
influence marijuana use and abuse/dependence; 3) medical endorsement of marijuana for 
medical purposes encourages acceptance and use; and 4) which is related to the 
availability of marijuana, such that legalization of medical marijuana may lead to greater 
commercial promotion and availability of the substance for recreational purposes, which 
may contribute to greater illicit use of marijuana. 
 In another study, three years after Colorado legalized marijuana for recreational 
use the Colorado Department of Public Health Environment and The Colorado 
Department of Public Safety published an article to address the lessons learned from 
recreational legalization (Ghosh, Vigil, Maffey, Tolliver, Van Dyke, Kattari, Krug, Reed 
& Wolk, 2017). After legalized sales of recreational marijuana began in 2014, the 
Colorado department of public health developed a framework to monitor, address and 
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prevent or reduce harmful effects on the population (Ghosh et al., 2017). The article 
presented here is a testament to the lessons learned thus far. These lessons were divided 
into the following three broad categories: 1) lessons on health behaviors; 2) lessons on 
health outcomes; and 3) lessons on health policy (Ghosh, et al., 2017). Considering the 
importance of monitoring trends in marijuana use and identifying high risk 
subpopulations. Ghosh et al., (2017) stressed how essential it is for states with legal 
marijuana and those considering legalization to establish surveys or add marijuana 
questions to population-based surveys to monitor regional trends in marijuana use. 
Optimally, these surveys or questions should be implemented prior to changes in policies 
that effect marijuana legalization (Ghosh et al., 2017).  
 In retrospect, lessons learned on health behaviors, Ghosh et al (2017) present 
some interesting trends. The first lesson learned was that marijuana use did not appear to 
increase as a result of recreational legalization (Ghosh et al., 2017). This trend was 
demonstrated among the adult and youth populations as past 30-day use among adults did 
not change significantly between 2014 when use was observed at 13.6% and 2015 when 
adult 30-days use was recorded at 13.4% (Ghosh et al., 2017). In contrast, high school 
student marijuana use in the past 30-days and lifetime demonstrated no statistically 
significant change between 2013 (30-day use: 19.7%; lifetime: 36.9%) and 2015 (30-days 
use 21.2%; lifetime 38.0%) (Ghosh et al., 2017). However, there was a small but 
statistically significant decrease in youth perception of perceived risk of marijuana use as 
this value decreased from 54% in 2013 to 48% in 2015 (Ghosh et al., 2017). This 
observation may explain why the highest rates of use were seen among young adults 
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between the age of 18 to 25 years old with a rate of 26.1% and high school juniors and 
seniors with a rate of 26.3% and 27,8%, respectively. Thus, marijuana legalization while 
not apparently affecting marijuana use at this time, may well influence future use as 
youth decreased perception of perceived risk may have a significant impact on future 
population use. It was also learned that individuals who identified as gay, lesbian, or 
bisexual were far more likely than heterosexuals to use marijuana (Ghosh et al., 2017). 
This trend was true for all ages as adult marijuana use among those who identify as gay, 
lesbian or bisexual was 36.9% versus adult heterosexuals with a rate of 12.4% and youth 
rates for those identifying as gay, lesbian, or bisexual demonstrating a rate of use of 
34.9% versus 19.5%, for heterosexual youths (Ghosh et al., 2017).  
In addition, while there was lower marijuana use among Asians, there was not a 
significant difference in use by race/ethnicity. Ghosh et al., (2017) also report what was 
learned about methods of marijuana use, frequency as well as marijuana storage habits. 
For instance, among adults it was reported that the most common methods of use 
included: smoking (83.2%); eating (34.4%) and vaping (32.4%) (Ghosh et al., 2017). 
However, while the majority of both adult and youth users report smoking as the most 
common method, approximately half report using marijuana by multiple methods, such 
as vaping, eating and/or dabbing (Ghosh et al., 2017). Vaping is a method of use that 
involves using a vaporizing device to heat marijuana and the user inhales vaporized 
marijuana instead of smoke (Ghosh et al., 2017). Dabbing on the other hand is method 
that involves using solvents such as butane to create a highly concentrated form of 
marijuana which the user then heats and inhales the smoke (Ghosh et al., 2017). Lessons 
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on behavior also revealed that 7.4% of parents who use marijuana report storing 
marijuana and 73.4% of these parent’s report storing marijuana in locked containers 
(Ghosh et al., 2017). This is an important public health concern as the unintentional 
exposure of children 8 years old and younger increased by 63% during the first year of 
legalization (Ghosh et al., 2017).  
 To evaluate health outcomes, Ghosh et al., (2017) observed data related to 
hospital discharges codes for marijuana related conditions and Emergency Department 
(ED) visits. These observations revealed a 70% increase for hospitalizations related to 
marijuana between 2013 and 2015 (Ghosh et al., 2017). These observations also 
demonstrated an increase of 19% for ED visits related to marijuana use (Ghosh et al., 
2017). However, it is important to mention that the observations for marijuana related ED 
and hospitalizations were significantly lower than alcohol as ED visits was approximately 
five times higher than marijuana and hospitalizations for alcohol was almost three times 
higher (Ghosh et al., 2017). Post-legalization observations also revealed an increase in 
calls to the Poison center for adult marijuana exposure (Ghosh et al., 2017). However, 
unlike children eight years old and younger where exposure was usually accidental, adult 
exposure was usually intentional and was approximately evenly distributed for smoked 
and edible marijuana consumption (Ghosh et al., 2017). In addition, marijuana-related 
DUI’s increased by 16% post-legalization and driving fatalities associated with a positive 
marijuana test increased by 80% (Ghosh et al., 2017). 
 Regarding marijuana policy post-legalization, Colorado implemented the 
following policy changes: added marijuana to its Clean Indoor Act; established 
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childproof packaging requirements for edible marijuana products; strengthened safety 
regulations for edible products by establishing limitations for the maximum amount of 
THC in a single serving; set requirements for sticker packaging or labels to identify 
marijuana products with universal symbols; and established restrictions to 
eliminate/reduce packaging of products that entice children (Ghosh et al., 2017). In 
addition, Colorado policy decisions were informed by social marketing research that 
revealed varying attitudes for marijuana use exist between the English and Spanish 
speaking populations, between users and non-users, and between older and younger 
populations (Ghosh et al., 2017). This information was used to maximize and target the 
impact of public health messaging for a variety of audiences (Ghosh et al., 2017). 
Informative messaging not only focused on health concerns, but also on general 
marijuana law awareness (Ghosh et al., 2017). A final major policy lesson learned was 
associated with aligning medical and recreational regulations. For instance, varying 
regulations between medical and recreational marijuana have contributed to discrepancies 
in marijuana taxation, testing requirements and labeling/packaging (Ghosh et al., 2017).   
 Ghosh et al (2017) concludes that many lessons were learned from the Colorado 
experience and recommends that states with and those considering marijuana legalization 
should establish strong surveillance systems. This system should be established to 
monitor both health behaviors and outcomes (Ghosh et al., 2017). Another key 
component should include a health policy approach that is adaptable to a rapidly 
changing and emerging environment (Ghosh et al., 2017). 
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 In yet another article entitled: “Marijuana Legalization: Impact on Physicians and 
Public Health” presents a review of marijuana legalization and the potential impact it 
may have on public health (Wilkinson et al., 2016). This article also presented a review 
of health conditions for which marijuana has been identified as a recognized treatment 
option (Wilkinson et al., 2016). Wilkinson et al (2016) posited that while the relationship 
between marijuana legalization and prevalence is not clear. There are still serious public 
health concerns that states should consider relevant, especially considering the continued 
widespread legalization of marijuana (Wilkinson et al., 2016). Some of these concerns 
include: the effects of acute marijuana intoxication on driving abilities; unintentional 
ingestion of marijuana products by children; the relationship between marijuana and 
opioid use; and whether there will be an increase in health problems related to marijuana 
use, such as dependence/addiction, psychosis, and pulmonary disorders (Wilkinson et al., 
2016). According to Wilkinson et al. (2016) in 2013 approximately 3.1 million 
Americans reported using marijuana in the last year and 8.1 million Americans reported 
using marijuana almost daily in the last month. Thus, addressing these concerns are 
essential given that marijuana is not only the most used illicit substance, but also gaining 
acceptance and the legalization trend continues as more states are considering legalizing 
marijuana for medical and/or recreational use (Wilkinson et al., 2016). Nevertheless, 
marijuana legalization remains a controversial topic as proponents persist that the 
positive aspects of marijuana legalization include the following: more stringent regulation 
and safer use of marijuana; more efficient use of law enforcement resources; a possible 
decline in the prevalence of marijuana use among adolescents; and a decline in the use of 
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“harder drugs” like cocaine and heroin (Wilkinson et al., 2016). In converse, opponents 
of marijuana legalization persist that adverse effects of legalization may include the 
following: an increase in marijuana use; and increases in health problems associated with 
marijuana use (Wilkinson et al., 2016). Thus, one of the primary arguments between 
advocates and opponents of marijuana legalization is the relationship between 
legalization and prevalence of use (Wilkinson et al. 2016). In general, according to 
Wilkinson et al. (2016), states with legalized marijuana tend to have higher rates of 
marijuana use than states without any form of marijuana legalization (Wilkinson et al. 
2016). However, Wilkinson et al. (2016) also points out that this was often the case prior 
to legalization. Thus, regional variances in acceptance and permissive attitudes that 
contribute to a decreased in perceived risk associated with marijuana use may be 
contributing factors of increased use in these states (Wilkinson et al. 2016). Another 
important public health concern is the prevalence of use among adolescents as this group 
may be more susceptible to the negative health consequences of marijuana as well as 
poor social outcomes (Wilkinson et al., 2016). These health consequences may include: 
increased susceptibility to addiction/dependence; psychosis and cognitive impairment 
(Wilkinson et al., 2016). While poor social outcomes may include: unemployment, lower 
income; and lower levels of life and relationship satisfaction (Wilkinson et al., 2016). 
These may well be warranted as previous research data has demonstrated a clear inverse 
relationship between marijuana use and the perceived risk of harm associated with 
marijuana use (Wilkinson et al., 2016). Such that as perceived risk decreases marijuana 
use increases (Wilkinson et al., 2016). 
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 Another public health concern is the diversion of legal medical and recreational 
marijuana from the adult population with legal access to adolescents or other individuals 
without legal access (Wilkinson, 2016). Support for this concern is demonstrated by a 
Colorado study of adolescents in outpatient treatment for substance-abuse (Wilkinson, 
2016). In which, approximately half of these adolescents reported using marijuana 
diverted from legal access (Wilkinson, 2016). In another study, the researchers 
discovered even higher rates of diversion as approximately 74% of adolescents 
participating in substance-abuse treatment reported using marijuana diverted from or 
intended for medical use (Wilkinson, 2016). This sort of de facto distribution of 
marijuana has contributed to the occurrence of unintentional ingestion of marijuana by 
children age nine or younger (Wilkinson, 2016). This evidenced by reports indicating that 
there were no such marijuana-related emergency room cases between 2005 to October 
2009 (Wilkinson, 2016). However, after October 2009 through 2011 there were 14 cases 
of unintentional marijuana ingestion by children nine years old or younger (Wilkinson, 
2016). This trend holds true across states where medical marijuana is legal as an analysis 
of national data of states with medical marijuana laws revealed that between 2005 to 
2011 there was a 30% annual rate of increase for unintentional ingestion of marijuana by 
children (≤ 9 yrs. old) (Wilkinson, 2016). In contrast, states without legalization 
demonstrated no change in the rates of unintentional ingestion by children (Wilkinson, 
2016). Another important concern is the association between marijuana and opioid use. 
Wilkinson et al. (2016) posited that while some evidence may indicate that marijuana 
and/or cannabinoids can be used to treat pain or discomfort. Thus, allowing opioid users 
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to taper off or reduce the amount of prescribed opioid they use to manage their condition. 
However, at the time of this study no clinical trials demonstrating that marijuana or 
cannabinoids could be used for this purpose (Wilkinson et al., 2016). In fact, marijuana 
use has traditionally been considered to contribute to an increase in opioid use 
(Wilkinson et al., 2016). In converse, a recent study demonstrated that MMLs may 
ultimately contribute to a decrease in opioid mortality when compared to estimates where 
these MMLs not been implemented (Wilkinson et al., 2016). However, Wilkinson et al 
(2016) indicates that “states with medical marijuana laws have higher rates of age-
adjusted opioid overdose mortality than do states without such laws”. Therefore, 
additional research is needed to further asses this relationship and determine if marijuana 
or its products will actually allow opioid patients to taper off or reduce the amount of 
prescribed opioid they use to manage their condition (Wilkinson et al., 2016, p. 459). 
 Additionally, while marijuana is still illegal at the federal level, there are several 
marijuana containing medications that have been approved by the Food and Drug 
Administration (FDA) for treatment of certain conditions (Wilkinson et al., 2016). These 
include: Dronabinol (Marinol®) approved for treatment of HIV/AIDS cachexia and 
chemotherapy induced nausea/vomiting; Nabilone (Cesamet®) for treatment of 
chemotherapy induced nausea/vomiting; and Nabiximols (Sativex®) approved in Canada 
and many European countries for spasticity in multiple sclerosis (Wilkinson et al., 2016).  
 Wilkinson et al (2016) ultimately concludes that given the ever-evolving legal 
landscape, growing social acceptance, and increasing potency of marijuana, more 
research is needed to ascertain the long-term effects of legalization on public health. 
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Literature Review on Marijuana and Mental Health Disorders 
 There is a growing body of evidence supporting the association between cannabis 
use and the development of psychotic or mental health disorders (Moore, et al., 2007). 
However, few studies have addressed this association since the rise in THC demonstrated 
post legalization. From a public health stance, addressing this concern is essential as 
individuals with marijuana use disorder are likely to continue use despite findings of 
clinically significant conditions such as mental health disorders (NIDA, 2016). For many 
years, substance abuse and substance dependence were considered two separate 
categories. However, in 2013 The Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5) was updated such that abuse, and dependence are classified under the category 
of substance use disorder (NIDA, 2016). In this case marijuana or cannabis use disorder 
 Volkow et al., (2014) posited that previous research has demonstrated that 
anxiety, depression, and psychosis are associated with regular marijuana use. However, 
causality is not well founded as addressing this association is hindered by confounders 
that also contribute to the development of these conditions (Volkow et al., 2014). For 
instance, individuals with a family history of schizophrenia and psychosis have a greater 
risk of developing these conditions (Volkow et al., 2014). In addition, heavy use of 
marijuana, highly potent marijuana and using   marijuana at an early age also exacerbate 
the occurrence of psychosis (Volkow et al., 2014). These findings provided additional 
support for the current study which intends to address the effects of marijuana 
legalization and the rising THC levels (increased drug potency) on mental health.  
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Volkow et al., (2014) indicated that in a predisposed individual the first psychotic 
episode can occur years sooner in the presence of marijuana use. The importance of 
addressing mental health concerns early in life is essential as the Substance Abuse and 
Mental Health Services Administration (2017) indicated that approximately half of adults 
with mental illness had signs and symptoms associated with their condition that began 
before age 14 and three-fourths of adult mental illness began before age 24 (SAMHSA, 
2017). Thus, addressing mental illness and factors such as marijuana use that may 
negatively impact, exacerbate or cause these conditions is a serious public health concern. 
This issue is especially concerning when considering current trends in attitude to toward 
marijuana and the rising THC levels exhibited post-legalization.  
 In a previous related study, Lev-Ran, et al. (2014), conducted a systematic review 
and meta-analysis of existing longitudinal studies to determine patterns of cannabis use 
that are associated with the development of depression. The authors of this study cited the 
following three reasons as cause for concern and justification for the study: 1) high 
cannabis use among adolescents and young adults; 2) the increasing potency of cannabis; 
and 3) the association between cannabis and mental illness (Lev-Ran, et al, 2014). 
 The researchers of the Lev-Ran study screened nearly 5000 peer-reviewed articles 
on marijuana use and the risk of developing depression. The criteria for depression was 
based on studies addressing major depressive disorder, dysthymia, or depressive 
symptoms. Ultimately, 57 studies were selected for the meta-analysis with 14 of these 
designated for quantitative analysis.  
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 Statistical analysis for this study used an odds ratio as measure of risk. Studies 
were pooled to determine the association or increased odds of developing depression with 
cannabis use versus controls (Lev-Ran et al., 2014). This procedure was followed for 
regular to moderate cannabis use and heavy cannabis use. The results demonstrated that 
regular or moderate marijuana users have an increased risk of developing depression 
when compared to those who do not use marijuana (Lev-Ran et al., 2014). In contrast, the 
greatest risk of developing depression was demonstrated by heavy marijuana users (Lev-
Ran et al., 2014). This is evidenced by an odds ratio of 1.17 for developing depression 
among regular or moderate marijuana users versus an odds ratio of 1.62 among heavy 
marijuana users (Lev-Ran et al., 2014).  
 Lev-Ran, et al. (2013) concluded that the risk of developing depressive disorders 
is increased by cannabis use, and this risk is more significant among heavy cannabis 
users and those with cannabis use disorder (CUD). Lev-Ran, et al. (2013) posited that the 
results of this study emphasize the importance of recognizing and addressing the potential 
risk of heavy cannabis use, especially among adolescents as this group has the highest 
rates of cannabis use.   
 These findings are supported by van Gastel et al. (2013) which also indicated that 
marijuana use has been associated with psychiatric symptoms and the risk is increased by 
regular or heavy marijuana use. In addition, according to van Gastel et al. (2013) the risk 
of developing depression is more pronounced in those who began using marijuana before 
age 16. Observations among young adolescent marijuana users typically included: 
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delinquent behavior; conduct disorder; attention problems; anxiety as well psychotic and 
depressive symptoms (van Gastel, 2013).  
Additionally, van Gastel, et al. (2013) further posited that among those who began 
using before the age of 16 the risk is more pronounced as increased rates of use among 
this group has resulted in an increase in the following: psychotic symptoms; adjustment 
problems; depression; crime and suicidal behavior; anxiety; externalizing behavior; 
attentional dysfunction; poor educational achievement and poor executive functioning.  
In the study by van Gastel, et al. (2013), the researchers conducted a population-
based analysis to determine whether cannabis use is associated with poor psychosocial 
functioning and therefore a risk factor for mental health problems in adolescents (van 
Gastel, et al., 2013). The sample population was select from Dutch secondary school 
children and included 5,179 girls and 5,145 boys ranging in age from 11 to 16 years 
(average age 13.9). A total of 10,324 participants who had completed a Public Health 
Service School Survey collecting information on demographics, substance use, school 
factors and stressful life events. Participants had also completed the Strengths and 
Difficulties Questionnaire (SQD) (van Gastel, et al., 2013). Researchers used an in-class 
computer-based assessment to gather data on psychosocial functioning, lifestyle and 
social environment, and perceived school safety (van Gastel, et al., 2013).  
Data analysis used the following measurements: psychosocial functioning; use of 
cannabis and other substances; sociodemographic factors; school variables; and stressful 
life events (van Gastel, et al., 2013). This information was obtained via the Strengths and 
Difficulties Questionnaire (SQD), which according to van Gastel, et al., (2013) is a self-
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reporting survey specifically designed for adolescents aged 11 to 16 years and intended to 
measure psychosocial adjustment and assess psychopathology. The SDQ reportedly has 
an accuracy as high as 91% for correctly predicting psychiatric diagnoses among 
adolescents (van Gastel, et al., 2013). Sociodemographic factors included the following 
four measures include: 1) age; 2) gender; 3) ethnicity; 4) level of education; and 4) 
household composition (refers to whether adolescent lived with both parents, just one 
parent or did not live with either parent) (van Gastel, et al., 2013). Additionally, having a 
parent that is mentally ill was considered as a genetic predisposition for mental health 
problems.  
While van Gastel, et al. (2013) indicated that there was no significant difference 
between groups with respect to age, gender, and ethnicity; the study ultimately concludes 
that cannabis use can be considered a “risk indicator for mental health problems in 
adolescents.” (van Gastel, et al., 2013). However, other confounding variables in the 
presence of cannabis use contribute to poor psychosocial functioning (van Gastel, et al., 
2013). Thus, cannabis use may serve as a “marker for adolescents at risk for mental 
health problems” (van Gastel, et al., 2013, para. 19).   
In yet another study, Medina et al. (2007) addressed the association between 
depression and marijuana use, decreasing white matter and hippocampal volumes in 
adolescents. Previous studies have demonstrated reductions in hippocampal volumes 
among adults with depression. Similarly, studies have demonstrated white matter 
reductions in adults with symptoms of depression and suicide ideation. These white 
matter reductions are revealed on brain magnetic resonance imaging (MRI) as 
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hyperintensities, which are lesions within brain white matter that results from the 
demyelination and degeneration of axons (Wardlaw, Hernandez, & Munoz-Maniega, 
2015). While these reductions were exhibited in depressed adults, this was not the case in 
depressed children and adolescents as these individuals typically displayed hippocampal 
and white matter volumes consistent with non-depressed (healthy) controls (Medina, 
Nagel, Park, McQueeny, & Tapert, 2007). This is of concern as addressing adolescent 
marijuana use is an important topic especially considering evidence indicating that 
marijuana is the most commonly used substance among high school students as 
approximately 42% of high school seniors admit to trying marijuana in their lifetime 
(Medina, Nagel, Park, McQueeny, & Tapert, 2007).  
The study conducted by Medina, Nagel, Park, McQueeny, and Tapert, (2007) 
focused on the following two goals: 1) the relationship between white matter and 
hippocampal volumes and depressive symptoms; and 2) whether marijuana use 
moderates the relationship between brain structure and depressive symptoms in a sample 
of 32 adolescents.  
In this study, participants were fluent English-speaking adolescents aged 16 to 18 
years with at least one parent or guardian available to give consent for those under age 18 
and provide a history for the participant (Medina, Nagel, Park, McQueeny, & Tapert, 
2007). The sample included 16 marijuana users and 16 non-drug users that were recruited 
from high schools, universities and through various ads (Medina, Nagel, Park, 
McQueeny, & Tapert, 2007). Marijuana users were excluded if they were considered 
heavy alcohol drinkers and if they used any substance other than marijuana, alcohol (in 
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moderation) or nicotine. The study also noted adolescent history, drug use and symptoms 
of depression with a parental interview conducted to corroborate information provided by 
their children  
The results of this study demonstrated an additive and interactive relationship 
between marijuana use and white matter volume for predicting depressive symptoms. 
However, it is not clear which came first as Medina et al., (2007) posited that “it remains 
difficult to determine whether abnormal neurodevelopment caused depression, or if 
depression interrupts developmental myelination” (para. 30). In contrast, this study did 
not demonstrate a significant association between hippocampal volume and depression. 
Nevertheless, this study demonstrated support for the hypothesized relationship between 
reductions in white matter volume, depression, and marijuana use (Medina, Nagel, Park, 
McQueeny, & Tapert, 2007). This is evident as the reductions in white matter was most 
prominent among marijuana users that also exhibited symptoms of depression (Medina, 
Nagel, Park, McQueeny, & Tapert, 2007).  
Marijuana and Psychosis  
 The notion that marijuana use may cause psychosis is not a new concept as 
several studies have demonstrated this association (Murray, Quigley, Quattrone, Englund 
& Di Forti, 2016). However, many of these previous studies were conducted prior to the 
legalization of marijuana and the concurrent increase in marijuana potency as the level of 
THC has been rising (Murray, Quigley, Quattrone, Englund & Di Forti, 2016). Therefore, 
the current study intended to address this gap in the research as the potential implications 
78 
 
of highly potent marijuana with elevated THC levels should be a major public health 
concern.  
In a related study, the researchers addressed the association between marijuana 
use, psychosis, and schizotypal personality disorder (Davis, Compton, Wang, Levin, & 
Blanco, 2013). While marijuana is the most commonly used as an illicit drug in the 
United States it is also the most commonly used substance among those with 
schizophrenia and there is a growing body evidence which suggest the substance may 
also increase the risk of developing schizophrenia (Davis, et al., 2013). However, Davis, 
et al. (2013) posited that marijuana use alone is insufficient to cause schizophrenia as a 
host of complex factors contribute to the development of this condition and marijuana 
may serve to exacerbate or promote the development of psychotic symptoms (Davis, et 
al., 2013). In order to examine the relationship between marijuana use and these 
psychotic symptoms, Davis (2013) and fellow researchers examined the association 
between marijuana use and schizotypal personality disorder (SPD). The primary 
difference between SPD and Schizophrenia is concerned with duration of signs and 
symptoms. In SPD these symptoms are transient and not as intense as those seen in 
schizophrenia (Mayo Clinic, 2017). 
 Participants for this study included 34,365 adults (aged 18 years and older) that 
were selected from those completing the National Epidemiologic Survey on Alcohol and 
Related Conditions (NESARC) (Davis, et al, 2013). This is a national survey that covered 
all 50 states and the District of Columbia. Diagnostic assessment for the study utilized the 
Alcohol Use Disorder and Associated Disabilities Interview Schedule, which is a 
79 
 
structured interview designed to assess mood, anxiety, psychotic, and personality 
disorders (Davis, et al., 2013). The DSM-IV was used to assess substance use disorder for 
marijuana and nine other drug classes. In addition to substance use disorder, respondents 
were also evaluated for drug-specific abuse and dependence for the selected substances 
(Davis, et al., 2013). Lifetime cannabis users were defined as those who used cannabis at 
least once in their lifetime. The study compared sex, age, and race of lifetime cannabis 
users and non-users and assessed the “percentage of participants with lifetime cannabis 
use, a diagnosis of lifetime schizophrenia or a psychotic illness or episode (SPIE), and 
Schizotypal Personality Disorder (SPD)” (Davis, et al., 2013, para. 15).  
The study used logistic regression to assess the association between the outcome 
variables psychosis and SPD and the following three predictor variables: 1) lifetime 
cannabis use; 2) lifetime cannabis abuse; and 3) lifetime cannabis dependence on 
psychosis (Davis, et al, 2013). This analysis provided the following results: for lifetime 
cannabis use “the association between cannabis use and psychosis was 1.27 (95% CI 1.03 
-1.57)” and for lifetime cannabis abuse the association was 1.79 (95% CI 1.35 – 2.38) 
and for lifetime cannabis dependence this association was 3.69 (95% CI 2.49 – 5.47) 
(Davis, et al., 2013). Thus, demonstrating a dose-dependent relationship between 
increasing cannabis use and psychosis. Similarly, the relationship between SPD and 
extent of cannabis use also demonstrated a dose-dependent relationship. As observations 
revealed an odds ratio (OR) of 2.02 for lifetime cannabis users; OR = 2.83 for lifetime 
cannabis abusers; and OR = 7.32 for lifetime cannabis dependence (Davis, et al, 2013).  
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The results of this population-based study demonstrated cannabis use as a possible risk 
factor for psychosis and SPD, and the risk increases with the extent of cannabis use in a 
dose-dependent fashion. Furthermore, Davis et al. (2013) posited that  
“the association between cannabis use and SPIE and SPD found in this study 
could be explained by three mechanisms: (1) Direct pharmacological effects of 
cannabis lead to psychosis or schizotypal traits; (2) Psychosis or schizotypal traits 
lead to cannabis use as a means for individuals to cope with these symptoms; or 
(3) Another associative factor influences both tendency toward psychosis or 
schizotypal traits and cannabis use” (Davis, et al., 2013, para. 19).  
 The study conducted by Davis, et al. (2013) is relevant to this current research 
effort as the results demonstrated a dose-dependent relationship between marijuana use 
and psychosis and schizotypal personality disorder. Thus, confirming the importance of 
addressing the effects of higher THC concentrations that would be expected to simulate a 
higher dose in this dose-dependent relationship. Therefore, these findings further support 
the gap in the research as one would expect an increased prevalence of psychosis and 
schizotypal personality disorder to coincide with rising THC levels. My study is intended 
to explore this hypothesis with respect to states legality status. In addition, data obtained 
for the study conducted by Davis et al. (2013) was collected between 2001 and 2002 for 
wave 1 and between 2004 and 2005 for wave 2 by which in either case was prior to the 
elevated THC levels in marijuana demonstrated post-legalization.  
 In another study, Moore et al. (2007) conducted a literature review to address the 
association between psychotic or affective mental health outcomes and cannabis use. The 
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authors of this study stressed the importance of addressing these concerns in adolescence 
as these individuals are particularly susceptible to environmental exposures, such 
cannabis use. Moore et al. (2007) further posited that while it is established that cannabis 
use can produce short-lived signs and symptoms associated with psychotic and affective 
mental health outcomes. The long-term or chronic effects are not clearly founded and 
present cause for greater public health concern. 
 In this review of the literature, only population-based longitudinal studies or case-
control studies with a longitudinal design were selected. For this study, the following 
conditions described psychosis: “schizophrenia, schizophreniform, schizoaffective, or 
psychotic disorders, non-affective or affective psychoses, psychosis not otherwise 
specified, psychotic symptoms, delusions, hallucinations, or thought disorder” (Moore, et 
al., 2007, para.10). In contrast, the following described affective health outcomes: 
“Affective, mood, or bipolar disorder, affective disorder not otherwise specified, 
depression, suicidal ideation or suicide attempts, anxiety, neurosis, and mania” (Moore, et 
al., 2007, para.10).  
 Overall, the results of this study demonstrated an increased incidence of psychosis 
among cannabis users wherein the rate of psychosis among regular to moderate cannabis 
users was approximately 40% (Moore et al., 2007). In contrast, these rates increased 
approximately 50-200% for heavy cannabis users as the relationship between psychosis 
and cannabis use exhibited a dose-response relationship (Moore, et al., 
2007). Furthermore, the concept that early age of cannabis use and development of 
psychosis is not necessarily associated with the sensitivity of younger individuals. But 
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more so with a cumulative exposure effect of cannabis (Moore, et al., 2007). The 
literature review conducted by Moore et al. (2007) also revealed that cannabis users were 
at greater risk for developing affective mental health outcomes. Such as, a psychotic 
illness.   
In a related study, Di Forti, et al. (2014) also addressed the association between 
the regular use of highly potent marijuana and the occurrence of psychosis. According to 
the researchers, marijuana users are subject to psychosis at an earlier age than non-users 
(Di Forti, et al., 2014). However, causality for this association is not fully understood (Di 
Forti, et al., 2014). Di Forte and colleagues posited that psychosis among marijuana users 
occurs approximately three years earlier than in non-users (Di Forti, et al., 2014). 
However, the researchers further posited that these results may not be generalizable as 
studies have demonstrated that males are subject to schizophrenia at an earlier age and 
are more susceptible to recreational drug use than females (Di Forti, et al., 2014). Thus, 
implicating gender as a potential confounding variable in previous studies (Di Forti, et 
al., 2014). Additionally, the association between psychosis and schizophrenia is relevant 
as the National Collaborating Centre for Mental Health (2014) indicates that “the term 
psychosis covers a set of related conditions, of which the commonest is schizophrenia, 
and includes schizoaffective disorder, schizophreniform disorder, delusional disorder and 
the so-called non-affective psychoses” (National Collaborating Centre for Mental Health 
[NCCMH], 2014, para.1). Nevertheless, causality for this association has been described 
by various theories. One of which suggest that the under-developed brain of an 
adolescent is more susceptible to marijuana’s adverse effects (Di Forti, et al., 2014). 
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While another theory describes the amount of time one uses marijuana as the cause of 
psychosis at an earlier age than non-users or less frequent users (Di Forti, et al., 2014). 
 Based on this understanding, Di Forte (Di Forti, et al., 2014). and colleagues 
aimed to assess whether psychosis at an early age is more associated with being male 
versus a specific pattern of marijuana use (Di Forti, et al., 2014). To accomplish this aim, 
in addition to gender, Di Forte et al. (2014) also addressed the following patterns of 
marijuana use: 1) how often individuals used marijuana; 2) the potency (‘low potency 
hash-type versus high potency skunk-type’) of marijuana used 3) whether an individual 
used marijuana or not and 4) for marijuana users the age that these individuals first began 
using marijuana. This study is particularly relevant to the current study because it 
addresses the effects of highly potent marijuana such as the Skunk type described here 
with an approximate THC level of 16% versus low potency marijuana (hash-type) with 
an approximate THC content of four percent (Di Forti et al., 2014).  
 Participants for this study ranged in age from 18 to 65 years and were selected 
from patients admitted to one of two mental health facilities in the United Kingdom with 
a diagnosis of either non-affective or affective psychosis (Di Forte, et al., 2014). This 
study had varying results. For instance, with respect to gender, the study demonstrated 
that both male and female marijuana users had a greater likelihood of psychosis at earlier 
age than non-marijuana users. However, while male users demonstrated an earlier age of 
psychosis than females with similar marijuana using patterns. This observation was not 
considered statistically significant (P=.28) for the association between gender and 
marijuana use according to the results of the regression analysis conducted (Di Forte, et 
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al., 2014). In contrast, individuals who used highly potent marijuana and those who used 
marijuana daily had an earlier onset of psychosis than those who used lower potency 
marijuana and those who used marijuana less than daily, respectfully (Di Forte, et al., 
2014). The study also revealed that individuals who began using marijuana at an earlier 
age (less than 15 years old) experienced their first psychotic episode at an earlier age (Di 
Forte, et al., 2014). Ultimately, daily marijuana users that preferred highly potent 
marijuana had the greatest risk of early psychosis (Di Forte, et al., 2014). This group on 
average experienced a psychotic episode approximately 6 years earlier than those who 
did not use marijuana (Di Forte, et al., 2014). 
The Endocannabinoid System 
The identification of THC as the psychoactive component in marijuana ultimately 
led to the discovery of an endogenous endocannabinoid system that is involved in a range 
of biological functions. The endocannabinoid system is comprised of cannabinoid 
receptors; endogenous cannabinoids; and enzymes involved in their regulation as well as 
an endocannabinoid receptor (Shonesy, 2014). The system is located in the central and 
peripheral nervous system (CNS & PNS) and mediated by two cannabinoid receptors 
referred to as CB1 & CB2 (Shonesy et al., 2014). CB1 receptors are primarily located in 
the CNS while CB2 receptors are located peripherally (Vinod and Hungund, 2006). 
However, recent evidence suggests that CB2 receptors are also located in the CNS 
(Vinod and Hungund, 2006). These receptors respond to both endogenous and exogenous 
stimulation (Shonesy et al., 2014). Natural endogenous stimulation of CB1 receptors 
occurs through one of two THC-like molecules, anandamide (AEA) and 2-
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arachidonoylglycerol (2-AG) (Shonesy et al., 2014). According to Shonesy (2014) this 
system “is heavily implicated in the modulation of anxiety and depression”. The THC in 
marijuana is capable of binding CB1 receptors of the system and affects mood (Shonesy 
et al., 2014). Such that reduced stimulation of these receptors results in mood 
destabilization and increased feelings of anxiety and depression (para. 1). Thus, 
marijuana users who suffer from these conditions may not be able to synthesize enough 
of THC-like molecules (particularly 2-AG) so they self-medicate with marijuana to 
compensate. Suggesting the potential for treatment regimens that focus on the 
endocannabinoid system and ligands that bind to its receptors (Shonesy et al., 2014). 
Finally, Shonesy, et al., (2014) posit that the data presented may well lend support 
for an endocannabinoid deficiency type state that can contribute to the development of 
anxiety and depression and therefore encourage the use of cannabis in an attempt to 
counter these effects. Shonesy et al., (2014) further posited that evidence demonstrating 
that restoration of the 2-AG signaling system can reverse the symptoms of anxiety and 
depression brought on by the endocannabinoid deficiency lends support for therapeutic 
approaches that target the ECS.  
In a related article, Vinod and Hungund (2006) provided support for a possible 
role of the endocannabinoid system (ECS) in depression, suicide, mood disorders and 
substance use disorders. This article presented a review of the literature on the role of the 
ECS. The authors explain that CB2 receptors are associated with the immune system and 
located peripherally (Vinod and Hungund, 2006). While CB1 receptors are located 
primarily in the CNS. More specifically, within the CNS CB1 receptors are most 
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abundant in the cortex, hippocampus, cerebellum, and basal ganglia (Vinod and 
Hungund, 2006). The authors further explained that depression and suicide are associated 
with alterations in the prefrontal region of the cortex (Vinod and Hungund, 2006). Such 
that alterations in glucose metabolism in this region has been implicated in the 
development of depression (Vinod and Hungund, 2006). In addition, depression is also 
associated with reduced activity and volume of the prefrontal cortex as well as injuries to 
this region are commonly observed in depressed patients (Vinod and Hungund, 2006). 
There are also possible implications of the prefrontal cortex in behavioral inhibition, 
decision making, and the expression of emotions (Vinod and Hungund, 2006).  
As previously indicated, the endogenous endocannabinoids (ECs), anandamide 
(AEA) and 2-arachidonoylglycerol (2-AG) are lipid mediators that act on cannabinoid 
(CB) receptors of the endocannabinoid system (Vinod and Hungund, 2006). These ECs 
are found in greatest abundance in the cerebral cortex, basal ganglia, and limbic 
structures (Vinod and Hungund, 2006). Post-mortem studies have demonstrated that 
depressed suicide patients have higher than normal levels of CB1 receptors in the pre-
fontal cortex and also demonstrate increased activation of these G-protein linked 
receptors (Vinod and Hungund, 2006). Studies have also implicated an association 
between cannabis use, mood alteration and the endocannabinoid system in the 
development of schizophrenia (Vinod and Hungund, 2006). This premise is supported by 
postmortem studies demonstrating high than normal CB1 receptors in schizophrenics 
(Vinod and Hungund, 2006). In addition, animal studies on the mechanism of action of 
antidepressant medications indicate a possible role of CB1 receptors. For instance, 
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administration of Fluoxetine, an antidepressant that acts by increasing 5-
hydroxytryptamine (5-HT) also known as Serotonin, a neurotransmitter that is associated 
with depression and suicide (Vinod and Hungund, 2006; Serra & Fratta, 2007). Animal 
studies have demonstrated that the rise in 5-HT caused by fluoxetine, in turn causes a 
decrease in CB1 receptors. Thus, suggesting a possible function of the endocannabinoid 
system CB1 receptors in the regulation of mood disorders (i.e. depression), cognition, 
motivation and emotional behavior (Vinod and Hungund, 2006).  
In yet another study, Serra & Fratta (2007) presented a synthesis of the literature 
on available studies that address the association between the endocannabinoid system and 
the development of depression. Serra & Fratta (2007) present current hypotheses that 
attempted to explain the neurobiology behind the development of depression. One of 
which is the monoamine hypothesis of depression. Which posited that the development of 
depression is caused by reduced monoaminergic transmission (Serra & Fratta, 2007). 
More specifically, reduced action of neurotransmitters like noradrenaline (NA) and 
serotonin (5HT) are associated with the depression (Serra & Fratta, 2007). This premise 
has led to the development of antidepressant drugs such as selective serotonin reuptake 
inhibitors (SSRIs) and selective noradrenaline reuptake inhibitors (SNRIs) that increase 
the availability of 5HT and NE by inhibiting the reuptake of these substances (Serra & 
Fratta, 2007). Thereby increasing the levels of 5HT and NE at the synaptic cleft which is 
located between neurons where monoaminergic transmission (Serra & Fratta, 2007). 
Another hypothesis of depression implicates reduced hippocampal volume with the 
development of depression (Serra & Fratta, 2007). This hypothesis is supported by 
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clinical neuroimaging studies that demonstrate reduced hippocampal volume in untreated 
depressed patients versus no reduction in hippocampal volume in patients treated with 
antidepressants (Serra & Fratta, 2007). These results suggested that long-term treatment 
with antidepressants, such as SSRIs & SNRIs in conjunction with electroconvulsive 
therapy (ECT) can lead to cell proliferation and neurogenesis resulting in an 
antidepressant effect (Serra & Fratta, 2007).  
Regulation or control of the endogenous endocannabinoids, anandamide (AEA) 
and 2-arachidonoylglycerol (2-AG) occurs via degradation that utilizes one of two 
enzymes (Serra & Fratta, 2007). Whereby the enzymes fatty acid amide hydrolase 
(FAAH) and monoacylglyceride lipase (MAGL) degrade and remove the activity of 
anandamide (AEA) and 2-arachidonoylglycerol (2-AG), respectively. Thus, studies 
addressing the effects of endocannabinoid system (ECS) on depression can proceed by 
inhibiting the activity of these enzymes (Serra & Fratta, 2007). In addition, studies of this 
system can also be conducted using substances that act as either agonist or antagonist of 
CB1 receptors (Serra & Fratta, 2007). For instance, an agonist of CB1 receptors would 
bind to and increase activity of this receptor. Whereas an antagonist would block or 
reduce the activity of CB1 receptors (Serra & Fratta, 2007). Therefore, an agonist of the 
ECS would be expected to increase antidepressant effects, thereby reducing symptoms of 
depression. Whereas, an antagonist would be expected to reduce or block the action 




Serra and Fratta (2007) present results from animal studies demonstrating that 
upon administration of either a re-uptake inhibitor, CB1 receptor agonist, or a 
competitive inhibitor of FAAH (all of which increase activity of CB1 receptors) results in 
an antidepressant like effect. These results support the notion that the ECS plays an 
important role in the development of depression. In contrast, the action of these 
substances is antagonized (blocked) by administration of a CB1 receptor blocker (Serra & 
Fratta, 2007). Thus, further supporting the role of the ECS in depression as stimulation of 
CB1 receptor results in antidepressant-like effect and blocking CB1 receptors reduces the 
antidepressant effects elicited by stimulation of these receptors (Serra & Fratta, 2007).   
In contrast, Serra and Fratta (2007) report on animal studies that utilize CB1 
knock out mice, which have been bred and manipulated to reduce or eliminate the 
presence of CB1 receptors. In this study researchers observed that CB1 knock out mice 
were more susceptible to developing depressive-like behavior (Serra & Fratta, 2007). 
These results provided additional support for the role of the ECS in the regulation of 
depression. 
In addition to depression, the ECS has also been implicated in the development of 
psychosis (Bioque et al., 2009). There are several hypotheses which exist to explain the 
development of psychosis. Among them include several demonstrating alterations in the 
immune system as a possible etiology (Bioque et al., 2009). It has been proposed that 
immune system involvement may include both the peripheral and central nervous system 
in this etiological explanation of psychosis (Bioque et al., 2009). As previously indicated, 
CB2 receptors of the ECS are primarily located in and associated with the peripheral 
90 
 
nervous system (PNS) (Vinod and Hungund, 2006). Bioque et al., (2009) conducted a 
study to assess the expression and involvement of components of endocannabinoid 
system in the development of first-episode psychosis (FEP) versus health controls. The 
employed multiple logistic regression to determine which components of the ECS have a 
potential role as either risk or protective factors in the development of FEP (Bioque et al., 
2009). This study also assessed possible alterations in the ECS due to prolonged heavy 
cannabis use (Bioque et al., 2009).” 
The ECS components identified and studied from peripheral blood mononuclear 
cells (PBMC) include: Protein expression of the cannabinoid receptor 2 (CB2), which is 
located the PNS and associated with immune system function (Bioque et al., 2009); 
Protein levels of N-acyl phosphatidylethanolamine (NAPE) and diacylglycerol lipase 
(DAGL), the main enzymes involved in the synthesis of regulatory endocannabinoids 
[i.e. anandamide (AEA) and 2-arachidonoylglycerol (2-AG)]; and Fatty acid amide 
hydrolase (FAAH) and monoacylglycerol lipase (MAGL) the main enzymes involved in 
the degradation, removal and therefore inactivation of regulatory enzymes of the ECS 
(Bisque et al., 2009).  
The researchers recruited 95 participants with FEP and 90 controls from among 
patients at Spanish university hospitals (Bisque et al., 2009). The results of this study 
revealed that individuals with FEP also had decreased expression of CB2 receptors 
suggesting reduced ECS activation as a possible contributor to FEP (Bisque, 2009). In 
addition, FEP patients also demonstrated decreased levels of NAPE and DAGL, the 
enzymes responsible for synthesizing the regulatory endocannabinoids, AEA and 2-AG 
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(Bisque, 2009). This suggest that reduced levels of these components may contribute to 
the development of FEP via reduced activity of the ECS (Bisque, 2009). In contrast, FEP 
individuals demonstrated an increased expression of FAAH and MAGL, the enzymes 
responsible for degrading and removing the activating/regulatory components of the ECS 
(Bisque, 2009). This implies that reduced activity of AEA and 2-AG led to reduced ECS 
function and increased risk of FEP (Bisque, 2009). Thus, CB2 receptor expression and 
the regulatory endocannabinoids may well serve as protective factors of the ECS, 
reducing the potential for the development of FEP (Bisque, 2009). While the degradation 
and removal enzymes, NAPE and DAG may serve as risk factors for FEP (Bisque, 2009). 
Finally, Bisque et al., (2009) suggest a potential role of heavy prolonged cannabis use in 
the etiology of FEP as these individuals demonstrated a large dysregulation of the ECS 
when compared to the healthy control group (Bisque et al., 2009).  
Therapeutic Effects of Marijuana on Mental Health 
While this literature review has focused on the causative nature of marijuana as 
the substance has been demonstrated to exacerbate or potentially cause psychosis, 
anxiety, and mental illnesses like depression and schizophrenia. However, ironically 
marijuana or more specifically its constituents has the potential to counteract these 
conditions. 
 Marijuana also known as Cannabis contains numerous Cannabinoids. Two of the 
most significant include Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD). 
According to Zuardi et al., (2006) these substances have a divergent pathway exhibiting 
properties that are opposite in nature. For instance, THC is reportedly responsible for the 
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psychoactive effects most recreational marijuana users seek. While CBD demonstrates 
the opposite effects as this cannabinoid has anti-psychotic activity (Zuardi et al., 2006).  
Zuardi et al. (2006) further posited that the cannabinoid, Delta-9-THC can cause 
anxiety and psychotic-like symptoms as demonstrated in healthy volunteers exposed to 
intravenous THC. Conversely, CBD does not produce these psychological effects (Zuardi 
et al., 2006). Studies assessing the interaction between CBD and THC demonstrated that 
CBD has anxiety reducing (anxiolytic) and anti-psychotic effects when co-administered 
with THC (Zuardi et al., 2006). Additional properties of CBD are associated with the 
following effects: hypnotic, anticonvulsive, neuroprotective, and hormonal (increased 
corticosterone and cortisol levels) (Zuardi et al., 2006). Thus, marijuana’s properties, 
effects, and potency can vary based on the ratio of THC and CBD, and this ratio can vary 
based on the particular strain of marijuana, the growing conditions, and other factors 
(Radhakrishnan, Wilkinson & D’Souza, 2014; Zuardi et al., 2006). Nevertheless, it is this 
researcher’s understanding that typically, as the amount of THC increases, the amount of 
CBD decreases and vice versa. This understanding is supported in a study by ElSohly et 
al. (2016) which concluded that  
“overall, the potency of illicit cannabis plant material has consistently risen over 
time since 1995 from approximately 4% in 1995 to approximately 12% in 2014. 
On the other hand, the CBD content has fallen on average from approximately 
0.28% in 2001 to <0.15% in 2014, resulting in a change in the ratio of THC to 
CBD from 14 times in 1995 to approximately 80 times in 2014” (ElSohly et al., 
2016, pg.613).  
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This observation provides further support to address the gap in the research 
created by highly potent marijuana as additional research is warranted to address the 
rising levels of THC demonstrated post-legalization.  
Individuals may unknowingly reduce the risk of psychosis by smoking marijuana 
that is high in CBD as evidenced in the study by Morgan & Curran (2008), wherein the 
researchers support the premise of opposing actions for THC (psychotomimetic) and 
CBD (antipsychotic; anxiolytic). Morgan & Curran (2008) examined hair samples of 
known drug users and non-drug users for the presence or absence of THC and CBD. The 
results of the hair samples identified the following four groups of individuals: 1) THC 
only; 2) THC and CBD; 3) CBD only; and 4) those with no cannabinoids. Among those 
identified as THC only, these individuals were included only if the hair sample contained 
the presence of Delta-9-THC-carboxylic acid in addition to the normal Delta-9-THC 
(Morgan & Curran, 2008). This is because the presence of Deltal-9-THC-carboxylic acid 
is indicative of actual marijuana use rather than secondary or passive exposure to the 
substance (Morgan & Curran, 2008). In addition, the CBD only group was excluded 
because this sample consisted of 8 individuals and too small for statistical analysis 
(Morgan & Curran, 2008). The final sample therefore included the following three 
groups: 1) THC only; 2) THC-CBD and 3) no cannabinoids (Morgan & Curran, 2008). 
The results of this study reveal that the THC only group was more prone to psychosis and 
unusual experiences (i.e. hallucinations and delusions) than both the no cannabinoid 
group and the THC-CBD group (Morgan & Curran, 2008). In addition, scores for 
delusional thinking was higher in the THC only group than in the no cannabinoid group 
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and the THC-CBD group (Morgan & Curran, 2008). However, this score was also higher 
in the THC-CBD group than in the no cannabinoid group (Morgan & Curran, 2008). 
Another interesting trend is lower scores for anhedonia in the THC-CBD group than in 
the THC only and no cannabinoid groups (Morgan & Curran, 2008). This observation 
may reflect some potential protective effects of CBD, as anhedonia is described as an 
inability to experience pleasure and this is one of the main symptoms associated with 
major depressive disorder, which is an important mental health issue (Brynie, 2009; 
Morgan & Curran, 2008).  
It is important to mention that the target population included ketamine users and 
this substance may have properties that could be confused with the mental health and 
psychotic-like conditions exhibited by THC in marijuana (Morgan & Curran, 2008; 
Davis, 2017). For example, ketamine is used recreationally for its hallucinogenic and 
dissociative properties (Davis, 2017). Thus, demonstrating a potential limitation of this 
study.  
 In yet another study, Morgan et al. (2012) further addressed the effects of 
THC/CBD ratios. In the previous study Morgan et al (2008) provided evidence indicating 
that individuals who smoked marijuana containing high or detectable levels of CBD were 
less prone to psychotic-like symptoms than individuals who smoked marijuana high in 
THC or no CBD. In this more recent study, Morgan et al. (2012) sought to determine if 
the potential protective effects of CBD extended beyond psychosis (psychotic-like 
symptoms). Thus, Morgan et al. (2012) addressed the effects of CBD on memory, 
depression, anxiety, and psychological well-being among marijuana users. In this study, 
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marijuana users were again placed into groups based on hair sample analysis. The results 
of this study demonstrated fewer psychosis-like symptoms in those with detectable levels 
of CBD than those without, and increased depression and anxiety among those with high 
levels of THC (Morgan et al., 2012). In addition, those with high THC levels had more 
problems with memory and recall than those with CBD detected (Morgan et al., 2012). 
Thus, while highly potent marijuana which has elevated THC levels may contribute to the 
development of mental health issues and psychosis (Morgan et al., 2012). This 
occurrence may be attenuated by marijuana with higher CBD/THC ratios as detectable 
levels of CBD may be protective in nature (Morgan et al., 2012).  
 In a related study, McGuire et al. (2017) addressed the potential antipsychotic 
properties of Cannabidiol (CBD) in the treatment of Schizophrenia (McGuire et al., 
2017). In this study, McGuire et al. (2007) added CBD to the existing treatment regimen 
of schizophrenia patients. The double-blind study randomly placed schizophrenia patients 
into two groups (McGuire et al., 2017). Group 1 or the treatment group received CBD as 
an adjunct to their existing treatment antipsychotic regimen. The control group received a 
placebo in addition to their regular antipsychotic medication (McGuire et al., 2017).  
 The study results demonstrated a reduction in positive psychotic symptoms 
among schizophrenic patients treated with CBD and their existing antipsychotic 
medication (McGuire et al., 2017). In addition, the evaluating clinicians report that the 
CBD group demonstrated reductions in disease severity, and general improvements in 
overall health and cognitive function (McGuire et al., 2017). A small percentage of 
patients in both the CBD and placebo groups report mild adverse effects with treatment. 
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However, most symptoms were mild and resoled without treatment (McGuire et al., 
2017). This is an important benefit as antipsychotic medications have been associated 
with adverse effects that can cause poor patient compliance resulting in less favorable 
health outcomes (McGuire et al., 2017). Another important aspect of this study is 
concerned with the mechanism of action associated with typical schizophrenia drugs. 
These drugs typically function through a dopamine receptor process (McGuire et al., 
2017). Therefore, CBD which does not use this mechanism of action may offer and 
alternative approach that can be used in conjunction with traditional drugs (McGuire et 
al., 2017).  
Marijuana Distribution and Preference 
 Since legalization began trends in marijuana potency, usage, distribution, 
preference and methods of use have also changed somewhat dramatically. For instance, 
during the period between the 1960s through the mid-1990s the THC content of 
marijuana ranged from 2 to 4%. Which is far less potent than marijuana used today as the 
THC content increased significantly by 212% between 1995 and 2015 (Stuyt, 2019). 
Such that by 2017 this sharp rise in THC concentration led to the availability of 
marijuana with THC levels ranging between 14 to 28 percent as found in Colorado 
dispensaries at that time (Stuyt, 2019). This dramatic rise in THC content is largely due 
to the unchecked growth and manipulation by the marijuana industry to produce far more 
potent strains of marijuana (Stuyt, 2019). The production of highly potent marijuana 
strains is advantageous to the marijuana industry as THC concentration is associated 
increased psychoactive effects, increased use and greater risk of addiction (Stuyt, 2019). 
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Ironically, this approach reflects a strategy employed by big tobacco companies. Which 
gradually developed and marketed tobacco products that were far more addictive, 
appealing and accepted (Richter & Sharon, 2014). These innovations led to changes in 
tobacco consumption from 1% among the American consumer in the 1880s to roughly 
half of the population using tobacco by the 1950s (Richter & Sharon, 2014).  
 As such, legalization has demonstrated a rise in marijuana use as according to 
Carroll (2018) “one in seven adults report using marijuana in 2017” with an overall use 
rate of 14.6 percent among adults in U.S. The portion of use also varies based on states 
legality status (para. 1). For instances, in states with no laws allowing marijuana use only 
12 percent of adult’s report using marijuana in the past year (Carroll, 2018). In contrast, 
in states with laws legalizing medical marijuana the rate of use for adults was 14 percent 
(Carroll, 2018). Whereas in states with recreational marijuana laws adult use in the past 
year rose to 20 percent (Carroll, 2018). Thus, the adult use of marijuana has doubled in 
the general population over the last decade according to reports in 2014. Indicating that 
13.3 percent of adults reported past-year marijuana use (Keyhani, et al., 2018). These 
statistics are the result of a national study reported in the Annals of Internal Medicine, 
entitled: Risks and Benefits of Marijuana Use: A National Survey of U.S. Adults 
(Keyhani, et al., 2018). In this study, Keyhani et al., (2018) used federal surveys, peer-
reviewed literature, and media reports to develop a comprehensive survey to gain a 
greater understanding of how adults in U.S. view marijuana. This national survey was not 
only designed to provide an understanding of opinions associated with marijuana 
acceptance and legalization. But also, to address topics such as: frequency of marijuana 
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use; reasons for using marijuana; as well as knowledge and behaviors associated with 
marijuana use (Keyhani, et al., 2018). In addition, specific areas of content included:  
“perceptions of specific risks and benefits of marijuana use, possible preventive 
health benefits of different methods of marijuana consumption (smoking, vaping, 
ingestion), addiction potential, safety of use during pregnancy, and societal effects 
(including secondhand smoke and driving under the influence)” (Keyhani, et al., 
2018, para 14).  
Finally, the survey addressed how adults view the use and effects of marijuana 
when compared to other legal drugs with abuse potential, such as tobacco and alcohol 
(Keyhani, et al., 2018).  
The results of this survey had surprising and widely varied results. Regarding 
perceived risks and benefits, the respondent’s results revealed that most adult in the U.S. 
(81%) believed that marijuana has at least one benefit with only 17% of respondents 
indicating that marijuana has no benefit (Keyhani, et al., 2018). The following is a list of 
perceived benefits identified and the percentage of respondents that believe marijuana is 
associated with those benefits. These include: 1) Pain management (65.7); 2) Treatment 
of disease (such as epilepsy or multiple sclerosis) (47.9%); 3) Relief of stress, anxiety, or 
depression (46.8%); 4) Improved appetite (35.1%); 5) Improved sleep (28.9%); 6) Help 
decreasing or stopping other medicines (23.3%); 7) Improved creativity (16.2%); 8) 
Improved focus or concentration (10.6%); 9) Increased energy (8.1%); and 10) Other 
benefit (5.1%) (Keyhani, et al., 2018). Regarding risk, the following is a list of the most 
common perceived risk identified by respondents: 1) Legal problems (51.8%); 2) 
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Addiction (50%); 3) Impaired memory (42%); Increased use of other drugs (37.4%); 
Personal or relationship problems (34.8%); Decrease in Intelligence (IQ) (28.6%); 
Decrease in energy (27.4%); New or worsening health problems (18%); Increase in 
stress, anxiety, or depression (15%); Disrupted sleep (11.3%).; and 8.8% of respondents 
believe marijuana use is without risk. However, most respondents (21.3%) indicated that 
addiction is the most important risk associated with marijuana use. The second most 
important risk identified was legal problems (20.7%) followed by an increased risk of 
using other drugs (18%) (Keyhani, et al., 2018). Nevertheless, based on the results 
identified it is evident that most adult respondents (81.1%) believe marijuana have some 
benefits whereas only 17% of respondents indicate that marijuana has no benefits. This 
finding is consistent with the growing trend in marijuana perception and acceptance as 
according to an article published by the Pew Research Center, approximately 62% of 
Americans believe marijuana should be legalized (Hartig & Geiger, 2018). Thus, 
reflecting a decrease in perceived risks associated with marijuana use. This belief and 
acceptance have increased steadily and relatively rapidly as in the year 2000 only 31% of 
Americans favored legalization (Hartig & Geiger, 2018). This finding is further 
evidenced by a national survey that indicates Americans perception of “great risk from 
weekly marijuana use dropped from 50.4% in 2002 to 33.3% in 2014” (Keyhani, et al., 
2018, para. 5). 
The results of Keyhani et al., (2018) also reveal that many Americans believe 
marijuana can reduce the risk of negative health outcomes. As 36.9% of U.S. adults 
surveyed believed to some degree that edible marijuana has some preventative health 
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benefits. Whereas, 61.9% of U.S. adults disagree with this notion (Keyhani, 2018). In 
contrast, 29.2% of respondents believe that smoking marijuana has some preventative 
health benefits with 69.8% of respondents disagreeing (Keyhani, 2018). Additionally, 
29.2% of respondents indicate that vaping marijuana has preventative health benefits 
while 69.6% disagreed to some degree (Keyhani, 2018). 
  All the same, while the most common method of use is still smoking as 12.9% 
report smoking as their preferred method of use (Carroll, 2018). There is growing 
preference for other methods of use that increase potency and duration of action as 6% of 
respondents prefer consumption of marijuana infused products (Carroll, 2018). Followed 
by vaping at 4.7% then use of marijuana concentrates 1.9%, and use of topical marijuana 
products 0.8% (Carroll, 2018). Thus, there is a growing preference among marijuana 
users for highly potent marijuana and marijuana products with higher THC levels, and 
methods of use that produce longer and more profound effects. 
In addition, when compared to other substances of use, misuse and abuse such as, 
tobacco and alcohol. Respondents generally believe marijuana is safer. For instance, 
more than one-third (37.3%) of adults surveyed believe that secondhand marijuana smoke 
is safer than secondhand tobacco smoke. Many respondents also believe secondhand 
marijuana smoke is completely safe for adults (18%) and children (7.6%). In addition, 
Keyhani et al., (2018) posited that 38.2% of respondents believe “that smoking 1 
marijuana joint a day is much safer or somewhat safer than smoking 1 cigarette a day”, 
and “about 13.5% agree that smoking 1 marijuana joint per day is safer than drinking 1 
glass of wine per day” (para. 18).  
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 Regardless of public perception, evidenced based research to substantiate the risk 
and benefits of marijuana is limited. Moreover, unlike tobacco and alcohol, the marketing 
of marijuana is relatively free of constraints (Keyhani, 2018). As public health leaders 
have yet to implement widespread accompanying messages to warn the public of the 
potential harms associated with marijuana use (Keyhani, 2018). With such unchecked 
promotion, growing acceptance and continued widespread legalization it is important 
now more than ever to emphasize these risks, and develop strategies and regulations to 
protect, warn and inform the public and future generations of the potential implications of 
continued widespread legalization and acceptance.  
Another growing concern in the wake of continued widespread legalization is 
trafficking and therefore distribution of legal marijuana. Which has been a concern since 
legalization began for recreational purpose in Colorado (Schwarz, 2017). This is 
evidenced by a lawsuit in which Nebraska and Oklahoma attempted to sue Colorado 
alleging that the state’s decision to legalize recreational marijuana is a violation of the 
U.S. constitution and places significant burden on bordering states’ law enforcement and 
legal systems (Schwarz, 2017). While the supreme court denied these challenges, the 
concern still exists as according to an article published by the Hazelden Betty Ford 
Foundation (HBFF) (2017),  
“Marijuana legalization efforts alter black market economics but are not effective 
in stopping black market sales. Perhaps due to poor regulation or supply chain 
issues, many young people I see from across the country talk about getting their 
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‘high quality’ marijuana and concentrates from ‘legitimate’ growers who liquidate 
their surplus at a heavily discounted price.” (para. 20)  
This premise is further evidenced by reports from California which indicated that 
the majority of marijuana produced within the state, approximately 85 to 90% is 
trafficked out to regions without laws legalizing marijuana (Fuller, 2019). In fact, the 
California Department of Food and Agriculture estimates that the state produces 
approximately 15.5 million pounds of marijuana annually and only consumes about 2.5 
million pounds within the state. This surplus marijuana is estimated at 13 times the total 
amount produced annually in Colorado (Fuller, 2019). Most of which is smuggled east 
across the Rocky Mountains and Mississippi into areas like Illinois, Connecticut and 
Washington, D.C. where this surplus marijuana can sale for as much as three times the 
original wholesale price (Fuller, 2019). Thus, highly potent marijuana produced and sold 
in states with medical and recreational laws is making its way into other areas without 
such laws (Fuller, 2019). While this trend in rising THC levels demonstrated nationally 
since legalization should be a growing concern. Another challenge for public health 
leaders is the methods of marijuana use as users and distributors are constantly finding 
new and innovative ways to use the substance (Keyhani, 2018). These methods have the 
potential to further enhance the effect of marijuana by increasing THC levels or duration 
of action. Dabbing, vaping, synthetic marijuana, shatter, and consumption of edible 
marijuana products are methods of use that have emerged to improve the psychoactive 
effects of marijuana (Keyhani, 2018; Murray, Quigley, Quattrone, Englund & Di Forti, 
2016). In states where marijuana has been legalized for medicinal and/or recreational 
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purposes these methods of use are growing in popularity and are increasingly widely 
available (Keyhani, 2018; Murray et al., 2016). Consumption of edible products and 
production of concentrated oils either increase duration of action and/or THC 
concentration (Murray et al, 2016). For instance, methods of extracting THC from the 
marijuana plant have been found to produce resin oils with a THC concentration as high 
as 80%. Additionally, other methods of use such as vaping and wax dabbing also deliver 
a high THC concentration to the user (Murray, et al., 2016).  
Dabbing is a method of marijuana use wherein the user smokes a highly potent 
marijuana extract commonly referred to as wax (Marijuana Factcheck-potency, 2019; 
Murray, et al., 2016). While dabbing or the use of butane hash oil is commonly 
considered a new method of marijuana use when in fact this method has been around 
since the 60s and may date back even further (Al-Zouabi, Stogner, Miller, Lane, 2018). 
During the Vietnam conflict (war) soldiers would use acetone or petrol to extract the 
THC in marijuana to create a liquid concentrate that could then be smeared on cigarettes, 
rolling papers or used to saturate tobacco prior to rolling or smoking by other means (Al-
Zouabi, et al., 2018). Nowadays marijuana users create THC concentrates using butane 
instead and therefore the resulting product is termed “butane hash oil” or BHO (Al-
Zouabi, et al., S2018). The concentrate produced is referred to by several names and the 
terminology typically describes the products consistency. For instance, other names of 
BHO, dabs and oils include: shatter; honeycomb; crumble wax; budder; and earwax (Al-
Zouabi, et al., 2018, para. 2). Among these shatter is considered the most difficult form to 
produce and appears as a clear amber solid (Stogner & Miller, 2015). Nevertheless, since 
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legalization of medical and recreational marijuana these extracts are becoming 
increasingly popular as evidenced by studies in the United States. For instance, Zhang, 
Zheng, Zeng, and Leischow (2016) conducted a case study in which the researchers 
tracked query searches on dabs or Dabbing of BHO concentrates in the United States 
from January 2004 to December 2015. The study revealed that dabbing searches 
increased with time to reach an estimated high of 1,526,280 searches on dabbing in 2015 
(Zhang, et al., 2016). In yet another study, Daniulaityte and colleagues (2015) conducted 
an analysis of “Twitter data on marijuana concentrates across the U.S.”. The results 
revealed that “dabs-related tweets were highest in states that allowed recreational and/or 
medicinal cannabis use and lowest in states that have not passed medical cannabis use 
laws” (Daniulaityte, et al., 2015, p. 307). Thus, resources and information are readily 
available as instructional videos on various websites, and social media platforms 
provided easy access for the recreational home users and producers (Stogner & Miller, 
2015). Reportedly these BHO concentrates can have THC levels that range as high as 80 
percent (Stogner & Miller, 2015). In one study conducted in Switzerland, researchers 
found that while the marijuana flowers being used had a THC level of 17% the BHO 
concentrate produced was as much as four times that with a THC concentration as high as 
71% (Cannabis Technology News, 2019).  
The BHO concentrate is commonly used by one of two methods, dabbing and/or 
vaping. Dabbing is a method that involves using conduction as the form of heating 
(Krauss, et al, 2015). In this process the user heats the dab (marijuana or BHO 
concentrate) to a high temperature using a torch on a conduction surface or hot plate 
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which is typically a nail. The user then inhales the vapor produced (Krauss, et al., 2015). 
Many marijuana users believe that dabbing is a cleaner method of using marijuana that is 
less harmful than smoking (Sandoiu, 2017). However, this may not be the case as 
discovered by Dr. Strongin and fellow researchers at the University of Portland. While 
simulating the conditions of dabbing in the lab and monitoring the composition of vapor 
produced (Sandoiu, 2017). They found that the butane hash oil produced relatively high 
levels of benzene, a known cancer-causing chemical as well as methacrolein. While 
methacrolein is generally considered a noxious irritant, another chemical acrolein which 
is similar in structure to methacrolein is also a known human carcinogen (Sandoiu, 2017). 
Dr. Strongin and colleagues posit that “Given the widespread legalization of cannabis in 
the [United States], it is imperative to study the full toxicology of its consumption to 
guide future policy” (Sandoiu, 2017, para. 17). 
In contrast, vaping and the use of e-cigarettes is growing in popular particularly 
among adolescents as according to one report “one in 11 middle and high school students 
report using an e-cigarette for marijuana, hash oil or wax” (Marijuana Factcheck [MFC]-
vaping 2019, para. 1). Unlike dabbing which uses conduction heating of a metal surface 
where heat is directly applied to and transferred to a heating element, vaping involves 
convection heat (Krauss, et al., 2015). In this process the material to be inhaled 
(marijuana leaves, BHO concentrated oil or dab) is heated indirectly usually using a 
battery powered heat source that heats the coil that heats the air. The hot air moves 
through the marijuana product, which is vaporized, and the resulting vapor is inhaled by 
the user (Lepkoff, 2018; Yang et al., 2018). Users prefer vaping and e-cigarettes (e-cigs) 
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because they are easily concealed as these methods do not produce visible smoke and are 
nearly odorless (MFC-vaping, 2019; Yang et al., 2018). Users also prefer vaping and e-
cigs because they are a cost-effective as a smaller amount of concentrated marijuana 
product (high potency THC) is required to achieve the desired effect (MFC-vaping, 2019; 
Yang et al., 2018).  
In addition, much like with dabbing many marijuana users believe that vaping and 
the use of e-cigarettes are safer than traditional methods of smoking marijuana (Yang et 
al., 2018). While not much is known about the long-term effects of vaping and e-
cigarettes as few to no studies have been conducted to address these concerns. There may 
be some merit to the perceived potential health benefits or reduced health risk (Budney, 
Sargent & Lee, 2015). This is because the use of e-cigarettes and/or vaping of marijuana 
and marijuana products such as waxes oils and concentrates does reduce the amount of 
toxins and carcinogens typically inhaled by traditional smoking methods. Thus, reducing 
the amount of carbon monoxide, tar, ammonia and hydrogen cyanide inhaled by the user 
(Budney, Sargent & Lee, 2015). In fact, Blundell, Dargan & Wood (2017) posited that 
“Cannabis smoke is also comparable to tobacco smoke containing phenols, ammonia, 
hydrogen cyanide, nitrosamines and carcinogens such as benzopyrene and 
benzanthracene” (para, 9). However, according to an article published in the Public 
Health England review. Vapor produced and inhaled from e-cigarettes is approximately 
“95% safer than cigarette smoke from this perspective as the harmful constituents of e-
cigarette vapour are below 5% of smoking doses and far below safety limits for 
occupational exposure” (para. 9).  
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Another potential benefit is a reduction in exposure to secondhand smoke to other 
non-users since these methods typically do not produce smoke and are virtually odorless 
(Budney, Sargent & Lee, 2015). Additionally, those who vape or use e-cigarettes to 
consume marijuana (cannabis) also report fewer symptoms of respiratory problems. 
However, once again no long-term studies are available to compare vaping versus 
traditional smoking methods (Budney, Sargent & Lee, 2015). 
Despite these seemingly potential benefits, vaping and use of e-cigarettes are not 
without risk and great concern for the community and public health leaders. Yang et al., 
(2018) points out a particularly troublesome aspect of these methods of use is marijuana 
marketing to our youths and young adults. Which is overwhelmingly provided, promoted 
and obtained through social media platforms that are difficult to monitor, control and/or 
regulate (Yang et al., 2018). These various sources often contribute to a reduction in 
perceived risk associated with vaping and the use of e-cigarettes. In one study by Budney, 
Sargent and Lee (2015), the researchers posited that several studies have been conducted 
and indicate that these reductions in perceived risk may in turn lead to the following: an 
earlier age of initial use; increased frequency of use; and a decreased motivation to quit 
or reduce use. In addition, marijuana users typically smoke or use less marijuana than the 
average tobacco user. This comparatively results in the perception (and rightly so) that 
marijuana users should have fewer concerns about complications associated with regular 
tobacco use (i.e. lung cancer and chronic lung disease). However, while this may be the 
case. The primary concerns with a reduction in perceived marijuana risk are associated 
with misuse and addiction. This is of particular importance for our youths and young 
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adults as according to Budney, Sargent & Lee (2015), chronic marijuana use can lead to 
the following psychological and neurocognitive consequences: increased risk behaviors; 
poor school or job performance; family and interpersonal problems; accidents; memory 
and motivational problems; and the development of addiction.  
Another concern associated with vaping and e-cigarettes is the use of these 
methods to inhale or ingest synthetic cannabinoids or other substances. The synthetic 
cannabinoids are structurally similar and function much like THC (Castellanos & 
Gralnik, 2016). These substances also known as cannabimimetics have been around since 
the 1960s. However, their popularity increased between 2004 and 2008 when they 
evolved into recreational drugs across Europe and then growing in acceptance worldwide 
(Castellanos & Gralnik, 2016). Since then producers have been developing newer and 
more potent forms that when coupled with methods of use like vaping and e-cigarettes 
pose a much more dangerous threat (Castellanos & Gralnik, 2016). Synthetic 
cannabinoids are a serious concern for public health leaders as youths and young adults 
are using and abusing these substances in increasing numbers. Which are reportedly 
much more potent than natural forms of marijuana (Castellanos & Gralnik; Pelt, 2012; 
Wood, 2013). 
Originally synthetic cannabinoids and synthetic stimulants referred to as incense 
and bath salts respectively were sold legally in the United States (Perrone, Helgesen & 
Fischer, 2013). The incense or synthetic cannabinoids are intended to mimic the effects 
of marijuana whereas the synthetic stimulants or bath salts are intended to mimic the 
effects of methamphetamine. As mentioned in the mid-2000s the US Drug Enforcement 
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Agency (DEA) had not yet banned mephedrone (the stimulant found in bath salts) nor 
had they banned the synthetic cannabinoids. Thus, many users perceived these substances 
as legal substitutes to the illegal substances they mimic (Perrone, Helgesen & Fischer, 
2013). In a study conducted by Perrone et al., (2013) some users sought to avoid positive 
test on drug screenings and still others sought to avoid criminal prosecution for position 
of illegal substances. While other users were classified as into one of the following 
groups: attending abstinence-only drug treatment programs; under community correction 
programs; or pursuing a career in the US military, all of which require mandatory random 
drug testing (Perrone et al., 2013). The availability of these substances is only 
exacerbated by the internet which has not only made it easier to purchase these 
substances, but also serves to promote their use as some websites not only promote these 
substances but also provide directions for new users (Pelt, 2012).  
 The trend in abuse of Bath salts and Synthetic Cannabinoids demonstrated an 
increase from 2009 to 2011 (Wood, 2013). However, in 2012 the abuse of bath salts 
began to decline while the abuse of synthetic marijuana increased with most bath salts 
users being young men who primarily inhaled the substance (Wood, 2013). In addition, 
Wood (2013) provides the following demographics for total exposure to synthetic bath 
salts and cannabinoids (THC) by age range for 2009 – 2012. For synthetic bath salts: Age 
range 13-19 (16.2%); 20-29 (43.1%); 30-39 (23.7%); 40-49 (12.1%); 50-59 (3.1%). For 
Synthetic THC: Age range 13-19 (48.8%); 20-29 (34.4%); 30-39 (9.1%); 40-49 (3.9%); 
50-59 (1.7%) (Wood, 2013). Values for age ranges below 12 years of age and above 60 
years of age were negligible. Nevertheless, this trend demonstrates that most bath salts 
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users were between the age of 20-29. Whereas most Synthetic marijuana users were 
between the ages of 13-19 (Wood, 2013).  
 The misconception that these substances are safe substitutes has been dismissed 
as the National Institute of health reports that “Thousands of teens and young adults, 
mostly young males, are ending up in emergency rooms with severe symptoms that may 
include vomiting, racing heartbeat, elevated blood pressure, seizures, or hallucinations” 
because of synthetic marijuana use (NIH-NIDA, 2013, para. 1). In addition, per a news 
release from the U.S. Substance Abuse and Mental Health Services Administration and 
reported in Health Day (2013) the “Street drugs called ‘bath salts’ were linked to nearly 
23,000 emergency department visits in the United States in 2011” (para. 1). 
 In a more recent study, Castellanos & Gralnik (2016) provided an update on 
synthetic cannabinoids informing pediatricians of clinical presentations to look for when 
treating adolescents and encourage physicians to become familiar with these drugs. 
According to the researchers, the synthetic cannabinoids have evolved rapidly since their 
introduction with the potential for dangerous health effects that exceed that of traditional 
marijuana use (Castellanos & Gralnik, 2016). The potential detrimental health effects of 
these compounds include: Gastrointestinal problems (nausea and vomiting); Neurologic 
signs and symptoms (such as tremors, ataxia, fasciculations, and hyperreflexia); 
Metabolic disturbances (hypokalemia, hyperglycemia, acidosis and diaphoresis); 
Rhabdomyolysis (muscle damage and breakdown); Renal Damage; Seizures; and 
Myocardial Infarction; (Castellanos & Gralnik, 2016; WebMD, 2019). In addition, 
Castellanos & Gralnik (2016) also report the following psychoactive effects: Cognitive 
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complications (attention, concentration and memory deficits, confusion); Affective 
disorders (anxiety and panic); as well as Behavioral disfunctions (restlessness, agitation, 
violence, and aggression) and Psychosis (hallucinations, delusions and disorganized 
thoughts). Further compounding the challenge of addressing this concern are the new 
methods of use. Vaping and e-cigarettes allow manufactures to present these products as 
natural cannabis resins, CBD oils, and liquid cartridges (Castellanos & Gralnik, 2016; 
Popp, 2018).   
 While the prevalence of marijuana use, vaping, dabbing and the use of 
concentrated products may be higher in areas with medical and/or recreational marijuana 
laws (Keyhani, 2018). Areas without medical marijuana laws or limited medical 
marijuana laws are not immune. For instance, in the Atlanta Georgia area with only 
limited medical marijuana laws there have been numerous incidents where individuals 
(most notably youths and young adults) have utilized these products with detrimental 
effects. In many cases they are being sold legally as bath salt or labeled as not for human 
consumption (Castellanos & Gralnik, 2016; Popp, 2018). In Forsyth County, which is 
located just North of Atlanta two high school students had to be transferred to the 
hospital in 2017 after vaping CBD oils (Popp, 2018). In another situation, authorities in 
Forsyth county have been warning parents and students about new types of synthetic 
THC and CBD oils (Popp, 2018). Proper use of these liquids involves adding them to e-
cigarette nicotine liquid allowing the user to achieve an added high. However, problems 
arise when individuals, mostly students, vape the liquid straight as oppose to adding them 
to nicotine liquid (Popp, 2018). Authorities warn that the outcome can be disastrous 
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resulting in a medical emergency with symptoms of suppressed respiratory function and 
increased heart rate. Consequently, mimicking that of an opioid overdose (Popp, 2018). 
The names of these products (synthetic marijuana or CBD oils) include: Kronic Juice, 
Galaxy, Diamond and Lyft and they are being sold in vape shops, head shops and CBD 
shops in and around the Atlanta area (Popp, 2018). Among these, Kronic Juice has been 
associated with seizures and unconsciousness when not used as instructed (Popp, 2018).  
One reason vaping, and e-cigarettes are growing in popularity is because the use 
of substances by these means are easily concealed, smokeless and virtually odorless 
(Yang et al., 2018; MFC-vaping, 2019). School administrators, principals and teachers in 
Forsyth county Georgia emphasize the problems with addressing this concern as they 
have observed vaping devices designed in the form of everyday objects like phones, pens, 
and flash drives (Popp, 2018). Thus, making them difficult to detect (Popp, 2018). 
While the use of concentrated marijuana products such as BHO and methods of 
use like dabbing, vaping and e-cigarettes are a growing concern. Another issue facing 
public health and health care professionals is the consumption of edible products infused 
with marijuana. These products are growing in popularity and come in many forms such 
as, candy; cookies; brownies; and even popular breakfast cereal (i.e. Fruity Pebbles) 
(Cao, Srisuma, Bronstein & Hoyte, 2016; Haney, 2019)  
Even though smoking marijuana remains the most common method of use 
(Keyhani et al., 2018). Since the implementation of medical marijuana laws alternative 
methods of marijuana use have been on the rise and warrants public health attention 
(Keyhani et al., 2016). This rise in alternative methods of use is evidenced in a study by 
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Borodovsky, Crosier, Lee, Sargent, & Budney (2016), in which the researchers sought to 
assess whether marijuana (cannabis) legalization impacted methods of marijuana use 
(Borodovsky, et al., 2016). Based on States medical marijuana status, duration of medical 
marijuana status, and the density of marijuana dispensaries in the state. The researchers 
analyzed whether individuals ever used marijuana, preference for marijuana use, and age 
at which individuals started smoking, vaping and eating marijuana (Borodovsky, et al., 
2016). The results revealed that in states with MMLs the odds of an individual using 
alternative methods were significantly higher for vaping and edibles (OR: 1.78, 99% CI: 
when compared to states without MMLs (Borodovsky, et al., 2016). The rise in use via 
vaping and edibles would be expectedly higher in states with both medical marijuana 
laws (MMLs) and recreational marijuana laws (RMLs) as in states with RMLs the 
availability of BHO concentrates and edible products is greater and more highly marketed 
to the public (Borodovsky et al.; 2016Carroll, 2018; Keyhani et al., 2018;).  
Thus, consumption of marijuana-infused products have been gaining popularity 
along with the spread of medical and recreational marijuana legalization (Barrus et al., 
2016; Montgomery, 2017). This is evidenced by booming sales of marijuana infused 
edibles and drinks in states like California and Colorado that have legalized recreational 
marijuana (Montgomery, 2017). For instance, in California edible marijuana sales 
reached $181 million in 2016, and in Colorado sales reached $53 million during the third 
quarter of 2016 where sales were just $17 million during the first quarter of 2014 
(Montgomery, 2017). Demonstrating a three-fold increase in Colorado sales in less than 
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two years. However, while consumption of marijuana products is growing in popularity it 
is not without risk and challenges.  
In a related article, Barrus et al. (2016) explores various aspects surrounding 
edible marijuana products with particular attention on challenges arising for users and 
policy makers as well as attempts at regulation (Barrus et al., 2016). The researchers first 
explain the process involved with producing the cannabinoid-infused oil required for 
making edible marijuana products (Barrus et al., 2016). This involves extracting the 
primary cannabinoids (THC & CBD) from the marijuana plant. Which is achieved by 
heating the raw female marijuana plant (flowers and leaves) in an oil-based liquid (Barrus 
et al., 2016). Heating of the marijuana plant products serves to convert THC from its non-
psychoactive form, Delta-9-tetrahydrocannbinolic Acid (THCA) into its psychoactive 
form, Delta-9-tetrahydrocannabinol (Δ9-THC) (Barrus et al., 2016). This psychoactive 
form is responsible for the high that many marijuana users seek. It along with other 
cannabinoids, such as CBD the medicinal (non-psychoactive) cannabinoid is extracted 
into the oil-based liquid (Barrus et al., 2016). The remaining plant products are removed 
and discarded, and the cannabinoid-infused oil is ready for use in consumable products 
and/or retail sale in dispensaries (Barrus et al., 2016). The researchers report that in 
Colorado, while consumption of edibles accounts for a significant amount of use by both 
medical and recreational marijuana users (Barrus et al., 2016). The actual rates of edible 
use by both populations is likely underestimated because data obtained only represents 
sales of cannabis-infused products. This data does not reflect how much cannabinoid-
infused oil or cannabis was bought and used by consumers to make homemade edibles. 
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Nor does it reflect inter-state transfer of these products to other regions (states) for 
medicinal and/or recreational use (Barrus, et al., 2016). Nevertheless, in Colorado in 
2014, medicinal cannabis infused products with high CBD low THC concentrations, and 
retail cannabis-infused products (high THC low CBD) accounted for approximately 45% 
of all cannabis sales in the state (Barrus et al., 2016).  
Barrus et al., (2016) identifies the following three perceptions that may be 
attributing to the increased interest in edible products: “(1) edibles are a discreet and 
more convenient way to consume cannabis; (2) edibles offer a “high” that is calmer and 
more relaxing than smoking cannabis; and (3) edibles avoid the harmful toxins and health 
risks that come with smoking cannabis” (para. 12). 
Regardless of the method of marijuana use, whether it be smoking, vaping, or 
consumption of edibles. Or the reason (medical or recreational) the primary goal among 
marijuana users is to feel better (Barrus et al., 2016). However, while there has been a 
significant amount of research conducted on the health benefits of marijuana. Most of 
these studies have focused on pharmaceutical preparations of synthetic analogs of THC 
as oppose to natural marijuana use, and/or products containing natural preparations of 
THC and CBD cannabinoids (Barrus, 2016). Nevertheless, the studies that have been 
conducted typically focused on the following limited number of medical conditions: 
muscle spasms; chronic pain; nausea and vomiting; epilepsy; appetite stimulation; cancer; 
post-traumatic stress disorder; anxiety; and depression (Barrus et al., 2016). Wherein the 
benefits of marijuana for these conditions has primarily been based personal 
proclamations rather than facts or research (Barrus et al., 2016). Thus, evidence based on 
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well controlled clinical studies is limited. Barrus et al., (2016) posited that the lack of 
strong studies on the therapeutic effectiveness of cannabis and cannabinoid products is 
due in part to the continued classification of cannabis (marijuana) as a Schedule I drug by 
the U.S. Drug Enforcement Agency. However, Barrus and fellow colleagues hold 
promise that the widespread and continued state-level legalization of medical and 
recreation marijuana may serve as the driving force to promote funding for better 
controlled studies (Barrus et al., 2016). Which is needed as there has only been a limited 
number of studies comparing pharmaceutical products of synthetic Δ9-THC to natural 
preparations and other methods of cannabis use. However, the limited studies available 
tend to indicate that most patients prefer natural products and uses as oppose to the 
synthetic preparations (Barrus et al., 2016). In addition, according to subjective patient 
reports the natural methods of smoking and consumption of edibles produce less adverse 
effects and better efficacy than synthetic preparations (Barrus et al., 2016). 
The consumption of edibles for medicinal and recreational purposes has several 
benefits. Among these include a longer duration of action when compared to smoking 
and the consumption of edibles in easier to conceal. Both of which are especially 
advantageous to the medicinal user as smoking marijuana is still illegal in many states 
with medical marijuana laws (Barrus el al., 2016). So, the medicinal user can consume 
edibles at work and in public without exposing their use, and the longer duration of action 
mean reduced dosing times. The concealability of marijuana infused products is also 
advantageous because despite growing acceptance many patients and recreational users 
still express concerns about the stigma associated with the perception of marijuana use 
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(Barrus et al., 2016). Thus, some users may prefer the consumption of edibles in public or 
in the workplace. Choosing to vape or smoke at home and outside of work (Barrus rt al., 
2016). Another significant reason why many users prefer the consumption of marijuana-
infused products is the perception that this method of use is less harmful than smoking 
marijuana (Barrus, 2016). This is because of the perception that smoking marijuana may 
pose risk and other harmful effects similar to smoking tobacco (Barrus, 2016). 
Until recent events in Colorado, marijuana had not been directly attributed to any 
lethal consequences as no deaths had been associated with acute marijuana toxicity 
(Barrus et al., 2016). However, serious and severe consequences have occurred in 
association with marijuana toxicity or overdose. Barrus et al., (2016) provided support for 
this understanding based on reports from 65% of medicinal cannabis users that indicate 
overuse has resulted in the following signs and symptoms: cognitive and motor 
impairment; extreme sedation; agitation; anxiety; cardiac stress; and vomiting (Barrus et 
al., 2016); In addition, larger doses of Δ9-THC have been associated with cannabis-
induced psychosis while usually transient in healthy adult users some users report 
symptoms that persist for several days. These psychotic symptoms reportedly can include 
hallucinations, delusions, and anxiety (Barrus et al., 2016).  
While the information on cannabis-induced psychosis is limited reports indicate 
than many of these cases are the result of ingestion/overconsumption of edible marijuana 
products (Barrus, et al., 2016). The reason why this may occur more commonly with 
ingestion as oppose to smoking is most likely associated with the route of administration 
and cannabinoid pharmacokinetics (Barrus et al., 2016). This simply means how 
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marijuana is processed by the body when it is eaten versus smoked. For instance, when 
someone ingestion cannabis-infused products it is first processed in the gastrointestinal 
tract where Δ9-THC is absorbed enters the blood stream and travels to the liver (Barrus et 
al., 2016). Once in the liver, Δ9-THC is converted to 11-hydroxytetrahydrocannabinol 
(11-OH-THC). This hydroxylation step is mediated primarily by the cytochrome-P450 
enzymatic system of the liver (Barrus et al., 2016). More importantly, 11-OH-THC is a 
potent psychoactive metabolite of Δ9-THC that can easily cross the blood brain barrier to 
elicit its effects (Barrus et al., 2016). Consequently, 11-OH-THC is more potent than Δ9-
THC and ingestion of marijuana results in higher blood levels of 11-OH-THC than 
smoking (Barrus et al., 2016). Hence, the stronger effects and longer duration of action 
demonstrated when someone ingest cannabis-infused products (Barrus et al., 2016).  
When someone smokes or vapes marijuana the effects are almost immediate, 
occurring within minutes and peaking about 20 to 30 minutes after inhalation (Barrus et 
al., 2016). With the effects usually lasting about 2-3 hours (Barrus et al., 2016). 
Conversely, when someone ingest marijuana it takes about 30 to 90 minutes for the 
psychoactive effects to kick in and they last longer as the effects of edibles does not 
typically peak until about 2 to 4 hours after ingestion (Barrus et al., 2016). Further 
complicating the matter is the fact that the concentration of Δ9-THC found in edible 
products can vary across edible products and batches (Barrus et al., 2016). This lack of 
consistency and delay onset of action may lead to increased ingestion of cannabis-infused 
products resulting in unintentional consequences (Barrus et al., 2016). Attempts at 
regulation have set the limit for a maximum recommend dose of Δ9-THC at 10 mg per 
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serving (Barrus et al., 2016). However, Barrus et al., (2016) posited that “a single 
chocolate bar could contain 100 milligrams (10) servings of Δ9-THC” (para. 31). But the 
delayed onset of action and small portions may make it difficult for the user to control 
their intake resulting in serious and potentially lethal consequences (Barrus et al., 2016). 
This is evidenced by one tragic event in which a 19-year-old Colorado man was 
instructed to eat just one-sixth (one serving) of a cookie that contained approximately 10 
mg of Δ9-THC (Barrus et al., 2016). However, after about an hour the man had not felt 
any effects and consumed the remain amount over a 2-hour period (Barrus et al., 2016). 
Unfortunately, the intoxicating effects resulted in his death after he jumped off a fourth-
floor balcony (Barrus et al., 2016). At autopsy the examiner identified cannabis 
intoxication as the primary cause of death. This event while tragic, lead to the 
implementation of packaging and labeling regulations in Colorado that require clear 
demarcations of the standardized 10 mg dose servings of cannabis-infused products 
(Barrus et al., 2016). The state of Washington has also implemented similar regulations 
(Barrus et al., 2016). 
Thus, regulation of edibles occurs at the state level, this is because marijuana is 
still illegal at the federal level (Barrus et al., 2016). Therefore, various entities within 
each individual state regulate the taxing, licensing for cultivation and distribution, and 
retail sales by marijuana dispensaries on a state-by-state basis (Barrus et al., 2016). 
Therefore, states that have legalized marijuana for recreational sales have specific state-
level requirements for labeling of cannabis-infused edibles (Barrus et al.,2016). 
Typically, these requirements must include warnings about potential harmful and 
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intoxicating effects as well as nutritional information (Barrus et al., 2016). However, 
nutritional information usually various by state. For instance, Colorado and Oregon 
require that information on labels of cannabis-infused products to be much like that on 
regular food products (Barrus et al., 2016). Whereas, Washington state only requires that 
labels include a listing of ingredients (Barrus et al., 2016). But most states have 
requirements for labeling that include pesticides used during production as well as 
requirements for an expiration or best if used by date (Barrus et al., 2016).  
Thus, while many medicinal and recreational users view consumption of 
marijuana edibles as a safe alternative method of with marijuana use that is more 
convenient and easier to conceal than smoking (Wardarski, 2015). It’s important to point 
out these are not the marijuana products of years ago and edible products are usually 
more potent than smokable marijuana products (Wardarski, 2015). For instance, while 
strains of marijuana sold in most dispensaries for smoking typically has a THC level in 
the range of 12 to 25 percent. Marijuana infused edibles are being made using marijuana 
concentrates as potent as 50 to 90 percent THC (Wardarski, 2015). This is a serious 
concern as in Colorado alone, where some doctors posited that consumption of edibles 
are responsible for the rise in marijuana related hospitalizations (Wardarski, 2015). 
Which has more than doubled since 2009 after commercialization and expansion of 
medical marijuana (Rocky Mountain High Intensity Drug Trafficking Area (RMHIDTA), 
2014; Wardarski, 2015;). 
Barrus et al., (2016) posited that an important concern for public safety is the lack 
of available research comparing the therapeutic efficacy and subjective effects of 
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marijuana ingestion to other methods of use. In addition, accidental ingestion and over 
consumption, whether it be intentional or unintentional is another concern for public 
health and health care leaders (Cao, Srisuma, Bronstein, & Hoyte, 2016). As previously 
stated, over consumption of edible products is commonly associated with the delayed 
onset of action observed with ingestion as the effects are not immediate like smoking 
(Barrus et al., 2016). This may prompt the user to consume more product in an attempt to 
achieve the desired effect resulting in over consumption and leading to unintended 
adverse effects (Barrus et al., 2016).  
In a related broad-based study, Cao, Srisuma, Bronstein, & Hoyte, (2016) 
conducted a national analysis of human exposure calls for consumption/ingestion of 
marijuana products reported to poison control centers around the United States. These 
state-level centers intern report data to the National Poison Data System (NPDS). In this 
retrospective study, Cao et al., (2016) obtained data reported to the NPDS over a 36-
month period between January 2013 through December 2015. The study analyzed 
subgroups based on age and state level marijuana laws for ingestion of edible marijuana 
products (Cao et al., 2016). The marijuana infused products included: cookies; candies; 
brownies; beverages and other food products (Cao et al., 2016, para. 1). The researchers 
also considered both intentional and unintentional exposures as these products are often 
indistinguishable from similar non-marijuana infused products (Cao et al., 2016). As 
children as well as adults are typically unable to recognize differences in taste or 
appearance (Cao et al., 2016).  
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The results of this study revealed that the majority of calls for exposure were for 
individuals less than or equal to five years of age (Cao et al., 2016). With 99% of these 
incidents due to unintentional exposure. Individuals age 1-19 years old represented the 
next highest age group for exposure calls with individuals age 20-29 years of age making 
up the third highest age group (Cao et al., 2016). Among these individuals those age 6-19 
predominated the intentional exposure group with 89% of these due to abuse versus 10% 
for misuse (Cao et al., 2016). Additionally, among the states observed Colorado and 
Washington led the way with the highest number of exposure calls as overall states with 
MMLs and/or RMLs accounted for approximately 91% of all calls (Cao et al., 2016). 
Thus, lending support to the premise that marijuana legislation effects marijuana use, 
abuse, misuse, exposure and preference. 
  Furthermore, the methods of use that further increase the potency of an already 
highly potent marijuana product should definitely be a serious concern of public health 
leaders. This is evidenced a related study conducted in the Netherlands researchers 
explored the relationship between changes in marijuana potency and admissions to drug 
treatment programs (Freeman, et al., 2018). This 16-year study analyzed THC 
concentrations sold at retail stores from the year 2000 through 2015. This analysis 
revealed that THC concentrations increased from 8.62% to 20.38 % from 2000 to 2004 
and decreased in 2015 to 15.31% (Freeman, et al., 2018). During this time first 
admissions to drug treatment increased from 7.08% to 26.36% between 2000 to 2010 and 
decreased to around 20% in 2015 (Freeman, et al., 2018).  
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Freeman, et al., (2018), concluded that a positive time-dependent association does 
exists between changes in marijuana potency and first-time admissions to drug treatment. 
The researchers also point out that other factors may also be important. Nevertheless, the 
results indicate that the strongest association occurred at 5 years into the study, and after 
adjusting for participant demographics and non-cannabis drug treatment admissions the 
results reveal a statistically significant positive association (Freeman, et al., 2018). Which 
is evident as Freeman, et al., (2018), posits that “each 1% increase in THC was associated 
with a 0.082 (0.052, 0.111) rise in first-time admissions per 100,000” (para.14). The 
researchers further posited that these trends are not confined to the Netherlands as 
increases in first time admissions to drug treatment programs for marijuana are consistent 
across all of Europe (Freeman, et al., 2018). As was indicated in an analysis submitted to 
the European Monitoring Centre for Drugs and Drug Addiction which reported increases 
in admissions in 16 out of 22 European countries examined (Freeman, et al., 2018).  
While there is limited literature available on the effects of medical and 
recreational marijuana laws on marijuana potency, that which is available suggest that 
these laws have not only led to increased potency but also to increases in unintentional 
childhood exposure as well as adult cannabis use and adult cannabis use disorder (Hasin, 
2017). In addition, some studies also suggest that medical marijuana laws have led to 
increased use of cannabis as substitutes for opioids and psychiatric medications (Hasin, 
2017). Thus, supporting to the premise that some marijuana users may be self-medicating 
for various conditions.  
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Based on my understanding of the literature review, as more states continue to 
implement MMLs and RMLs access to marijuana and marijuana products will continue 
to increase while public perception of risk and social stigma associated with marijuana 
use will continue to decrease. Thus, the combined effects of these events may lead to an 
overall increase in marijuana use and exposure, both intentional and unintentional. In 
addition, there is also lack of sufficient literature from evidenced-based studies on the 
long-term effects of legalization, rising THC levels, consumption of marijuana-infused 
products, use of concentrated marijuana products, and methods of marijuana use like, 
dabbing, vaping and e-cigarettes.  
Therefore, peer-reviewed articles such as those presented here provide additional 
support for the premise of this study which seeks to explore the possible associations 
between medical and recreational laws, marijuana potency and the effects on mental 
health conditions like depression and suicide ideation. This is particularly important as 
those who serve in public health and health care have an obligation to inform the public 
about the risk associated with marijuana use, especially when considering trends of 
increasing potency, growing public acceptance, decreased risk perception of marijuana 
use and the continued wide spread legalization of marijuana. 
Critique of Methods 
 Salomonsen-Saulel et al. (2012) utilized the several tools to measure and analyze 
adolescent use of medical marijuana among patients treated at two substance abuse 
facilities in Denver Colorado. The results of this study demonstrated that the majority of 
adolescents, approximately 74% of the 164 adolescents in treatment, had used medical 
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marijuana obtained from registered medical marijuana patients (Salomonsen-Saulel, et 
al., 2012). Thus, demonstrating a high rate and widespread pattern of medical marijuana 
use by the non-patient recreational using population (Salomonsen-Saulel, et al., 2012). 
However, the study results may be limited by a lack of comparison between states where 
marijuana is legal versus illegal. One example wherein this comparison would be relevant 
is in areas where legalization of medical marijuana contributed to greater acceptance of 
marijuana because of a more favorable marijuana attitude or a decrease in perceived risk 
post-legalization (Salomonsen-Saulel et al., 2017). As a result, the use of marijuana may 
be higher in these areas and reflected in the results of the study versus areas without 
legalization where marijuana use may be lower. In addition, this study was conducted at 
two rehabilitation facilities at one point in time (Salomonsen-Saulel et al., 2017). This 
would in turn effect determination of causality (Salomonsen-Saulel, et al., 2017). Thus, 
comparing marijuana use to states with varying laws in other states and at different points 
in time is essential to making inferences about causality (Salomonsen-Saulel et al., 2017). 
Finally, Salomonsen-Saulel et al. (2012) also indicates that the timing of marijuana law 
implementation may also affect studies on patterns of marijuana use. Therefore, 
additional time may be needed to observe the effects of recently implemented laws 
(Salomonsen-Saulel et al., 2017). 
In a related study by Wen, Hockenberry, & Cummings (2015), the researchers 
addressed the effect of medical marijuana laws on marijuana use in ten states with 
medical marijuana laws. The study also addressed the effects of MMLs on the use of use 
alcohol, and other hard drugs (such as, cocaine and heroin) as well as pain medication 
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misuse (Wen et al., 2015). While this study presented relevant data implementing MMLs 
to a rise in marijuana use as well as an increase in abuse/dependence among participants 
age 21 and older. A potential limiting factor is concerned with the National Survey on 
Drug Use and Health (NSDUH) used in this study. This survey does not differentiate 
between the marijuana patient and non-patient populations participating in the study 
(Wen et al., 2015). Thus, the spillover effect may not solely reflect an increased 
marijuana use among registered marijuana patients as the non-patient or recreational 
using population may potentially contribute to a greater percentage of the individuals 
participating in the study (Wen et al., 2015). This limitation is evidenced by Wen et al., 
(2015) which indicates that, among the states studied with MMLs, medical marijuana 
patients comprised only 0.8 percent of the total population.  
 Regarding methods used to assess the association between mental health and 
marijuana use. A notable study reviewed here by van Gastel, et al., (2013), used a 
population-based analysis to determine whether cannabis use is associated with poor 
psychosocial functioning and therefore a potential risk factor for future mental health 
problems (van Gastel, et al., 2013). While the results of this study demonstrated a 
potential association between the use of marijuana and future mental health problems, the 
study was not without limitations. Most importantly, is the cross-sectional approach that 
is limited because it provides an analysis of the association between variables (exposure 
and outcome) at one point in time and therefore does not provide information relevant to 
the time spatial association between the exposure and outcome variables (Christian, 
2015). Thus, limiting conclusions with respect to the causal inference between these 
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conditions. In addition, since the methods used to gather data involved self-reporting then 
another study limitation may result from over or under reporting which is observed when 
gathering information of sensitive issues, such as drug use (van Gastel, et al., 2013).  
 The notion that marijuana use may cause psychosis is not a new concept as 
several studies have demonstrated this association (Murray, Quigley, Quattrone, Englund 
& Di Forti, 2016). In one such study, Davis, Compton, Wang, Levin, & Blanco (2013) 
conducted a population-based study demonstrating that the use of marijuana may serve as 
a possible risk factor for psychosis and schizotypal personality disorder (SPD). The study 
further demonstrated that the risk of psychosis and SPD increased with the extent of 
marijuana use in a dose-dependent fashion (Davis et al., 2013). Which supports this 
current studies premise that highly potent marijuana would be expected to increase the 
occurrence or exacerbate these conditions. However, the cross-sectional nature of this 
population-based study limits inferences about causality or the time-spatial relationship 
between marijuana use and the development of psychosis and SPD (Davis et al., 2013). 
In addition, this study used self-reporting to gather data on the participants diagnosis of 
schizophrenia or psychotic disorders. And according to Davis et al (2013) the reliability 
of self-reporting on these diagnoses is questionable. Which may limit the results of this 
study. In addition, self-reporting may also be subject to recall bias (Hasan, 2005). And 
finally, the cross-sectional nature of this study may limit inferences on causality as 
observations are made at one point in time (Davis et al., 2013). However, the researchers 
also point out that previous studies utilizing self-reporting for these diagnoses are 
consistent with the findings presented (Davis et al., 2013).  
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 In a related literature review, Moore et al. (2007) provided support for the results 
observed in the study by Davis and fellow colleagues. Wherein Moore et al. (2007) 
addressed the association between marijuana use and the development of psychosis or 
affective mental health outcomes. This study demonstrated an increase in psychosis and 
affective mental health outcomes with a dose-response relationship as the rate of 
psychosis increased 50 to 200% for heavy marijuana users versus moderate users and 
non-marijuana users (Moore et al., 2007). However, since a review of the literature is 
typically observational in nature, then the study is subject to several limitations. One 
limitation of this approach is publication bias as studies presenting statistically significant 
results may be selected for publication and cited more often than others and are therefore 
more likely to be included in literature reviews (Egger, Dickersin & Smith, 2001). 
Another limitation is the methodology or findings of the articles reviewed. If the data or 
results of these studies are compromised, then the results presented by the literature 
review will subsequently be affected as well (Egger et al., 2001). In addition, a literature 
review may be subject to a form of selection bias, wherein researchers select particular 
articles or studies for review based on the results that favor the researchers’ premise 
(Egger et al., 2001).  
Knowledge Gap 
 The study conducted by Salomonsen-Saulel and colleagues which demonstrated 
that medical marijuana is finding its way into the hands of the non-patient recreational 
using population in Denver, CO (Salomonsen-Saulel et al., 2012). However, this study 
was limited to adolescent patients from two substance abuse treatment facilities 
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(Salomonsen-Saulel, et al., 2012). Therefore, demonstrating a potential gap in the 
research as the results may not be representative of the general population of marijuana 
users. Support for this premise is provided by Salomonsen-Saulel, et al. (2012) which 
posited that additional research should focus on patterns of medical marijuana use and 
diversion of medical marijuana within the general adolescent population (Salomonsen-
Saulel, et al., 2012). Addressing his gap would also require focusing on young and older 
adults in the population as these groups also contribute to the general marijuana using 
population  
 Sevigny, Pacula & Healon, (2014) addressed the effects of marijuana legalization 
on potency ultimately demonstrating no statistically significant association between these 
two variables. However, the authors acknowledge that previous studies on the effect on 
legalization on potency have revealed mixed results both for and against the premise that 
marijuana legalization has contributed to a rise in marijuana potency. However, Sevigny 
et al., (2014) further identified a possible gap in the research as the lack of studies to 
assess the effects of rising marijuana potency on marijuana use.  
Sevigny et al., (2014) also identified other areas for future research. For instance, 
the researchers surmised that use of highly potent marijuana could possibly result in a 
decrease in marijuana use as less marijuana would be required to achieve the desired 
effect. Another area for additional research is the possibility that highly potent marijuana 
may also contribute to a decrease in charges for Driving While Impaired (DWI) as 
individuals who use both alcohol and marijuana would be less prone to drive after 
concurrent use of these substances (Sevigny et al, 2014)  In addition, Sevigny et al., 
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(2014) further posited that the use of highly potently marijuana may result in a decrease 
in the amount of opiate pain relievers taken as less medication may be required due to the 
pain relieving effects of highly potent marijuana. In fact, some patients taking opiate pain 
relievers may opt to use marijuana for pain relief as oppose to narcotics (Sevigny, Pacula 
& Healon, 201). 
  The study conducted by van Gastel, et al., (2013), presented relevant information 
on the association between the use of marijuana and future mental health problems. This 
study demonstrated that marijuana use, and factors associated with marijuana use and 
poor psychosocial functioning may serve as indicators of risk for future adolescent 
mental health problems (van Gastel, et al., 2013). The researchers however point out that 
future research and public health efforts should focus on using the indicators of risk 
identified in this study to design an adolescent risk profile (van Gastel, et al., 2013).  
 The study conducted by Moore et al. (2007) served to demonstrate an increase in 
psychosis and affective mental health outcomes with a dose-response relationship among 
marijuana users. The researchers point out the need for additional research to determine if 
younger marijuana users are subjected to greater risk or more harmful effects (Moore et 
al., 2007). The researchers also indicate that additional research should address the 
effects of genetics and other factors on these results (Moore et al., 2007). 
Summary and Conclusions  
In the United States, substance abuse and addiction cost the American tax payer 
over $700 billion dollars a year (NIDA, 2016). The consequences of substance abuse are 
evidenced by approximately 90,000 Americans that die every year as a result of illicit and 
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prescription drug and alcohol use (NIDA, 2016). Thus, substance abuse is an important 
public health concern that has a prodigious impact on our society.  
Among the substances of abuse, marijuana is by far the most commonly used as 
in 2018, 43 million Americans reportedly used marijuana in the past year (Statista, 2019). 
A growing public health concern is the potency of marijuana as the level of 
Tetrahydrocannabinol (THC) has been increasing since legalization began in 2012 
(Cabrera, 2016). This is a growing concern since THC elicits the desired psychological 
effects most marijuana users seek (Bradford, 2015).  
Lab test reveal that the potency of marijuana in Colorado since legalization is 
more than twice as potent as illegal marijuana of the past ten years and some strains of 
legal marijuana is three times as potent (Briggs, 2015). Prior to legalization the levels of 
THC were typically below 10 percent. However, research now indicates that the post-
legalization levels of Colorado’s marijuana averages around 18.7 percent with some 
marijuana strains containing THC levels of 30 percent or more (Briggs. 2015). These 
results were provided by Charas Scientific, a Denver based lab licensed and hired by the 
state to test and measure the THC levels of marketable marijuana (Briggs, 2015).  
Addressing this concern at this point in time is particularly important because as 
of as 2019, 33 states and the District of Columbia plus Guam and Puerto Rico have had 
passed laws legalizing medical marijuana with 11 of these states and the District of 
Columbia also implementing recreational marijuana laws (Hartig & Geiger, 2018; NCSL, 
2019; Governing Data, 2019) However, these laws vary by state. For instance, Colorado 
has legalized marijuana for both recreational and medical use (Governing, 2018). While 
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other states, like Georgia have only legalized medical marijuana products that have High 
CBD/Low THC concentrations for specific medical conditions (Governing Data, 2018; 
National Conference of State Legislatures [NCSL], 2019). With only a few states like 
Idaho that have not legalized marijuana for any reason (Governing, 2018; NCSL, 2019). 
Nevertheless, the trend in attitude toward marijuana is ever evolving. My study was 
intended to address the effects of continued marijuana legalization on the mental health 
conditions, depression and suicide ideation. This aim was achieved by comparing the 
year 2008 when only 13 states had legalized medical marijuana to the year 2017 when 27 
states and District of Columbia had legalized medical marijuana with seven of these 
states and the District of Columbia also legalizing recreational marijuana (Governing 
Data, 2018; NCSL, 2019).  
In the United States, marijuana has experienced a controversial and highly 
debated path. For several years proponents of marijuana have lobbied for legalization of 
the substance touting the medical implications and attempting to the discredit the 
implications of its harmful effects. However, despite these efforts the Drug Enforcement 
Administration (DEA) still classifies marijuana as a schedule I controlled substance (U.S. 
Department of Justice, 2017). Nevertheless, the current trend in attitude favoring 
marijuana use for medical and recreational purposes is growing. This is evidenced by 
reports indicating a decline in individuals who consider the occasional use (1-2 times per 
week) of marijuana as a perceived risk (Schuermeyer et al., 2014). For instance, in 
Colorado the percent of those who believe marijuana use is a perceived risk declined 
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from 45% to 31% between groups studied from 2007 to 2008 and those studied from 
2010 to 2011, respectively (Schuermeyer, et al, 2014). 
Considering the current trend in marijuana liberalization, it is more important now 
than ever for policy makers, public health and health care personnel to emphasize or 
reiterate the potential adverse effects of the substance. This is especially important given 
the rising THC levels seen in medical and recreational marijuana and products produced 
from marijuana. It is also reasonable to assume that as legalization gains greater 
acceptance the use of marijuana will also increase and therefore so will the occurrence of 
adverse effects.  
Sevigny et al., (2014) addressed the potency of medical marijuana that has 
reportedly increased since legalization. This increase in potency is presumably due to less 
restrained regulations that created an environment of improved cultivation and production 
techniques. Sevigny et al., (2014) identified two marijuana markets, medical and 
recreational, and these markets are interrelated such that cross over in technological 
advances for production and cultivation occurs. The authors further posited that surplus 
medical marijuana is being diverted to the recreational market (Sevigny, Pacula, & 
Heaton, 2014). The results of the first model in this study demonstrated a significant 
increase in marijuana THC content in jurisdictions that legalized marijuana for medical 
purposes (Sevigny et al., 2014). However, the remaining models added potentially 
competing variables which provided results that were not statistically significant.  
In addition, support for the cross-over or diversion of marijuana premise 
presented by Sevigny and colleagues is provided in a related study. In which 
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Salomonsen-Saulel, et al. (2012) addressed the extent of medical marijuana use by the 
non-registered (non-patient) marijuana using population. The results of this study 
demonstrated that the majority, approximately 74% adolescents in treatment had used 
medical marijuana obtained from registered medical marijuana patients (Salomonsen-
Saulel et al., 2012). Thus, demonstrating a high rate and widespread pattern of medical 
marijuana use by the non-patient recreational using population. Thus, the effects of 
producing high-potency medical marijuana potentially impacts the quality and 
availability of these highly potent marijuana strains to the recreational using market. 
In another study, Wen, Hockenberry, and Cummings (2015) addressed the effects 
of MMLs on the use of marijuana and other controlled substances. This study 
demonstrated that implementation of MMLs resulted in a parallel increase in marijuana 
use among participants age 21 and older (Wen et al., 2015). These increases occurred 
immediately after MMLs were implemented and continued for three years after 
implementation (Wen et al., 2015). In addition, Wen et al., (2015) reported a 10% 
increase in marijuana abuse/dependence among participants age 21 and older. Thus, 
indicating cause for public health concern as MMLs may have the potential to increase 
risk of progressing to marijuana abuse/dependence (Wen et al., 2015).  
The effects of marijuana potency on health is an important public health concern 
as there is a growing body of evidence supporting the association between cannabis use 
and the development of psychotic or mental health disorders (Moore et al., 2007). 
However, few studies have addressed this association since the rise in THC demonstrated 
post legalization. Volkow et al., (2014) posited that previous research has demonstrated 
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that anxiety, depression, and psychosis are associated with regular marijuana use. 
However, causality is not well founded as determining causality is hindered by 
confounders that also contribute to the development of these conditions (Volkow et al., 
2014). 
In a previous related study, Lev-Ran et al. (2014) conducted a systematic review 
and meta-analysis of existing longitudinal studies to determine patterns of cannabis use 
that are associated with the development of depression. Lev-Ran et al. (2013) concludes 
that the risk of developing depressive disorders is increased by cannabis use, and this risk 
is more significant among heavy cannabis users and those with cannabis use disorder. 
These findings are supported by van Gastel et al. (2013) which also indicates that 
marijuana use has been associated with psychiatric symptoms and the risk is increased by 
regular or heavy marijuana use. 
These studies demonstrate support for the gap in the research that highly potent 
marijuana presents and this study intended to address. The notion that marijuana use may 
cause or exacerbate mental illness and psychosis is not a new concept as several studies 
have demonstrated this association (Murray et al., 2016). However, many of these 
previous studies were conducted prior to the legalization of marijuana and the concurrent 
increase in marijuana potency as the level of THC has been rising. The use of highly 
potent marijuana would be expected to have effects similar to that seen in heavy users or 
those who abuse marijuana. Additional support for this gap in the research is provided by 
Di forte et al. (2009) which posited that previous studies have demonstrated an increase 
of psychosis in association with marijuana use. However, Di forte et al. (2009) further 
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posited that “these studies have not collected detailed data on the patterns of use or 
potency of the cannabis used, which may be important factors moderating the associated 
risk” (para. 6). Therefore, my current study intended to address this gap in the research as 
the potential implications of widespread legalization and highly potent marijuana with 
elevated THC levels should be a major public health concern. Chapter three which 
follows is intended to provide an in-depth description of the research design and 




Chapter 3: Research Method 
Population 
The NSDUH is conducted by RTI International, Research Triangle Park, North 
Carolina and sponsored by the Center for Behavioral Health Statistics and Quality 
(CBHSQ), Substance Abuse and Mental Health Services Administration (SAMHSA), an 
agency within the U.S. Department of Health and Human Services (NSDUH-codebook, 
2017; NCBI, 2018). The mission of SAMHSA is “to reduce the impact of substance 
abuse and mental illness on America's communities” (National Center for Biotechnology 
[NCBI], 2018; para. 1). Therefore, understanding the nature of the relationship between 
marijuana and mental health conditions is important to developing evidence-based health 
policies as this information can serve to inform policy makers, practitioners, and public 
health professionals. 
Sampling  
In order to ensure adequate representation, the NSDUH sampling plan used 
multilayer stratification which consisted of three levels or strata. For the first or primary 
level, each state was divided into state sampling regions (SSRs) that were approximately 
equal in size geographically. Such that each SSR would yield about the same number of 
interviews per sampling period. Nevertheless, in all the United States was divided into 
750 SSRs, with the following breakdown by state,  
“36 SSRs in California; 30 SSRs each in Florida, New York, and Texas; 24 SSRs 
each in Illinois, Michigan, Ohio, and Pennsylvania; 15 SSRs each in Georgia, 
138 
 
New Jersey, North Carolina, and Virginia; and 12 SSRs each in the remaining 38 
states and the District of Columbia” (NSDUH-codebook, 2015, p. i-14).  
The second level (strata) was based on census tracts that were aggregated within 
SSRs to meet the minimum number of dwelling unit (DU) requirements by state. Each 
SSR included 48 census tracts. The third level or strata was created by establishing 
census block groups within each census tract. Each census block group was then 
partitioned into smaller geographical regions and grouped into adjacent clusters. These 
geographical clusters or tertiary sampling units (TSUs) were used for the coordinated 
sampling design (NSDUH-codebook, 2017. 
Data Collection 
Prior to participant recruitment, census tracts, census blocks, and census segments 
were selected within each SSR (NSDUH-codebook, 2017). After which DUs were then 
identified within each census segment. DU selection was based on the classification of 
the state where the segment belonged (NSDUH-codebook, 2017). Once the DUs were 
identified, individuals were then selected based on the age of residents within the DU 
(NSDUH-codebook, 2017). The DU would then receive an introductory letter informing 
the residents that they had been randomly selected for participation in the NSDUH 
(Center for Behavioral Health Statistics and Quality [CBHSQ], 2016). The field 
interviewer conducted in-person interview with an adult respondent of the dwelling unit 
to obtain basic demographic information. Then depending on the composition of the 
household, two residents of the DU were selected for interviewing based on a 
preprogrammed selection algorithm (CBHSQ, 2016). After the screening process, the 
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interview was conducted in a private area of the home. The interviewer used both 
computer-assisted personal interviewing (CAPI) and audio computer-assisted self-
interviewing (ACASI) techniques (CBHSQ, 2016). The CAPI portion of the interview 
was used to collect and record verbal responses to questions read aloud by the interviewer 
who entered these responses into a computer (CBHSQ, 2016). In contrast, the ACASI 
portion of the interview is used to collect information on answers to sensitive questions 
(NSDUH-codebook, 2017). During this portion of the interview, respondents use 
headphones to listen to questions and enters responses directly into a computer (NSDUH-
codebook, 2017). Throughout the interview process (written and oral) respondents are 
assured that their confidentiality, anonymity, and responses are protected and handled 
according to federal law compliance regulations (CBHSQ, 2016; NSDUH-codebook, 
2017). After the respondent completed the ACAI portion of the interview, the field 
interviewer returned to CAPI mode to complete the interview by asking questions 
pertaining to the respondent’s household composition, health insurance, and personal and 
family income, handled in strict compliance with federal law (CBHSQ, 2016). Finally, 
each respondent that completed the survey process was given $30 cash incentive 
(CBHSQ, 2016). 
Data Analysis Plan 
In my study, I assessed whether the trend in marijuana policies and legalization 
which favor marijuana acceptance for both medical and recreational use effects mental 
health conditions. Moreover, I addressed depression and suicide ideation and compared 
early marijuana legalization years when only a few states had medical marijuana laws to 
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later marijuana legalization years when numerous states have adopted medical and 
recreational marijuana laws. For this purpose, two years were selected for comparing 
these periods in time. For early marijuana legalization period, 2008 NSDUH data was 
selected and for later marijuana legalization period, 2017 NSDUH data was selected. In 
2008, only 13 states had implemented laws legalizing marijuana use for medical purposes 
only (NCSL, 2019). By 2017, 29 states and the District of Columbia had passed laws 
legalizing medical marijuana with seven of these states and the District of Columbia also 
implementing recreational marijuana laws (Governing Data, 2018; NCSL, 2019). Further 
support for the premise of this study is provided by Keyhani, et al., (2018) who posited 
that “these legal changes have been accompanied by an increase in daily marijuana use, 
as well as in marijuana dependence, among adults in the U.S. population” (para. 1). This 
is evidenced by an increase in prevalence for marijuana use among adults in the general 
population which has doubled over the course of the last decade as 13.3% of respondents 
in this group reported using marijuana during the past year in 2014 (Keyhani, et al., 
2018). 
 I used Chi-Square and complex samples logistic regression analyses in this 
quantitative study to assess the statistical significance of marijuana use and mental health 
as legalization changed from 2008 to 2017. In order to derive the weighing amounts, 
certain calculations were made first. Three steps of calculations were made for sample 
weights. First of all, the final probability was determined by calculating the product of the 
probability of an individual being selected, the probability of the household being 
selected, the probability of the section of the PSU being selected, and the probability of 
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the PSU being selected (CDC, 2020). This then had to be adjusted for nonresponse. The 
final adjustment that is made is the poststratification adjustment for the purpose of 
matching the control totals derived from the year 2000 and 2010 United States Census 
population. SPSS statistical software was used to perform all calculations. Descriptive 
statistics include past year marijuana use, state medical marijuana status, age, sex, and 
socioeconomic status, as well as adult and youth major depressive episodes and suicide 
ideation in the past year. 
 Inferential statistics for this analysis were conducted based on the following 
research questions and hypotheses. 
Research Questions 
 This study was guided by three research questions to assess the association 
between marijuana and depression, between marijuana and suicide ideation, and whether 
these associations were stronger in 2017 than in 2008 for both adults and adolescents. 
The research questions were as follows.  
RQ1: Is marijuana use associated with depression and suicidal ideation in adults 
in 2008 and 2017, either in isolation using raw (unadjusted) values or using values 
adjusted for age, sex, annual family income, and education? 
RQ2: Is marijuana use associated with depression and suicidal ideation in 
adolescents in 2008 and 2017, either in isolation using raw (unadjusted) values or using 
values adjusted for age, sex, annual family income, and education? 
RQ3: Are the associations between marijuana use and depression and between 
marijuana use and suicide ideation higher in 2017 than in 2008 for both adults and 
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adolescents, either in isolation using raw (unadjusted) values or using values adjusted for 
age, sex, annual family income, and education? 
Study Hypotheses 
 Accordingly, the hypotheses for this study, each stated in null form, were as 
follows. 
For the 2008 data: 
H01: There will be no statistically significant relationship between MJ use and 
depression (major depressive episode in the last year) in the adult 2008 cohort, 
either in isolation using raw (unadjusted) values or using values adjusted for age, 
sex, annual family income, and education. 
H02: There will be no statistically significant relationship between MJ use and 
suicidal ideation in the adult 2008 cohort, either in isolation using raw 
(unadjusted) values or using values adjusted for age, sex, annual family income, 
and education. 
H03: There will be no statistically significant relationship between MJ use and 
depression (major depressive episode in the last year) in the adolescent 2008 
cohort, either in isolation using raw (unadjusted) values or using values adjusted 
for age, sex, annual family income, and education. 
H04: There will be no statistically significant relationship between MJ use and 
suicidal ideation in the adolescent 2008 cohort, either in isolation using raw 




For the 2017 data: 
H05: There will be no statistically significant relationship between MJ use and 
depression (major depressive episode in the last year) in the adult 2017 cohort, 
either in isolation using raw (unadjusted) values or using values adjusted for age, 
sex, annual family income, and education. 
H06: There will be no statistically significant relationship between MJ use and 
suicidal ideation in the adult 2017 cohort, either in isolation using raw 
(unadjusted) values or using values adjusted for age, sex, annual family income, 
and education. 
H07: There will be no statistically significant relationship between MJ use and 
depression (major depressive episode in the last year) in the adolescent 2017 
cohort, either in isolation using raw (unadjusted) values or using values adjusted 
for age, sex, annual family income, and education. 
H08: There will be no statistically significant relationship between MJ use and 
suicidal ideation in the adolescent 2017 cohort, either in isolation using raw 
(unadjusted) values or using values adjusted for age, sex, annual family income, 
and education. 
For comparing 2008 and 2017 data: 
H09: There will be no statistically significant increase in the strength of the 
relationships between MJ use and depression (Major Depressive Episode in the 
last year) in the adult 2017 cohort compared to the adult 2008 cohort. 
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H010: There will be no statistically significant increase in the strength of the 
relationships between MJ use and suicidal ideation in the adult 2017 cohort 
compared to the adult 2008 cohort. 
H011: There will be no statistically significant increase in the strength of the 
relationships between MJ use and depression (Major Depressive Episode in the 
last year) in the adolescent 2017 cohort compared to the adolescent 2008 cohort. 
H012: There will be no statistically significant increase in the strength of the 
relationships between MJ use and suicidal ideation in the adolescent 2017 cohort 
compared to the adolescent 2008 cohort. 
I used crosstabs and a logistic regression analysis to assess the association 
between the dependent variable(s) and the independent variable. The early legalization 
year was appointed as 2008 and later legalization year as 2017. The independent variable 
for these research questions was past year marijuana use while the dependent variables 
were depression and suicide ideation. I also used Pearson’s χ2 test to determine 
inferential statistics for H01 and Ha1. To reject the null hypotheses the proper P-value is 









Variable Name Type Variable Level of Measurement 
Marijuana Use Independent Variable  Nominal Dichotomous 
Age Control Variable Interval/Ratio 
Sex Control Variable Nominal Dichotomous 
Level of Education Control Variable Interval/Ratio 
Family Income Control Variable Interval/Ratio 
Depression Dependent Variable Nominal Dichotomous 
Suicide Ideation Dependent Variable Nominal Dichotomous 
 
Measures 
 The NSDUH-Codebook (2017) provides the following descriptions and recoding 
for measures (variables & covariates) used:  
Marijuana Past Year Use 
The independent variable MRJYR defines marijuana use in the past year. The 
variable was recoded as “0 = Did not use in the past year” and “1= used within the past 
year” (NSDUH-codebook, 2008 p.130).”  
Adolescent (Youth) Major Depression Past Year 
This variable was coded as YMDEYR and identifies and individual as having a 
major depressive episode in the past year. The variable was recoded as YMDEYR = 1 for 
“respondents who were classified with lifetime MDE (YMDELT=1) and who reported 
that during the past 12 months they had a period of depression lasting 2 weeks or longer, 
while also having some of the other symptoms mentioned, were classified as having past 
year depression” (NSDUH-codebook, 2017, p. 454-455). While YMDEYR = 2 for 
“respondents with no lifetime MDE (YMDELT=1 for youths) or respondents with 
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lifetime MDE (YMDELT=1) but no period of depression lasting 2 weeks or longer while 
having other symptoms were defined as not having past year MDE” (NSDUH-codebook, 
2017, p.454-455).  
Adult Major Depression Past Year 
This variable was coded as AMDEYR and identifies and individual as having a 
major depressive episode in the past year. The variable was recoded as AMDEYR = 1 for 
“respondents who were classified with lifetime MDE (AMDELT=1) and who reported 
that during the past 12 months they had a period of depression lasting 2 weeks or longer, 
while also having some of the other symptoms mentioned, were classified as having past 
year depression” (NSDUH-codebook, 2017, p.454-455) While AMDEYR = 2 for 
“respondents with no lifetime MDE (AMDELT=2 for adults) or respondents with 
lifetime MDE (AMDELT=1) but no period of depression lasting 2 weeks or longer while 
having other symptoms were defined as not having past year MDE” (NSDUH-codebook, 
2017, p.454-455).  
Suicide Ideation 
This variable was coded as MHSUITHK and identifies individuals that “seriously 
thought about killing self in past year” (NSDUH-codebook, 2008, p.464, 467).” The 
variable was coded as SUICTHNK. Wherein 0 = No (SUICTHNK=2) and 1 = Yes 




This covariable coded as CATAG6 defines the age of participants and was 
recoded as “1=12-17 years old,” “2=18-25 years old,” “3=26-34 years old,” “4=35-49,” 
“5=50-64 years old,” “6=65 or older” (NSDUH-codebook, 2017, p.548).  
Sex 
This covariable SEX defines the gender of participants and recoded as 1=Male, 
and 2=Female. 
Socioeconomic Status 
Respondent’s Family income was used for Socioeconomic Status. The variable 
IRFAMIN3 defines the income of the household that the participant resides in. This 
variable was recoded as “1 = Less than $10,000”, “2 = $10,000 - $19,000,” “3 = $20,000 
- $29,999,” “4 = $30,000 – 39,999”; “5 = $40,000 – 49,999”; “6 = $50,000 - $74,999” 
and “7 = $75,000 or More” (NSDUH-codebook, 2017, P.575). 
Education 
 For Adult level of education, this covariable coded as EDUCCAT2 defines the 
level of education adults achieved. This variable was recoded as “1= Less than High 
School Diploma”, “2 = Completed High School”, “3 = Some College”, “4 = Completed 
College” and “5 = 12 to 17-year old” (NSDUH-codebook, 2008, p. 598). 
 For Adolescent level of education, this covariable coded as EDUSCHGRD2 
defines the level of education adolescents achieved “1 = 5th Grade or lower”, “2 = 6th 
Grade”, “3 = 7th Grade”, “4 = 8th Grade”, “5 = 9th Grade”, “6 = 10th Grade”, “7 = 11th 
Grade”, “8 = 12th Grade”, 9 = College or university/1st year”, 10 = College or 
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university/2nd Year, 3rd year, 11 = College or university/4th Year, 5th or higher year” 
(NSDUH-codebook, 2017, p. 550).  
Threats to Validity 
 Addressing threats to external validity is important to ensuring that the research 
study sample and results are generalizable to the population of interest as well as across 
different populations, settings, & time (Laerd dissertation, 2012). Researchers must 
therefore mitigate these threats to ensure that conclusions or inferences made are due to 
the study design and not some other factor (Creswell, 2009). Threats to internal validity 
occurs when there are problems with the experimental procedure, treatments or 
participant experiences that threaten the researchers’ ability to make correct inferences 
about the population of interest using the data obtained. According to Creswell (2009) the 
following list represents examples of threats to internal validity: History; Maturation; 
Regression; Selection; Mortality; Diffusion; Compensatory Demoralization; 
Compensatory Rivalry; Testing and Instrumentation. This study utilizes secondary data 
obtained from the NSDUH which utilizes a cross-sectional, non-experimental, random 
selection approach which served to reduce or eliminate many of these threats. For 
instance, the cross-sectional approach reduces or eliminates threats associated with 
history, maturation, and testing (Laerd Dissertation – Internal Validity, (2012), p.1-3). In 
contrast, the non-experimental nature of the study reduces threats associated with 
diffusion of treatment, compensatory demoralization, and compensatory rivalry (Laerd 
Dissertation – Internal Validity, 2012, p.4). Finally, random selection reduces threats 
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associated with regression and selection (Laerd Dissertation – Internal Validity, (2012), 
p.5).   
In contrast, threats to external validity occurs when the researcher applies 
incorrect inferences to other populations, settings, or time (Creswell, 2009). Thus, threats 
to external validity are concerned with the generalizability of the study’s results 
(Frankfort-Nachmias & Nachmias, 2007). According to Frankfort-Nachmias and 
Nachmias (2007) there are three major concerns when addressing external threats to 
validity these include: 1) Representativeness of the sample; and 2) Reactive 
rearrangements in the research procedure; and  3) Interaction of selection and treatment; 
To reduce these threats the NSDUH sampling plan utilized multilayer stratification which 
consisted of three levels or strata (NSDUH-codebook, 2017). For the first or primary 
level, each state was divided into State Sampling Regions (SSRs) that were 
approximately equal in size geographically; such that each SSR would yield about the 
same number of interviews per sampling period (NSDUH-codebook, 2017). The second 
level (strata) was based on census tracts that were aggregated within SSRs to meet the 
minimum number of dwelling unit (DU) requirements by state. The third level or strata 
was created by establishing census block groups within each census tract. Each census 
block group was then partitioned into smaller geographical regions and grouped into 
adjacent clusters. These geographical clusters or tertiary sampling units (TSUs) were 
used for the coordinated sampling design (NSDUH-codebook, 2017). External threats 
were further reduced by the data collection process, wherein the interview was conducted 
in a private area of the home using both computer-assisted personal interviewing (CAPI) 
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and audio computer-assisted self-interviewing (ACASI) techniques (CBHSQ, 2016). The 
CAPI portion of the interview was used to collect and record verbal responses to 
questions read aloud by the interviewer who entered these responses into a computer and 
the ACASI portion of the interview is used to collect information on answers to sensitive 
questions (CBHSQ, 2016; NSDUH-codebook, 2017). During the ACASI portion of the 
interview, respondents used headphones to listen to questions and enter responses directly 
into a computer (NSDUH-codebook, 2075). All information was de-identified and 
throughout the interview process (written and oral) respondents were assured that their 
confidentiality, anonymity, and responses were protected and handled according to 
federal law compliance regulations (CBHSQ, 2016; NSDUH-codebook, 2017). 
Sample Size 
The sample size for the 2008 and 2017 NSDUH datasets consisted of responses 
from 67,928 and 68,032 participants, respectively (NSDUH-codebook, 2008; NSDUH-
codebook, 2017). In this study I evaluated U.S. residents 12 years and older residing in 
all 50 states and the District of Columbia. The quantitative approach allows one to study 
effects in small groups of people and make inferences about larger populations (Ellis, 
2010). However, obtaining statistically significant results is reliant on sample size as the 
larger the sample size the more likely an effect will be accepted as statistically significant 
(Ellis, 2010). For instance, Ellis (2010) posit that “if the expected effect size is 
overestimated, required sample sizes will be underestimated and the study will be 
inadequately powered” (p.61).  
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 Determining an appropriate sample size relies on three variables: 1) the 
significance level or criterion (α), the power (1-β), and the effect size (d) (Ellis, 2010). 
The significance criterion or Alpha (α) level is the error rate that the researcher is willing 
to accept and is often set at .05 or .01 (Ellis, 2010; Suresh & Chandrashekara, 2012). In 
this study, I used an Alpha level of .05 and this means I was willing to accept that there is 
a 5% (or five percent?) chance that the study results are due to chance (Ellis, 2010; 
Suresh & Chandrashekara, 2012). The alpha (α) level is a measure of Type I error which 
occurs when the null hypothesis is inadvertently rejected when it is actually true 
(Banerjee, Chitnis, Jadhav, Bhawalkar, & Chaudhry, 2009). In contrast, power refers to 
the likelihood that a statistical analysis will correctly identify an effect in a population if 
one exists. Power (1-β) is inversely related to the probability of making a type II error 
which occurs when the null hypothesis is not rejected when it is actually false (Banerjee, 
Chitnis, Jadhav, Bhawalkar, & Chaudhry, 2009). The commonly set value for power is 
0.80 (Ellis, 2010). Type I and II errors can lead to erroneous inferences that researchers 
seek to avoid by selecting an appropriate sample size as larger sample sizes are less likely 
to differ substantially from the study population (Banerjee et al., 2009). Finally, effect 
size is related to the magnitude of difference that exists between two groups and is 
quantified as the size of the association that a study seeks to detect in a sample (Ellis, 
2010; Banerjee et al., 2009).  
 The sample size was calculated utilizing G*Power software, obtained from the 
Heinrich Heine University website (Heinrich Heine University Dusseldorf [HHU], 2018). 
In this study I used multiple logistic regression with one dependent variable and multiple 
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independent variables. Therefore, the test family selected was “z tests” with logistic 
regression selected as the statistical test. The following values were entered into the 
G*Power software: an α error probability of 0.05, the desired power was 0.80, and an 
effect size (odds ratio) of 1.3 was designated as demonstrated in similar studies of this 
type (Han, Compton, Blanco, & Jones, 2018). The G*Power software estimated a 
minimal sample size of 1,447. To ensure adequate power, I used a larger sample size than 
the minimal recommended by G*Power software. 
Ethical Considerations/Procedures 
 Since I used secondary data obtained from the NSDUH then informed consent 
was obtained, and data was de-identified prior to my use (NSDUH-codebook, 2017). For 
instance, in order to protect the confidentiality of data the NSDUH used a statistical 
disclosure limitation method which served to eliminate all personal identifying 
information such as, name, phone number, address, and geographical information 
(NSDUH-codebook, 2017). In addition, the NSDUH obtains information in a secure 
manner and this data is available for public use. Nevertheless, the Walden Institutional 
Review Board (IRB) confirmed that this doctoral capstone meets the University’s ethical 
standards and will oversee the capstone data analysis and results reporting. Approved on 
12-3-2018, IRB Approval number 12-3-18-0188278.  
Summary 
This chapter presents a detailed description of the research methods used in this 
study. The chapter begins with a description of the NSDUH, the source of secondary data 
intended for use in this study, a description of the research design and rationale and the 
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methodology used to identify the target population, as well as sampling, and data 
collection methods. This chapter then describes the data analysis plan which includes the 
research questions and a description of the independent and dependent variables, 
measures, and coding/re-coding of variables. Finally, this chapter describes and addresses 
threats to validity, provides an explanation for determining sample size and discusses 
ethical considerations of the study.  Chapter 4 which follows will serve to analyze, 
present, and describe research findings.   
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Chapter 4: Results  
Introduction 
 This quantitative study was designed to investigate whether there were 
statistically significant associations between marijuana use and the mental health 
conditions (MHC) of MDE and suicide ideation in adolescents and adults, and whether 
these associations increased from 2008 to 2017. Study data from the NSDUH database 
were used to compare an early medical marijuana legalization year (2008), when only 13 
states had legalized marijuana for medicinal purposes only, to a more current legalization 
year (2017), when 28 states and the District of Columbia had implemented medical 
marijuana laws and eight of these states plus the District of Columbia also legalized 
recreational marijuana (Governing Data, 2018; NCSL, 2019). 
 This chapter begins with a review of the research questions and study hypotheses. 
Data collection steps are reviewed, followed by a review of the data analysis plan. 
Results from hypothesis testing are provided. This chapter ends with a summary of major 
findings. 
Research Questions 
 In this study I was guided by three research questions to assess the association 
between marijuana and depression, between marijuana and suicide ideation, and whether 
these associations were stronger in 2017 than in 2008 for both adults and adolescents. 
The research questions were as follows.  
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RQ1: Is marijuana use associated with depression and suicidal ideation in adults 
in 2008 and 2017, either in isolation using raw (unadjusted) values or using values 
adjusted for age, sex, annual family income, and education? 
RQ2: Is marijuana use associated with depression and suicidal ideation in 
adolescents in 2008 and 2017, either in isolation using raw (unadjusted) values or using 
values adjusted for age, sex, annual family income, and education? 
RQ3: Are the associations between marijuana use and depression and between 
marijuana use and suicide ideation higher in 2017 than in 2008 for both adults and 
adolescents, either in isolation using raw (unadjusted) values or using values adjusted for 
age, sex, annual family income, and education? 
Study Hypotheses 
 Accordingly, the hypotheses for this study, each stated in null form, were as 
follows. 
For the 2008 data: 
H01: There will be no statistically significant relationship between marijuana (MJ) 
use and depression (major depressive episode in the last year) in the adult 2008 
cohort, either in isolation using raw (unadjusted) values or using values adjusted 
for age, sex, annual family income, and education. 
H02: There will be no statistically significant relationship between MJ use and 
suicidal ideation in the adult 2008 cohort, either in isolation using raw 




H03: There will be no statistically significant relationship between MJ use and 
depression (major depressive episode in the last year) in the adolescent 2008 
cohort, either in isolation using raw (unadjusted) values or using values adjusted 
for age, sex, annual family income, and education. 
H04: There will be no statistically significant relationship between MJ use and 
suicidal ideation in the adolescent 2008 cohort, either in isolation using raw 
(unadjusted) values or using values adjusted for age, sex, annual family income, 
and education. 
For the 2017 data: 
H05: There will be no statistically significant relationship between MJ use and 
depression (major depressive episode in the last year) in the adult 2017 cohort, 
either in isolation using raw (unadjusted) values or using values adjusted for age, 
sex, annual family income, and education. 
H06: There will be no statistically significant relationship between MJ use and 
suicidal ideation in the adult 2017 cohort, either in isolation using raw 
(unadjusted) values or using values adjusted for age, sex, annual family income, 
and education. 
H07: There will be no statistically significant relationship between MJ use and 
depression (major depressive episode in the last year) in the adolescent 2017 
cohort, either in isolation using raw (unadjusted) values or using values adjusted 
for age, sex, annual family income, and education. 
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H08: There will be no statistically significant relationship between MJ use and 
suicidal ideation in the adolescent 2017 cohort, either in isolation using raw 
(unadjusted) values or using values adjusted for age, sex, annual family income, 
and education. 
For comparing 2008 and 2017 data: 
H09: There will be no statistically significant increase in the strength of the 
relationships between MJ use and depression (Major Depressive Episode in the 
last year) in the adult 2017 cohort compared to the adult 2008 cohort. 
H010: There will be no statistically significant increase in the strength of the 
relationships between MJ use and suicidal ideation in the adult 2017 cohort 
compared to the adult 2008 cohort. 
H011: There will be no statistically significant increase in the strength of the 
relationships between MJ use and depression (Major Depressive Episode in the 
last year) in the adolescent 2017 cohort compared to the adolescent 2008 cohort. 
H012: There will be no statistically significant increase in the strength of the 
relationships between MJ use and suicidal ideation in the adolescent 2017 
cohort compared to the adolescent 2008 cohort. 
Data Collection 
 Data were obtained from the years 2008 and 2017 NSDUH databases. Since this 
study used deidentified secondary data, there was no direct contact with survey 
participants. After receiving approval from the Walden University (approval number 12-
03-18-0188278) and registration with the Interuniversity Consortium for Political and 
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Social Research, the 2008 and 2017 data were downloaded from NSDUH in SPSS 
(Statistical Package for the Social Sciences, version 23) format. The 2008 NSDUH 
dataset included 37,504 adult cases and 17,606 adolescent cases. The 2017 NSDUH 
dataset included 42,554 adult cases and 13,722 adolescent cases (NSDUH-codebook, 
2008; NSDUH-codebook, 2017). Cases for each analysis were included if they were not 
missing the data necessary to address the research questions, so the sample sizes varied 
somewhat from analysis to analysis. For example, the sample sizes for adolescent suicidal 
ideation were smaller than for adolescent MDE because of missing values for the 
adolescent cohorts.  
Data Analysis 
 Data descriptive included frequencies percentages or means and standard 
deviation, as appropriate, for sex, age, level of education, family income distribution, 
major depression episode and suicide ideation. Hypothesis testing with inferential 
statistics consisted odds ratios (ORs) with 95% confidence intervals derived from 
crosstabs to determine ORs in isolation and with binary logistic regression to account for 
age, sex, family income, and education. Differences were considered to be statistically 
significant at the p < .05 threshold. For simplicity, results are presented for 2008 adults, 
2008 adolescents, 2017 adults, and 2017 adolescents, with a summary section to address 
the research questions.  
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2008 Adult Results 
2008 Adult Descriptive Statistics 
Table 4 shows that the 2008 adult sample was well divided between males (47%) 
and females (53%). Ages ranged from 18 to over 65. Roughly half of cases were between 
20 and 34 years old (51%). Education levels ranged from less than high school diploma 
to college degree. Roughly half (49%) had some college education or completed college. 
Annual family incomes ranged from less than $10,000 to $75,000 or greater. Roughly 





2008 Adults Demographic Frequencies and Percentages (N = 34,504) 
Demographic n % 
Sex 
      Males 
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      19 
      20 
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      22 or 23 
      24 or 25 
      26 to 29 
      30 to 34 
      35 to 49 
      50 to 64 


























      Less than High School Diploma 
      Completed High School 
      Some College 











Family Income Distribution 
      Less than $10,000 
      $10,000 - $19,999 
      $20,000 - $29,999 
      $30,000 - $39,999 
      $40,000 - $49,999 
      $50,000 - $74,999 





















2008 Adult Hypothesis Testing 
Marijuana use and depression, 2008 Adults. Overall MJ use was 18% in the 
2008 Adult cohort (6810 of 37186) for this analysis and the rate of MDE was 8% (3024 
of 37186). Table 5 shows that 12% of MJ users reported MDE in the recent year 
compared to (7%) for non-MJ users. This disproportionality was statistically significant, 
2 (df = 1) = 171.8, p < .0001. The odds of MDE was 0.14 for users and .08 for non-
users. The odds ratio of 1.75, indicated that adult MJ users had 75% greater odds of 
having MDE in the previous year than non-users (see Gertsman, 2008). This statistically 
significant finding rejected Null Hypothesis 1 (H01).  
Table 5 
Marijuana and Depression: 2008 Adults 
Marijuana    Major Depressive Episode     
Use Stat Yes No Total Odds 
No Count 2203 28173 30376 0.08 
 % 7% 93% 100%  
Yes Count 821 5989 6810 0.14 
 % 12% 88% 100%  
Total Count 3024 34162 37186 1.75 
  % 8% 92% 100% Odds Ratio 
 
Table 6 shows that, after accounting for age, sex, family income, and education 
level, the odds ratio for the relationship between MJ and MDE in adults was 1.39 (p < 
.0001). This finding indicates that adult MJ users had 39% greater odds of having MDE 
in the previous year than non-users (see Gertsman, 2008), after accounting for age, sex, 
family income, and level of education. This statistically significant finding rejected Null 




Coefficients Table: 2008 Adults MDE 
Variable B S.E. df p-value OR Confidence 
Intervals 
Marijuana Use        
  Yes 
  No 
.33 
Reference 
0.11 1 0.005 1.39 1.11 1.75 
 Sex        
       Female .88 0.12 1 <.0001 2.42 1.87 3.13 
       Male Reference       
Income -.04 0.02 1 0.09 0.95 0.90 1.01 
Education        
  Less than   
  High School                                        
-.03 0.12 1 0.82 0.97 0.77 1.23 
  High School    
  Graduate        
-.40 0.16 1 0.02 0.68 0.49 0.94 
  Some College -.04 0.14 1 0.78 0.96 0.73 1.26 
  Completed     
  College 
Reference       
 Age .02 0.03 1 0.48 1.02 0.96 1.09 
Note: The degrees of freedom in computing the confidence limits is 60 
 
 
Marijuana use and suicidal ideation, 2008 Adults. Overall adult MJ use in the 
2008 cohort was 18% (6,849 of 37,360) for this analysis. Table 7 shows that 11% of MJ 
users reported suicidal ideation in the recent year compared to 5% for non-MJ users. This 







Marijuana and Suicidal Ideation: 2008 Adults 
Marijuana    Suicidal Ideation     
Use Stat Yes No Total Odds 
No Count 1383 29128 30511 0.05 
 % 5% 95% 100%  
Yes Count 706 6143 6849 0.11 
 % 10% 90% 100%  
Total Count 2089 35271 37360 2.42 
  % 94% 6% 100% Odds Ratio 
 
The odds of suicide ideation were 0.11 for users and 0.05 for nonusers. The odds 
ratio of 2.42 indicated that adult MJ users had more than double the odds of having 
suicidal ideation in the previous year than nonusers. This statistically significant finding 
rejected Null Hypothesis 2.  
Table 8 shows that, after accounting for age, sex, family income, and education 
level, the odds ratio for the relationship between MJ and suicidal ideation was 1.50 (p = 
.0016) This finding indicates that adult MJ users had 50% greater odds of having suicidal 
ideation in the previous year than nonusers (see Gertsman, 2008), after accounting for 
age, sex, family income, and level of education. This statistically significant finding 






Coefficients Table: 2008 Adults Suicide Ideation 
Variable B S.E. d
f 




       
Yes .40 .12 1 .002 1.50 1.18 1.92 
       No Reference       
Sex        
       Female .33 .14 1 .02 1.40 1.05 1.87 
       Male Reference       
Income -.01 .02 1 .63 .99 .94 1.04 
Education -.08 .06 1 .18 .92 .81 1.04 
  Less than    
  HS                                     
.16 .43 1 .71 1.17 .50 2.77 
  HS    
  Graduate 
.04 .48 1 .93 1.04 .40 2.70 
At least some 
College 
Reference       
Age -.05 .03 1 .16 .95 .89 1.02 
Note: The degrees of freedom in computing the confidence limits is 60 
 
Summary of 2008 Adult Cohort. Combined, these findings indicate a 
statistically significant relationship between MJ use and MDE (H01) and between MJ use 
and suicidal ideation (H02) in the 2008 Adult cohort.  
2008 Adolescent Results 
2008 Adolescent Descriptive Statistics 
Table 9 shows that the 2008 adolescent sample was well divided between males 
(51%) and females (49%). Ages ranged from 12 to 17. Roughly half of cases were less 
than 15 years old (47%). Education ranged from fifth grade to college level. Roughly half 
(55%) reported an education level of ninth grade or lower. Annual family incomes ranged 
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from less than $10,000 to $75,000 or greater. Roughly half (49%) reported annual family 
incomes of less than $50,000. 
Table 9 
2008 Adolescent Demographic Frequencies and Percentages (N =17,606) 
Demographic n % 
Sex 
      Males 
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      16 
















      5th Grade 
      6th Grade 
      7th Grade 
      8th Grade 
      9th Grade 
      10th Grade 
      11th Grade 
      12th Grade 





















Family Income Distribution 
      Less than $10,000 
      $10,000 - $19,999   
      $20,000 - $29,999 
      $30,000 - $39,999 
      $40,000 - $49,999 
      $50,000 - $74,999 
























2008 Adolescent Hypothesis Testing 
Marijuana use and depression, 2008 Adolescents.  Overall MJ use was 14% in 
the 2008 Adolescent cohort (2,348 of 17,254) for this analysis and the rate of MDE was 
8% (1,471 of 17,254). Table 10 shows that 18% of MJ users reported MDE in the recent 
year compared to 8% for non-MJ users. This disproportionality was statistically 
significant, 2 (df = 1) = 141.9, p < .0001. The odds of MDE was 0.18 for users and 0.08 
for nonusers. The odds ratio of 2.15 indicated that 2008 adolescent MJ users had greater 
than double the odds of having MDE in the previous year than nonusers. This statistically 
significant finding rejected Null Hypothesis 3.  
Table 10 
Marijuana and Depression: 2008 Adolescents 
Marijuana    Major Depressive Episode     
Use Stat Yes No Total Odds 
No Count 1121 13785 14906 0.08 
 % 8% 92% 100%  
Yes Count 350 1998 2348 0.18 
 % 15% 85% 100%  
Total Count 1471 15783 17254 2.15 
  % 9% 91% 100% Odds Ratio 
 
Table 11 shows that, after accounting for age, sex, family income, and education 
level, the odds ratio for the relationship between MJ and MDE in 2008 adolescents was 
1.99 (p < .0001). This finding indicates that adolescent MJ users had double odds of 
having MDE in the previous year than non-users (see Gertsman, 2008), after accounting 
for age, sex, family income, and level of education. This statistically significant finding 




Coefficients Table: 2008 Adolescent MDE 
Variable B S.E. df p-value OR Confidence Intervals 
Marijuana 
Use 
       
  Yes .68 .09 1 <.0001 1.99 1.63 2.42 
  No Reference       
Sex        
       Female 1.17 .08 1 <.0001 3.24 2.72 3.86 
       Male Reference       
Income -.006 .02 1 .77 0.99 0.95 1.04 
Education -.02 .05 1 .40 0.95 0.85 1.07 
Age .20 .06 1 .002 1.22 1.08 1.38 
Note: The degrees of freedom in computing the confidence limits is 60 
 
Marijuana use and suicidal ideation, 2008 Adolescents.  Overall MJ use was 
22% in the 2008 Adolescent cohort (1867 of 2623) for this analysis and the rate of 
suicidal ideation was 71% (1471 of 2623). Table 12 shows that 78% of MJ users reported 
suicidal ideation in the recent year compared to 69% for non-MJ users. This 
disproportionality was statistically significant, 2 (df = 1) = 17.5, p < .0001. The odds of 
suicidal ideation were 3.59 for users and 2.25 for non-users. The odds ratio of 1.59, 
indicated that adolescent MJ users had 59% greater odds of having suicidal ideation in 
the previous year than non-users (see Gertsman, 2008). This finding rejected Null 







Marijuana and Suicidal Ideation: 2008 Adolescents 
Marijuana    Suicidal Ideation     
Use Stat Yes No Total Odds 
No Count 1422 632 2054 2.25 
 % 69% 31% 100% 
 
Yes Count 445 124 569 3.59 
 % 78% 22% 100% 
 
Total Count 1867 756 2623 1.59 
  % 71% 29% 100% Odds Ratio 
 
 
Table 13 shows that, after accounting for age, sex, family income, and education 
level, the odds ratio for the relationship between MJ and suicidal ideation in 2008 
adolescents was 1.74 (p = .0001). This finding indicates that adolescent MJ users had 
74% greater odds of having suicidal ideation in the previous year than non-users, after 
accounting for age, sex, family income, and level of education (Gertsman, 2008). This 
statistically significant finding rejected Null Hypothesis 4.  
Table 13 
 
Coefficients Table: 2008 Adolescent Suicide Ideation 
 
Variable B S.E, df p-value OR Confidence Intervals 
Marijuana       
Use        
Yes .55 .13 1 .0001 1.74 1.33 2.29 
No Reference       
Sex        
Female .58 .12 1 <.0001 1.80 1.40 2.32 
  Male Reference       
Income -.01 .02 1 .69 .99 .93 1.05 
Education -.02 .09 1 .80 .98 .80 1.19 
Age -.02 .10 1 .84 .98 .80 1.20 
Note: The degrees of freedom in computing the confidence limits is 60 
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Summary of 2008 Adolescent Cohort.  Combined, these findings indicate a 
statistically significant relationship between MJ use and MDE (H03) and between MJ use 
and suicidal ideation (H04) in the 2008 Adolescent cohort.  
2017 Adult Results 
2017 Adult Descriptive Statistics 
Table 14 shows that the 2017 adult sample was well divided between males 
(47%) and females (53%). Ages ranged from 18 to over 65. Roughly half of cases were 
between 20 and 34 years old (53%). Education levels ranged from less than high school 
diploma to college degree. More than half (61%) had some college education or 
completed college. Annual family incomes ranged from less than $10,000 to $75,000 or 














2017 Adults Demographic Frequencies and Percentages (N = 42,554) 
Demographic n % 
Sex 
      Males 
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      19 
      20 
      21 
      22 or 23 
      24 or 25 
      26 to 29 
      30 to 34 
      35 to 49 
      50 to 64 


























      Less than High School Diploma 
      Completed High School 
      Some College 











Family Income Distribution 
      Less than $10,000 
      $10,000 - $19,999 
      $20,000 - $29,999 
      $30,000 - $39,999 
      $40,000 - $49,999 
      $50,000 - $74,999 
























2017 Adult Hypothesis Testing 
Marijuana use and depression, 2017 Adults.  Overall MJ use was 21% in the 
2017 Adult cohort (8912 of 42066) for this analysis and the rate of MDE was 9% (3024 
of 42066). Table 15 shows that .19 of MJ users reported MDE in the recent year 
compared to 0.08 for non-MJ users. This disproportionality was statistically significant, 
2 (df = 1) = 633.8, p < .0001.  
Table 14 
Marijuana and Depression: 2017 Adults 
Marijuana    Major Depressive Episode     
Use Stat Yes No Total Odds 
No Count 2497 30657 33154 0.08 
 % 8% 93% 100%  
Yes Count 1452 7460 8912 0.19 
 % 16% 84% 100%  
Total Count 3949 38117 42066 2.39 
  % 9% 91% 100% Odds Ratio 
 
The odds of MDE was 0.19 for users and .08 for non-users. The odds ratio of 2.39 
indicated that adult MJ users had more than double the odds of having MDE in the 
previous year than non-users (see Gertsman, 2008). This statistically significant finding 
rejected Null Hypothesis 5. 
Table 16 shows that, after accounting for age, sex, family income, and education 
level, the odds ratio for the relationship between MJ and MDE in 2017 adults was 2.19 (p 
< .0001). This finding indicates that adult MJ users had more than double the odds of 
having MDE in the previous year than non-users, after accounting for age, sex, family 





Coefficients Table: 2017 Adult MDE 
 
Variable B S.E. df p-value OR Confidence Intervals 
Marijuana       
Use        
Yes .78 .05 1 <.0001 2.19 1.97 2.43 
No Reference       
Sex        
Female .58 .04 1 <.0001 1.79 1.63 1.97 
  Male Reference       
Income -.11 .01 1 <.0001 .89 .862 .913 
Education .07 .01 1 <.0001 1.08 1.05 1.11 
Age -.11 .01 1 <.0001 .89 .876 .911 
Note: The degrees of freedom in computing the confidence limits is 50 
 
Marijuana use and suicidal ideation, 2017 Adults.  Overall MJ use was 21% 
(8952 of 42240) for this analysis. Table 17 shows that 12% of MJ users reported suicidal 
ideation in the recent year compared to 4% for non-MJ users. This disproportionality was 
statistically significant, 2 (df = 1) = 744.2, p < .0001. The odds of suicide ideation were 
0.14 for users and 0.05 for non-users. The odds ratio of 2.98 indicated that adult MJ users 
had roughly three times greater odds of having suicidal ideation in the previous year than 









Marijuana and Suicidal Ideation: 2017 Adults 
Marijuana    Suicidal Ideation     
Use Stat Yes No Total Odds 
No Count 1490 31798 33288 0.05 
 % 4% 96% 100%  
Yes Count 1098 7854 8952 0.14 
 % 12% 88% 100%  
Total Count 2588 39652 42240 2.98 
  % 6% 94% 100% Odds Ratio 
 
Table 18 shows that, after accounting for age, sex, family income, and education 
level, the odds ratio for the relationship between MJ and suicidal ideation was 2.29 (p < 
.0001) This finding indicates that adult MJ users had more than double the odds of having 
suicidal ideation in the previous year than non-users, after accounting for age, sex, family 
income, and level of education (see Gertsman, 2008). This statistically significant finding 
rejected Null Hypothesis 6. 
Table 18 
 
Coefficients Table: 2017 Adult Suicide Ideation 
 
Variable B S.E. df p-value OR Confidence Intervals 
Marijuana       
Use        
Yes .82 .06 1 <.0001 2.29 2.00 2.61 
No Reference       
Sex        
Female .18 .05 1 .003 1.21 1.07 1.36 
  Male Reference       
Income -.10 .01 1 <.0001 .90 .87 .93 
Education .03 .01 1 .108 1.03 .99 1.08 
Age -.16 .01 1 <.0001 .85 .83 .87 




Summary of 2017 Adult Cohort.  Combined, these findings indicate a 
statistically significant relationship between MJ use and MDE and between MJ use and 
suicidal ideation in the 2017 Adult cohort.  
2017 Adolescent Results 
2017 Adolescent Descriptive Statistics 
Table 19 shows that the 2017 adolescent sample was well divided between males 
(51%) and females (49%). Ages ranged from 12 to 17. Roughly half of cases were less 
than 15 years old (47%). Education ranged from fifth grade to college level. Roughly half 
(55%) reported an education level of ninth grade or lower. Annual family incomes ranged 
from less than $10,000 to $75,000 or greater. Roughly half (49%) reported annual family 












2017 Adolescent Demographic Frequencies and Percentages (N = 13,722) 
Demographic n % 
Sex 
      Males 
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Family Income Distribution 
      Less than $10,000 
      $10,000 - $19,999   
      $20,000 - $29,999 
      $30,000 - $39,999 
      $40,000 - $49,999 
      $50,000 - $74,999 



















2017 Adolescent Hypothesis Testing 
Marijuana use and depression, 2017 Adolescents.  Overall MJ use was 14% in 
the 2017 Adolescent cohort (1814 of 13330) for this analysis and the rate of MDE was 
8% (2348 of 13330). Table 20 shows that 25% of MJ users reported MDE in the recent 
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year compared to (12%) for non-MJ users. This disproportionality was statistically 
significant, 2 (df = 1) = 235.1, p < .0001. The odds of MDE was 0.33 for users and 0.13 
for non-users. The odds ratio of 2.50 indicated that 2017 adolescent MJ users had two 
and a half times odds of having MDE in the previous year than non-users (see Gertsman, 
2008). This statistically significant finding rejected Null Hypothesis 7.  
Table 17 
Marijuana and Depression: 2017 Adolescents 
Marijuana    Major Depressive Episode     
Use Stat Yes No Total Odds 
No Count 1359 10157 11516 0.13 
 % 12% 88% 100%  
Yes Count 455 1359 1814 0.33 
 % 25% 75% 100%  
Total Count 1814 11516 13330 2.50 
  % 14% 86% 100% Odds Ratio 
 
 
Table 21 shows that, after accounting for age, sex, family income, and education 
level, the odds ratio for the relationship between MJ and MDE in 2017 adolescents was 
1.81 (p < .0001). This finding indicates that adolescent MJ users had 81% greater odds of 
having MDE in the previous year than non-users, after accounting for age, sex, family 
income, and level of education (see Gertsman, 2008). This statistically significant finding 








Coefficients Table: 2017 Adolescent MDE 
 
Variable B S.E. df p-value OR Confidence Intervals 
Marijuana       
Use        
Yes .59 .08 1 <.0001 1.81 1.53 2.14 
No Reference       
Sex        
Female 1.22 .08 1 <.0001 3.41 2.89 4.03 
  Male Reference       
Income .02 .01 1 .16 1.03 ..99 1.06 
Education .07 .04 1 .12 1.08 .98 1.18 
Age .15 .05 1 .004 1.16 1.05 1.29 
Note: The degrees of freedom in computing the confidence limits is 50 
 
 
Marijuana use and suicidal ideation, 2017 Adolescents.  Overall MJ use was 
23% in the 2017 Adolescent cohort (643 of 2623) for this analysis and the rate of suicidal 
ideation was 77% (2127 of 2623). Table 22 shows that 81% of MJ users reported suicidal 
ideation in the recent year compared to 76% for non-MJ users. This disproportionality 
was statistically significant, 2 (df = 1) = 8.5, p < .01. The odds of suicidal ideation were 
4.40 for users and 3.16 for non-users. The odds ratio of 1.39 indicated that 2017 
adolescent MJ users had 39% greater odds of having suicidal ideation in the previous 
year than non-users (see Gertsman, 2008). This statistically significant finding rejected 







Marijuana and Suicidal Ideation: 2017 Adolescents 
Marijuana    Suicidal Ideation     
Use Stat Yes No Total Odds 
No Count 1603 507 2110 3.16 
 % 76% 24% 100% 
 
Yes Count 524 119 643 4.40 
 % 81% 19% 100% 
 
Total Count 2127 626 2623 1.39 
  % 77% 23% 100% Odds Ratio 
Table 23 shows that, after accounting for age, sex, family income, and education 
level, the odds ratio for the relationship between MJ and suicidal ideation in 2017 
adolescents was 1.24 (p < .0001). This finding indicates that in 2017 adolescent MJ users 
had 24% greater odds of having suicidal ideation in the previous year than non-users, 
after accounting for age, sex, family income, and level of education (see Gertsman, 
2008). This statistically significant finding rejected Null Hypothesis 8.  
Table 23 
 
Coefficients Table: 2017 Adolescent Suicide Ideation 
 
Variable B S.E. df p-value OR Confidence Intervals 
Marijuana       
Use        
Yes .21 .17 1 .22 1.24 .87 1.76 
No Reference       
Sex        
Female .54 .10 1 <.0001 1.73 1.39 2.15 
  Male Reference       
Income -.003 .03 1 .92 .99 .93 1.07 
Education -.05 .09 1 .56 .95 .79 1.14 
Age .06 .09 1 .49 1.06 .89 1.28 




Summary of 2017 Adolescent Cohort.  Combined, these findings indicate a 
statistically significant relationship between MJ use and MDE (H07) and between MJ use 
and suicidal ideation (H08) in the 2017 Adolescent cohort.  
Comparisons Between 2008 and 2017 Results 
It was hypothesized that the relationship between MJ use and depression and the 
relationship between MJ use and suicidal ideation would increase in magnitude from 
2008 to 2017 for adults and for adolescents. To test these hypotheses, the ORs for 2017 
were assessed to determine whether they were outside of the 95% confidence intervals 
(95% CI) for the corresponding 2008 OR results. This assessment was conducted for 
depression and for suicidal ideation, with analyses for adults and adolescents conducted 
in parallel analyses. ORs were tested using both raw (unadjusted) values and using ORs 
that were adjusted for age, sex, annual family income, and level of education. If a 2017 
OR was outside of the 95% CI for the corresponding 2008 data, the difference was 
statistically significant at the p < .05 threshold.  
MJ and Depression Changes from 2008 to 2017 
The depression ORs for MJ users and non-users for the Adult and Adolescent 
2008 and 2017 cohorts are displayed in Table 24. The 95% CIs are also included to foster 
testing the hypotheses. 
Adult MJ-related depression changes from 2008 to 2017.  The 2017 raw 
(unadjusted) Adult OR of 2.39 was higher than the 95% CI for the 2008 unadjusted OR 
(1.61-1.91). The 2017 adjusted Adult OR of 2.18 was higher than the 95% CI for the 
2008 adjusted OR (1.10-1.74). These findings rejected null hypothesis 9 (H09), which 
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stated that there will be no significant increase in the strength of the relationships 
between MJ use and MDE (see Gertsman, 2008).  
Adolescent MJ-related depression changes from 2008 to 2017.  The 2017 raw 
(unadjusted) Adolescent OR of 2.50 was higher than the 95% CI for the 2008 unadjusted 
OR (1.90-2.46). The 2017 adjusted Adolescent OR of 1.81 was not outside of the 95% CI 
for the 2008 adjusted OR (1.63-2.41). These findings partially rejected null Hypothesis 
11 (H011), which stated that there will be no statistically significant increase in the 
strength of the relationships between MJ use and MDE in the adolescent 2017 cohort 
compared to the adolescent 2008 cohort (see Gertsman, 2008).  
Table 19  
Depression Raw and Adjusted ORs for Adults and Adolescents: 2008 and 2017 
Age Year 
Raw  95% CI Adjusted 95% CI 
OR Lower Upper OR Lower Upper 
Adult 
2008 1.75 1.61 1.91 1.39 1.10 1.74 
2017 2.39 2.23 2.56 2.18 1.96 2.43 
Child 
2008 2.16 1.90 2.46 1.98 1.63 2.41 
2017 2.50 2.22 2.82 1.81 1.53 2.13  
 
MJ and Suicide Ideation Changes from 2008 to 2017 
The suicide ideation ORs for MJ users and non-users for the Adult and 
Adolescent 2008 and 2017 cohorts are displayed in Table 25. The 95% CIs are also 
included to foster testing the hypotheses. 
Adult MJ-related suicidal ideation changes from 2008 to 2017.  The 2017 raw 
(unadjusted) Adult OR of 2.98 was significantly higher than the 95% CI for the 2008 
unadjusted OR (2.20-2.66). The 2017 adjusted Adult OR of 2.40 was higher than the 95% 
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CI for the 2008 adjusted OR (1.89-2.31). These findings rejected the null hypothesis 10 
(H010), which stated that there will be no statistically significant increase in the strength 
of the relationships between MJ use and suicide ideation in the adult 2017 cohort 
compared to the adult 2008 cohort (see Gertsman, 2008).  
Adolescent MJ-related suicide ideation changes from 2008 to 2017.  The 2017 
raw (unadjusted) Adolescent OR of 1.39 was within the 95% CI for the 2008 unadjusted 
OR (1.28-2.01). The 2017 adjusted Adolescent OR of 1.24 was not outside of the 95% CI 
for the 2008 adjusted OR (1.32-2.29). These non-significant findings failed to reject the 
null hypothesis 12 (H012), which stated that there will be no statistically significant 
increase in the strength of the relationships between MJ use and suicidal ideation in the 
adolescent 2017 cohort compared to the adolescent 2008 cohort (see Gertsman, 2008).  
Table 20 
Suicidal Ideation Raw and Adjusted ORs for Adults and Adolescents: 2008 and 2017 
Age Year 
Raw  95% CI Adjusted 95% CI 
OR Lower Upper OR Lower Upper 
Adult 
2008 2.42 2.20 2.66 1.50 1.17 1.92 
2017 2.98 2.75 3.24 2.28 2.00 2.60 
Child 
2008 1.61 1.28 2.01 1.74 1.32 2.29 
2017 1.39 1.11 1.74 1.24 .877 1.76 
 
Summary of Results 
 The summary of results by hypothesis are displayed in Table 26. This study of 
data from the 2008 and 2017 National Survey on Drug Use and Health (NSDUH) 
database revealed that MJ use was associated with significant odds of greater depression 
and suicidal ideation for adults and for adolescents in 2008 and in 2017. These findings 
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were consistent whether ORs were calculated using raw (unadjusted) values or when 
values are adjusted for age, sex, family income, and education level using binary logistic 
regression. These findings reject Null Hypothesis 1 (H01) through Null Hypothesis 8 
(H08) and were consistent with the alternative hypothesis that MJ use was associated with 
both depression and suicidal ideation in adults and adolescents in the 2008 and the 2017 
cohorts.  
Table 21 
Summary of Results by Hypothesis 







H01 2008 Adult Depression Yes Yes 
H02 2008 Adult Suicidal Ideation Yes Yes 
H03 2008 Adolescent Depression Yes Yes 
H04 2008 Adolescent Suicidal Ideation Yes Yes 
H05 2017 Adult Depression Yes Yes 
H06 2017 Adult Suicidal Ideation Yes Yes 
H07 2017 Adolescent Depression Yes Yes 
H08 2017 Adolescent Suicidal Ideation Yes Yes 
H09 2008 vs 2017 Adult Depression Yes Yes 
H010 2008 vs 2017    Adult Suicidal Ideation Yes Yes 
H011 2008 vs 2017 Adolescent Depression Yes No 
H012 2008 vs 2017 Adolescent Suicidal Ideation No No 
Note. MHC = mental health condition. 
 
 There were statistically significant increases in the strength of the relationships 
between MJ use and depression (H01) and between MJ use and suicidal ideation (H010) 
in adults between 2008 and 2017. Adolescent results were mixed regarding changes over 
time. There was a statistically significant increase in the strength of the relationship 
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between MJ use and depression between 2008 and 2017 in adolescents using raw 
(unadjusted) values (H011), but this pattern was not statistically significant when values 
were adjusted for age, sex, annual family income, and education. Further, there was no 
evidence of statistically significant increases in the strength of the relationships between 
MJ use and suicidal ideation from 2008 to 2017 in Adolescents (H012). Thus, the Null 
hypothesis (H012) is not rejected.  
 The following chapter provides a summary of the present study, along with 




Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The changing epidemiology of marijuana legalization, use, acceptance, and 
potency and the effects on mental health conditions is an important concern for policy 
makers as well as public health and health care professionals. The purpose of this study 
was to assess the association between marijuana use, the continued widespread 
legalization of marijuana, the availability of highly potent marijuana and the effects on 
mental health conditions. The literature review suggested that marijuana legalization has 
led to the production of highly potent marijuana strains. This is evidenced by reports 
indicating that since legalization the THC level of marijuana can now range from 6% to 
28 % as oppose to pre-legalization lower potency levels that typically ranged between 4% 
to 13 % (Cabrera, 2016; Ramaekers et al., 2006). Furthermore, the notion that marijuana 
use is associated with the development of psychosis and mental health disorders is well 
founded (Moore et al., 2007; Volkow, Ruben, Baler, Compton, & Weiss, 2014). As 
previous research has demonstrated that in addition to psychosis, conditions like anxiety 
and depression are also associated with regular marijuana use (Moore et al., 2007; 
Volkow et al., 2014). However, very little research has been conducted post-legalization 
to assess the effects of legalization and the rising THC levels. Nevertheless, since THC is 
the responsible agent for the psychoactive effects of marijuana then it is highly probable 
that this rise in THC concentration and ease of marijuana accessibility may contribute to 
an increase in mental health consequences. This premise is evidenced by increases in 
hospital admissions for psychosis and overdoses associated with marijuana intoxication 
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since widespread legalization began. For instance, in Colorado, the higher levels of THC 
have had a serious health toll on inexperienced users. According to the Colorado 
Department of Public Health and Environment, emergency room visits for marijuana 
associated conditions, such as psychosis, has increased 29% for since legalization 
(Cabrera, 2016). However, when inexperienced users take in too much highly potent 
marijuana, they are more likely to experience extreme anxiousness and report feelings of 
“impending dome” when compared to the regular heavy marijuana users that have built 
up a tolerance (Cabrera, 2016, para. 23). This is evidenced by out of state users that are 
inexperienced when it comes to the high levels of THC elicited by Colorado’s legal 
marijuana (Manella, 2016). Hospitalizations for out of state visitors has risen 
dramatically, from 78 per 10,000 visits in 2012 to 163 per 10,000 in 2014, reflecting an 
increase of 109% between the years of 2012 and 2014 (Manella, 2016).  
Interpretation of Findings 
Present findings revealed that marijuana use increased among the adult cohort 
between 2008 and 2017. This increase in marijuana use may be the result of easing of 
marijuana acceptance and reduced stigma associated with marijuana use. This finding 
could also be attributed to the continued spread of marijuana legalization. In 2008, only 
13 states and the District of Columbia had implemented laws legalizing marijuana use for 
medical purposes only (Governing Data, 2019; NCSL, 2019), but by 2017, 29 states and 
the District of Columbia had medical marijuana laws, with seven of these states and the 
District of Columbia also implementing recreational marijuana laws (Governing Data, 
2018; Hartig & Geiger, 2018; NCSL, 2019). Thus, more adults may use marijuana now 
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that the risk of legal actions are reduced. Further support for this premise is provide by 
Keyhani, et al. (2018), which posited that changes in marijuana laws “have been 
accompanied by an increase in daily marijuana use, as well as in marijuana dependence, 
among adults in the U.S. population” (para. 1). This is supported by an increased 
prevalence of marijuana use among adults in the general population, which has doubled 
over the course of the last decade (Keyhani et al., 2018).  
Research Question 1 
RQ1 asked whether marijuana use was associated with depression and suicide 
ideation in adults in 2008 and 2017, either in isolation using raw (unadjusted) values or 
using values adjusted for age, sex, annual family income, and education. The prevalence 
of MDE) was higher among marijuana users than nonusers in the adult 2008 cohort, and 
adult marijuana users had three times greater odds of having MDE in the previous year 
than nonusers in the 2008 cohort. This statistically significant finding was also evident 
after accounting for age, sex, family income, and education level. In the 2017 adult 
cohort, adult marijuana users had more than double the odds of having MDE in the 
previous year than nonusers, even after accounting for age, sex, family income, and 
education level.  
There is a growing body of evidence supporting the association between cannabis 
use and the development of psychotic or mental health disorders (Moore, et al., 2007). 
However, Volkow et al. (2014) posited that causality is not well founded because 
addressing this association is hindered by confounders that also contribute to the 
development of these conditions. Lev-Ran et al. (2014) conducted a systematic review 
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and meta-analysis of existing longitudinal studies to determine patterns of cannabis use 
that are associated with the development of depression. Lev-Ran, et al. cited three reasons 
as cause for concern and justification for the study: (a) high cannabis use among 
adolescents and young adults, (b) the increasing potency of cannabis, and (c) the 
association between cannabis and mental illness. Further, regular or moderate marijuana 
users have an increased risk of developing depression when compared to those who do 
not use marijuana, with the greatest risk of developing depression in heavy marijuana 
users (Lev-Ran et al., 2014). Lev-Ran et al. emphasized the importance of recognizing 
and addressing the potential risk of heavy cannabis use, especially among adolescents 
because this group has the highest rates of cannabis use. 
 However, conversely a study by Denson and Earleywine (2006) found the risk of 
depression is not increased in adults by the use of marijuana. As according to Denson and 
Earleywine, “those who used once per week or less had less depressed mood, more 
positive affect, and fewer somatic complaints than non-users (p.738).” In addition, “daily 
users reported less depressed mood and more positive affect than non-users” (Denson & 
Earleywine, 2006, p.738). These findings are supported Hader, Morral, and Arkes (2006), 
which concluded that, “past-year marijuana use does not significantly predict later 
development of depression” (p. 1463). Thus, causality between marijuana use and 
depression is not well founded. 
Regarding suicide ideation among adults in 2008, the results of this study 
revealed that in the 2008 adult cohort, marijuana users had more than double the odds of 
having suicidal ideation in the previous year than nonusers. This statistically significant 
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findings were consistent after accounting for age, sex, family income, and education 
level. The adult 2017 cohort demonstrated that adult marijuana users again had more than 
double the odds of having suicide ideation in the previous year than nonusers, even after 
accounting for age, sex, family income, and education level.  
In a related study, Oquendo, Currier, and Mann, (2006) addressed predictive risk 
factors associated with suicidal behavior in major depressive disorders and found that the 
best predictors of suicidal behavior were a past history of suicidal behavior and a history 
of refractory or recurrent depressions. This evidence was consistent with the results of the 
present study, which found an increase in suicidal ideation and an increase in depression 
in 2017 versus 2008. Thus, the increase in suicide ideation may be associated with the 
increasing rates of depression. It is also important to mention that these rates increased 
concurrently with the continued spread of legalization and rising potency of marijuana. 
Only 13 states and the District of Columbia had implemented laws legalizing marijuana 
use for medical purposes only in 2008(NCSL, 2019; Governing Data, 2018). In 2017, 29 
states and the District of Columbia had medical marijuana laws with seven of these states 
and the District of Columbia also implementing recreational marijuana laws (Governing 
Data, 2019; Hartig & Geiger, 2018; NCSL, 2019). Additionally, prior to legalization, 
THC levels ranged from a low of 4% to a high of 13% (Ramaekers et al. 2006). But, 
since legalization these ranges have increased dramatically, such that marijuana can now 
range from a low of 6% THC to a high of 28% THC (Cabrera, 2016). 
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Research Question 2 
 RQ2 asked whether marijuana use evaluated marijuana use and the association 
with depression and suicide ideation for adolescents in 2008 and 2017, either in isolation 
using raw (unadjusted) values or using values adjusted for age, sex, annual family 
income, and education.  
Marijuana use among the adolescent cohorts did not change between 2008 and 
2017, with both adolescent cohorts measured at 14% marijuana use. This contrast with 
the increase in adult marijuana use may be attributed to the fact the adults can legally buy 
marijuana while adolescents cannot (Governing Data, 2018; NCSL, 2019).  
Among the 2008 adolescent cohort, marijuana users had greater than double the 
odds of having MDE in the previous year than non-users, even after accounting for age, 
sex, family income, and education level. In comparison, among the 2017 adolescent 
cohort, marijuana users had two and a half times greater odds of having MDE in the 
previous year than nonusers, even after accounting for age, sex, family income, and 
education level. Thus, the rates of marijuana associated depression increased concurrent 
with the continued widespread legalization of marijuana. These rates are also concurrent 
with the rising THC levels in marijuana that has occurred with the continued widespread 
legalization (Cabrera, 2016). 
Additionally, these findings are supported by previous research as van Gastel et 
al. (2013) which indicated that marijuana use has been associated with psychiatric 
symptoms and the risk is increased by regular or heavy marijuana use. According to van 
Gastel et al., the risk of developing depression is more pronounced in those who began 
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using marijuana before age 16. Observations among young adolescent marijuana users 
typically include “delinquent behavior; conduct disorder; attention problems; anxiety as 
well psychotic and depressive symptoms” (van Gastel, 2013, p.1849). Thus, developing 
evidenced based interventions to address the association between marijuana and mental 
health conditions is essential to ensuring the health and well fare adolescents and 
therefore future generations. 
With regard to suicide ideation among the 2008 adolescent cohort, marijuana 
users demonstrated a doubled risk of suicide ideation than nonusers, even after 
accounting for age, sex, family income, and education level, with even higher values for 
the 2017 adolescent cohort. These results are consistent with peer-reviewed research 
showing that suicidal ideation, attempts, and completions have been associated with both 
depression and substance use in adolescence (Chabrol, Chauchard, & Girabet, 2008; 
Field, Diego, & Sanders, 2001). Social factors and mental health problems in general 
have been identified as associated risk factors for suicidal behaviors in adolescents. 
Among these, depression has been established as a significant or major risk factor for 
suicide behaviors (Chabrol et al., 2008; Field et al., 2001). In addition, Field et al. (2001) 
identified marijuana use and a family history of depression, particularly maternal 
depression, as important variables in adolescent suicide ideation.  
Research Question 3 
RQ3 asked whether the associations between marijuana use and MDE and 
between marijuana use and suicidal ideation are significantly higher in 2017 than in 2008 
for both adults and adolescents. Adult MDE and suicidal ideation increased significantly 
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from 2008 to 2017. Results for the adolescents were mixed, with statistically significant 
increases in depression from 2008 to 2017 evident using unadjusted values, but not 
accounting for age, sex, family income, and education level. Further, not statistically 
significant increases from 2008 to 2017 in suicidal ideation for adolescents were present. 
Suicide is one of the most common causes of death worldwide among adolescents 
and young adults aged 10-24, (Serafini et al., 2013). Previous research suggests that 
marijuana use may be a contributing factor in the development of suicide behavior and 
depression (Gander, 2019; Serafini et al., 2013). For example, Gander (2019) pooled 
existing studies to assess the association between marijuana use, depression and suicidal 
behavior and found that adolescents who use marijuana are at a greater risk of 
experiencing depression and suicidal behavior, including suicide ideation and suicide 
attempts. However, Gander acknowledged that it is difficult to assess whether 
confounding variables may have affected the results, such as amount of marijuana use, 
use of other substances of abuse, and marijuana potency (which has increased 
substantially since legalization). Gander further offered that individuals with a 
predisposition to depression or those who begin to experience symptoms of depression 
may self-medicate as a way to ease these symptoms or just think and/or feel better. In 
contrast, Anderson, Rees, and Sabin (2014) compared the rates of suicide in states with 
medical marijuana legalization to states that did not legalize medical marijuana and found 
a decrease in suicides among men aged 20 to 39 in states with medical marijuana laws. 
Anderson et al. (2014) hypothesized that this negative relationship between marijuana 
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legalization and suicide rates may be attributed to the use of marijuana as a method of 
coping with stress.  
Analysis of Theoretical Framework  
There are several theoretical models developed for understanding drug use, abuse, 
prevention, and cessation. For instance, there is a growing body of evidence supporting 
the association between self-medicating with marijuana and depression (Shonesy et al., 
2014). Research supports the use of the SEM to understand substance use and abuse from 
a multifaceted perspective (American College Health Association [ACHA], 2018). 
Theorists of the self-medication theory of addiction developed by Khantzian (1977, 1974) 
suggested that individuals who are afflicted with substance abuse may also have a 
predisposition for psychological conditions or psychosis (Burnett & Reiman, 2014). Self-
medication theory has over 30 years of use in research (Hall & Queener, 2007). 
Therefore, I used both the self-medication theory of addiction and SEM as the conceptual 
frameworks.  
Shonesy (2014) explored the relationship between mental health conditions, like 
depression and anxiety, and receptors that respond to THC in the central nervous system. 
This system is known as the endocannabinoid system and is medicated by two 
cannabinoid receptors, CB1 and CB2 (Shonesy et al., 2014). These receptors respond to 
both endogenous and exogenous stimulation (Shonesy et al., 2014). Natural endogenous 
stimulation of CB1 receptors occurs through one of two THC-like substances, 
anandamide (AEA) and 2-arachidonoylglycerol (2-AG, Shonesy et al., 2014). According 
to Shonesy (2014) this system “is heavily implicated in the modulation of anxiety and 
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depressive behavior and emotional learning” (p.1644). The THC in marijuana is capable 
of binding CB1 receptors of the system and affects mood, such that reduced stimulation 
of these receptors results in mood destabilization and increased feelings of anxiety and 
depression (Shonesy et al., 2014). Thus, marijuana users who suffer from these 
conditions may not be able to synthesize enough of THC-like molecules (particularly 2-
AG) so they use marijuana to compensate, suggesting that individuals may actually self-
medicate without knowing it to compensate for their inherent low levels of THC-like 
molecules (Curry, 2014; Shonesy et al., 2014). 
However, results of the present study and other supporting literature suggest that 
marijuana use is associated with an increased risk of depression and suicide ideation. 
Nevertheless, an explanation for these contradicting theories may lie in the ratio of THC 
to CBD in marijuana. It has been demonstrated that CBD has effects that counteract the 
effects of THC (Niesink & van Laar, 2013). CBD is a compound found in marijuana that 
is being used for medical benefits. CBD does not produce the psychoactive effects caused 
by the THC found in marijuana. In fact, CBD can serve to counteract the psychoactive 
effects of THC and is used for treating marijuana induced psychosis (Niesink & van Laar, 
2013). Thus, it is possible marijuana that has a high CBD to THC ratio may counter the 
effects of THC-induced depression. 
 The (SEM is a theory-based multifaceted approach to understanding the dynamics 
associated individual and population level determinants of health (ACHA, 2018). The 
SEM recognizes that health is determined by influences from multiple societal and 
environmental factors that affect the individual (ACHA, 2018). According to the SEM, 
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the dynamic interrelationships between five levels or factors of health determinants are 
significant and essential to the health behaviors of the individual (ACHA, 2018). These 
five levels include (a) individual, (b) interpersonal, (c) organizational/institutional, (d) 
community, and (e) policy (CDC-SEM, 2018). The first or individual level is concerned 
with sociodemographic (i.e., age, gender, religion, etc.) and intrapersonal factors or 
characteristics such as knowledge, beliefs, attitudes, and behaviors of the individual that 
affect health decisions and outcomes (ACHA, 2018; CDC-SEM, 2018). The second or 
interpersonal level is concerned with close personal relationships or associates that 
influence the behavior and contributes to the life experience of the individual (ACHA, 
2018; CDC-SEM, 2018). This can include family members, friends, coworkers, health 
care providers, and community health workers (ACHA, 2018; CDC-SEM, 2018). These 
first two levels may be associated with an increase in marijuana use as continued 
legalization may result in decreased perceived risk and reduced stigma associated with 
marijuana use.   
The third level of SEM is concerned with local organizations and institutions that 
affect individual and population health by influencing organizational systems and policies 
(ACHA, 2018; CDC-SEM, 2018). This includes health care systems; state and local 
health departments; professional organizations; and healthcare plans (ACHA, 2018; 
CDC-SEM, 2018). The fourth level explores community and social relationships that 
influence individual health determinants. This can include employers/worksites, 
businesses such as bars and restaurants, community-based organizations, the media as 
well as community, state and regional organizations (ACHA, 2018; CDC-SEM, 2018). 
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Thus, the third and fourth levels may be associated reduced or no change in marijuana 
use. This is because the third level associated with health care systems, state and local 
health departments, professional organizations, and healthcare plans, may serve to inform 
individuals and the public about the negative impact or consequences of marijuana use. In 
addition, the fourth level is associated with organizations such as employers/worksites 
many of which require drug screenings that include marijuana, thus deterring marijuana 
use. 
The fifth level of SEM is associated with interpreting and implementing local, 
state, national, and federal laws and policies (ACHA, 2018; CDC-SEM, 2018). This level 
is of particular interest to the present study, given the current trend in marijuana policies 
that favor relaxed laws and increased community acceptance of legalization for 
recreational and medicinal purposes. The fifth level may thereby be associated with an 
increase in marijuana use as state laws favoring marijuana continue to spread. As 
individuals may feel more comfortable purchasing and using marijuana without legal 
consequences. However, this fifth level may result in a decrease or no change in 
marijuana use as federal laws still prohibit marijuana use. Therefore, this SEM model can 
be used to inform States local marijuana policies and may serve to inform the 
implementation of federal laws and regulations as well.  
With respect to this study, the SEM suggest that the first (individual), second 
(interpersonal), and fifth (policy) levels may be associated with increased marijuana use. 
As increased legalization (policy), reduced stigma associated with marijuana use and 
decreased perceived risk associated with the individual, interpersonal and community 
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effects may serve to increase marijuana use and affect the results of this study. In 
contrast, the third (organizational/institutional) and fourth (community) levels may be 
associated with a decrease or no change in marijuana use as the groups associated with 
these levels may serve to deter marijuana use. 
Limitations 
 In this study I was limited by sample, measures, and research design. The target 
population for the NSDUH included non-institutionalized civilians 12 years and older 
living in the United States at the time of the survey. Approximately three percent of the 
US population was excluded this includes active-duty military and institutionalized 
groups, such those in prisons, hospitals, nursing homes, treatment centers, etc. In all the 
2008 and 2017 NSDUH datasets consisted of responses from 67,928 and 68,032 
participants, respectively (NSDUH-codebook, 2008; NSDUH-codebook, 2017). Based on 
this information it is important to acknowledge the exclusion of institutionalized, 
incarcerated and homeless individuals because according to a report provided by the 
Center for Prisoner Health and Human Rights (2019), “approximately half of prison and 
jail inmates meet the requirements of the Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition (DSM-IV) for drug abuse or dependence” (para. 2). In addition, 
according to the U.S Department of Housing and Urban Development (2016), among the 
roughly 550,000 homeless persons, approximately 95,500 (17%) of these individuals 
suffer from chronic substance abuse. So, inclusion of the incarcerated and homeless 
populations in the demographics of NSDUH would have increased the number of users in 
the study disproportionately and potentially altered the outcomes observed. Thus, while 
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exclusion of these individuals may have limited the representativeness of the sample, 
inclusion of these individuals may have altered the study’s results by increasing the 
number of marijuana users disproportionately.  
Even though the NSDUH presented samples that were stratified to be 
representative of the nation’s adult and adolescent populations, in my present study I did 
not explore state by state differences. Thus, while a nationwide analysis was conducted, 
the NSDUH does not differentiate between states with marijuana laws compared to states 
without marijuana laws. In addition, THE NSDUH was retrospective in nature and it did 
not include random assignment into group or experimentally controlled levels of 
marijuana use. In contrast with a true experimental design that would include random 
assignment and experimentally controlled usage to assess true cause-and-effect 
relationships (Creswell, 2009). 
 In this study I was also limited by self-reporting, which is subject to recall bias, 
which can therefore result in erroneous responses due to lapses in memory (Althubaiti, 
2016). Self-reporting is also subject to social desirability bias, especially in this case 
which involves responses related drug use (Althubaiti, 2016). To alleviate these concerns, 
the NSDUH interviewer conducted the interview in a private area of the home and used 
both computer-assisted personal interviewing (CAPI) and audio computer-assisted self-
interviewing (ACASI) techniques (CBHSQ, 2016). The CAPI portion of the interview 
was used to collect and record verbal responses to questions read aloud by the interviewer 
who enters these responses into a computer (CBHSQ, 2016). In contrast, the ACASI 
portion of the interview was used to collect information on answers to sensitive 
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questions. During his portion of the interview, respondents used headphones to listen to 
questions and enters responses directly into a computer (NSDUH-codebook, 2017). 
Throughout the interview process (written and oral), respondents were assured that their 
confidentiality, anonymity, and responses were protected and handled according to 
federal law compliance regulations (CBHSQ, 2016; NSDUH-codebook, 2017). 
Nevertheless, even though the NSDUH assured participants anonymity and 
confidentiality, respondents may still have felt uncomfortable and may therefore not have 
been completely truthful about marijuana use or may have underestimated usage amounts 
or frequency (Althubaiti, 2016). Thus, socially acceptable or bias responses could have 
therefore effected survey results on the prevalence and extent of marijuana use because 
individuals may still have concerns about social stigma or self-incrimination (McDonald, 
2008). 
 In my present study I only used one measure per construct. In addition, my study 
was missing important variables, such as frequency and amount of marijuana use. I did 
not assess whether respondents had a history of major depressive episode or suicide 
ideation prior to marijuana use. 
 My present study was also limited by the design. Even though my study was 
longitudinal in nature regarding statistical comparisons of cohorts at two time periods, the 
same respondents were not followed over time because there was no tracking between the 
cohort years of 2008 and 2017. Therefore, there is no way to tell if respondents changed 
behavior based on marijuana laws or trends in growing acceptance of marijuana use. 
Also, there was no long-term follow up after 2017. Because this was not a true 
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longitudinal study, cause and effect inference is limited, and the results do not provide 
strong evidence of causality between marijuana use and the mental health conditions of 
MDE and suicide ideation  
Areas for Future Research 
 An important approach for future scholars is to replicate this research using 
methods to address, overcome, or reduce the limitations of this study. For instance, future 
research should include variables with multiple measures of construct, such as how much 
or how often individuals use marijuana. Another limitation that should be addressed are 
those associated with self-reporting, including overcoming recall and social desirability 
biases.  
Another important approach for future scholars is to explore state-level data to 
compare states with marijuana laws to states without marijuana laws. In states with 
marijuana laws, future researcher should explore changes in mental health status in years 
prior to legalization of marijuana to years after legalization (pre vs post-legalization). In 
my present study I sought to explore and compare state-level data. However, this 
information is only available on-site at one of three Research Data Centers (RDCs) in the 
U.S. managed by the National Center for Health Statistics.      
 Future scholars should also consider whether participants had previous history of 
marijuana use as well as histories of MDE and suicide ideation prior to using marijuana. 
Additionally, future research should consider conducting long-term follow up as well. 
Thus, to guarantee optimal outcomes and present strong evidence of causality, future 
research is warranted to confirm the present findings and assess (determine) whether the 
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effects observed in this study would be statistically significant in a true longitudinal 
study.  
Implications for Positive Social Change  
 The results of my study may contribute to positive social change by contributing 
to present knowledge on the association between marijuana use and the mental health 
conditions, depression and suicide ideation. The findings presented here imply that 
marijuana use can increase the risk of depression and suicide ideation.  
 Addressing these concerns at this time is of particular importance given the trends 
in marijuana legalization and growing acceptance. Current trends indicate that, as 
marijuana legalization continues to spread, the perceived risk of marijuana use is 
decreasing. These trends may contribute to an increase in marijuana use as was 
demonstrated among the adult cohorts from 2008 compared to 2017 (Lynskey & Hall, 
2016). In addition, with the exception of marijuana use, substance use in general has 
declined among high school seniors (Lanza, Vasilenko, Dziak & Butera, 2015). 
Marijuana is still the most widely used illicit substance in the world and in the United 
States as in 2018, approximately 43 million Americans reportedly used marijuana in the 
past year (Statista, 2019). Among these were approximately 11.8 million young adults 
that reported using marijuana in the past year in 2018 (NIH-NIDA, 2019). The World 
Health Organization (2018) further emphasizes the widespread use of marijuana in a 
report indicating that approximately 147 million people or 2.5% of the world population 
utilize marijuana in some form each year. This is compared to 0.4% combined totals of 
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the world’s population that consume cocaine and opiates annually (WHO, 2018)., 
demonstrating that marijuana is by far the most widely used illicit substance in the world.  
 The findings presented here also contribute to positive social change because 
according to the NSDUH, in 2017 approximately 17.3 million adults 18 years old or older 
and 3.2 million adolescents aged 12-17 years old had at least one major depressive 
episode (NIMH, 2019). In addition, suicide is the tenth leading cause of death in the 
United States. Thus, addressing suicidal behavior, such as suicide ideation is an important 
preventive measure for public health concern. 
 The results of my study demonstrated a statistically significant association 
between marijuana use an increased risk of major depressive episode (MDE) in both 
adults and adolescents, and therefore support and extend previous reports. Furthermore, 
my study also demonstrated positive correlations between time (corresponding to 
increasing marijuana legalization) and rising rates or risk for MDE and suicide ideation 
as the rates for these conditions increased for marijuana users from 2008 to 2017. The 
findings presented here along with continued widespread marijuana legalization, 
increasing permissive attitudes toward marijuana use, and decreasing perceived risk 
demand that policymakers and public health professionals direct informative and 
preventive efforts to reduce these risks. 
 The increasing permissive attitudes and decreasing perceived risk of marijuana 
use among adolescents is a serious concern for the future of public health as these 
individuals are entering their reproductive years and will therefore affect future 
generations. In addition, it has also been demonstrated that an association exists between 
202 
 
age of initiation of substance use and increased risk of substance dependency later in life 
(Jordan & Andersen, 2017; CDC, 2019). Therefore, a positive social change implication 
is to encourage policy makers and public health professionals in jurisdictions with laws 
legalizing marijuana and those considering legalization of marijuana, to take these results 
into consideration and improve efforts to inform the public about the increased risk 
associated with marijuana use and the potential effects on mental health.  
Another contribution to positive social change addressed by my study is the 
increasing potency of marijuana and marijuana products. Prior to legalization, THC 
levels ranged from a low of 4% to a high of 13% (Ramaekers, et al. 2006). However, 
since legalization these ranges have increased dramatically. For instance, growers in 
Colorado have produce strains that range from a low of 6% THC to a high of 28% THC 
in the Williams’ Screaming Gorilla strain (Cabrera, 2016). This concern was addressed 
by the Colorado state legislator which proposed an amendment to limit the THC 
concentration of marijuana to 16% (Cabrera, 2016). However, these efforts failed as the 
amendment did not get enough support. Previous studies have been conducted assessing 
the lower levels of THC fewer studies have been conducted to assess higher levels. My 
study contributes to positive social change by informing future generations of the risk 
associated with highly potent marijuana and the implications of marijuana legalization on 
the prevalence of mental illnesses like depression. In addition, among the health and 
safety concerns addressed by the Colorado state legislator, the effects of THC on 
adolescent brains was one of the primary concerns of the proponents of this amendment 
(Cabrera, 2016). Thus, adolescents were included in the target population of my study 
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which intended to contribute to positive social change by making information available to 
inform and understand the effects on future generations as a future return on investments. 
  Conclusions 
 In my study I found that higher rates of major depressive episode and suicide 
ideation in adults and adolescents were associated with marijuana use. Furthermore, I 
also found that there were statistically significant increases in the strength of the 
relationships between marijuana use and depression and between marijuana use and 
suicidal ideation in adults between 2008 and 2017, as marijuana legalization increased. 
However, adolescent results were mixed. In addition, the adult rates of marijuana use 
increased between 2008 and 2017. These findings may be attributed to by the fact adults 
can legally buy marijuana therefore increasing availability and use among this group. 
Additionally, adults in states with recreational marijuana laws have greater access to the 
highly potent marijuana being sold in dispensaries. Thus, more adults may use marijuana 
now that the risk of legal actions are reduced contributing to the results observed in this 
study.  
 Finally, the increasing permissive attitudes and decreasing perceived risk of 
marijuana use among adolescents is a serious concern for the future of public health 
because these individuals are entering into their reproductive years and will therefore 
affect future generations. In addition, it has also been demonstrated that an association 
exists between age of initiation of substance use and increased risk of substance 
dependency later in life (Jordan & Andersen, 2017; CDC, 2019). As adolescents aged 12-
17 years old are considered to be in the critical risk period of life for initiation of 
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substance use associated with greater risk of substance abuse and dependence in later life 
(Strashny, 2014). Therefore, policy makers and public health professionals in 
jurisdictions with laws legalizing marijuana and those considering legalization of 
marijuana have an obligation to intervene in this vulnerable population. In an effort to 
improve prevention and inform the public about the increased risk associated with 
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